20-F

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report

For the transition period from to

Commission file number: 001-41433

Warrantee Inc.

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant’s name into English)

Japan

(Jurisdiction of incorporation or organization)

1103, Kitahama Craft

2-4-1 Doshomachi, Chuo-ku

Osaka City, Osaka 541-0045, Japan

+81(0)6-6227-8775

(Address of principal executive offices)

Yusuke Shono, Chief Executive Officer

Telephone: +81(0)6-6227-8775

Email: y.shouno@warrantee.co.jp

At the address of the Company set forth above

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American depositary shares, each representing one common share	WRNT	The Nasdaq Stock Market LLC
Common shares*		The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the registration of the American depositary shares on The Nasdaq Stock Market LLC. Each American depositary share represents one common share.

Securities registered or to be registered pursuant to Section 12(g) of the Act.

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 22,404,000 common shares

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Emerging growth company	☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☒ International Financial Reporting Standards as issued by the International Accounting Standards Board ☐ Other ☐

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

TABLE OF CONTENTS

INTRODUCTION		1
PART I		2
ITEM 1.	IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS	2
ITEM 2.	OFFER STATISTICS AND EXPECTED TIMETABLE	2
ITEM 3.	KEY INFORMATION	2
ITEM 4.	INFORMATION ON THE COMPANY	21
ITEM 4A.	UNRESOLVED STAFF COMMENTS	31
ITEM 5.	OPERATING AND FINANCIAL REVIEW AND PROSPECTS	31
ITEM 6.	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES	41
ITEM 7.	MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS	47
ITEM 8.	FINANCIAL INFORMATION	49
ITEM 9.	THE OFFER AND LISTING	50
ITEM 10.	ADDITIONAL INFORMATION	50
ITEM 11.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	59
ITEM 12.	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES	59
PART II		62
ITEM 13.	DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES	62
ITEM 14.	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS	62
ITEM 15.	CONTROLS AND PROCEDURES	62
ITEM 16.	[RESERVED]	63
ITEM 16A.	AUDIT COMMITTEE FINANCIAL EXPERT	63
ITEM 16B.	CODE OF ETHICS	63
ITEM 16C.	PRINCIPAL ACCOUNTANT FEES AND SERVICES	64
ITEM 16D.	EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES	64
ITEM 16E.	PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS	64
ITEM 16F.	CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT	64
ITEM 16G.	CORPORATE GOVERNANCE	64
ITEM 16H.	MINE SAFETY DISCLOSURE	65
ITEM 16I.	DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	65
ITEM 16J.	INSIDER TRADING POLICIES	65
ITEM 16K.	CYBERSECURITY	65
PART III		66
ITEM 17.	FINANCIAL STATEMENTS	66
ITEM 18.	FINANCIAL STATEMENTS	66
ITEM 19.	EXHIBITS	67

INTRODUCTION

In this annual report on Form 20-F, unless the context otherwise requires, references to:

● “ADRs” are to the American Depositary Receipts that may evidence the ADSs (defined below);

● “ADSs” are to the American Depositary Shares, each of which represents one Common Share (defined below);

● “Common Shares” are to the common shares of Warrantee (defined below);

● “Exchange Act” are to the Securities Exchange Act of 1934, as amended;

● “Japanese yen,” “¥,” or “JPY” are to the legal currency of Japan;

● “Securities Act” are to the Securities Act of 1933, as amended;

● “U.S. dollars,” “$,” and “dollars” are to the legal currency of the United States;

● “U.S. GAAP” are to accounting principles generally accepted in the United States of America;

● “we,” “us,” “our,” “our Company,” or the “Company” are to Warrantee and its wholly-owned subsidiary, Warrantee Pte. Ltd., a Singapore company, as the case may be; and

● “Warrantee” are to Warrantee Inc., a joint-stock corporation organized under the laws of Japan.

This annual report on Form 20-F includes our audited consolidated financial statements for the fiscal years ended March 31, 2023, 2022, and 2021. Our functional currency and reporting currency is the Japanese yen. Convenience translations included in this annual report of Japanese yen into U.S. dollars have been made at the exchange rate of JPY132.75 = $1.00, which was the foreign exchange rate on March 31, 2023 as reported by the Board of Governors of the Federal Reserve System (the “U.S. Federal Reserve”) in its weekly release on April 3, 2023. Historical and current exchange rate information may be found at https://www.federalreserve.gov/releases/h10/20230403/.

On October 12, 2021, we effected a 1,500-for-one forward split of all issued and outstanding shares. All historical share amounts and share price information presented in this annual report have been proportionally adjusted to reflect the impact of the forward split.

On November 29, 2022, we effected a two-for-one forward split of all our issued and outstanding shares. All historical share amounts and share price information presented in this annual report have been proportionally adjusted to reflect the impact of the forward split.

We have made rounding adjustments to some of the figures included in this annual report. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them.

Non-GAAP Financial Measures

In addition to U.S. GAAP measures, we use Non-GAAP EBITDA and Non-GAAP EBITDA Margin as described under “Item 5. Operating and Financial Review and Prospects—Non-GAAP Financial Measures” in various places in this annual report. These financial measures are presented as supplemental disclosure and should not be considered in isolation of, as a substitute for, or superior to, the financial information prepared in accordance with U.S. GAAP, and should be read in conjunction with our consolidated financial statements and the notes thereto included elsewhere in this annual report. Non-GAAP EBITDA and Non-GAAP EBITDA Margin may differ from similarly titled measures presented by other companies.

1

Part I

Item 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not Applicable.

Item 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not Applicable.

Item 3. KEY INFORMATION

A. [Reserved]

B. Capitalization and Indebtedness

The following table sets forth our cash and cash equivalents, debt, and capitalization as of March 31, 2023:

• on an actual basis;

• on a pro forma basis to give effect to the issuance of 2,400,000 ADSs in our initial public offering (“IPO”) at the initial public offering price of $4.00 per ADS, after deducting underwriting discounts, non-accountable expense allowance, and offering expenses payable by us.

	As of March 31, 2023
(in thousands, except share amounts)	Actual ($)		Actual (¥)		Pro Forma(1) ($)		Pro Forma(1) (¥)
Cash and cash equivalents	$	13	¥	1,728	$	7,204	¥	956,305
Debt(2)	$	606	¥	80,384	$	606	¥	80,447
Shareholders’ equity:
Common shares – 40,000,000 shares authorized, 20,004,000 shares issued and outstanding as of March 31, 2023; 40,000,000 shares authorized, 22,404,000 shares issued and outstanding, pro forma		1,029		136,636		1,029		136,600
Additional paid-in capital		2,541		337,299		9,732		1,291,897
Retained earnings (accumulated deficit)		(3,545)		(470,605)		(3,545)		(470,599)
Accumulated other comprehensive income		5		688		5		664
Treasury stock, at cost		—		—		—		—
Total shareholders’ equity (deficit)		30		4,018		7,221		958,562
Total capitalization	$	636	¥	84,402	$	7,828	¥	1,039,008

(1) The number of common shares outstanding immediately after the IPO is based on the issuance of 2,400,000 ADSs in the IPO and does not include up to an aggregate of 2,073,000 common shares issuable upon the exercise of stock options outstanding as of March 31, 2023 at a weighted average exercise price of JPY55.20 per share.

(2) Our debt is comprised of loans borrowed from three Japanese financial institutions: SBI Estate Finance Co., Ltd., Resona Bank, Limited, and Japan Finance Corporation. See “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Outstanding Loans from Financial Institutions.”

C. Reasons for the Offer and Use of Proceeds

Not applicable.

2

D. Risk Factors

Risks Related to Our Company and Our Business

We have a limited operating history applying our trinity model to conduct campaigns for corporate sponsors upon which investors can evaluate our future prospects.

We started to apply our trinity model to conduct campaigns for corporate sponsors in 2018. We have a limited operating history, in this respect, upon which an evaluation of our business plan or performance and prospects can be made. The business and prospects of our Company must be considered in light of the potential problems, delays, uncertainties, and complications encountered in connection with a newly established business model. The risks include:

● the possibility that we will not be able to develop functional and scalable services, or that, although functional and scalable, our services will not be economical to market;

● that our competitors may market and provide superior or more effective services;

● that we are not able to upgrade and enhance our technologies to accommodate new needs and expanded service offerings;

● the limitations that applicable laws and regulations place on the types of insurance coverage we can offer and/or the maximum amounts of such insurance coverage; or

● the failure to comply with the applicable laws and regulations for our services as we conduct our current business and expand into new markets, including markets outside Japan.

To successfully introduce and market our services at a profit, we must establish goodwill and brand name recognition among the public so that potential customers of our corporate sponsors will agree to participate in the campaigns we conduct for our corporate sponsors to gather relevant customer data or market our corporate sponsors’ products and services. There are no assurances that we can successfully address these challenges and, if unsuccessful, we and our business, financial condition, and operating results could be materially and adversely affected.

We have operated on a leanly staffed, labor efficiency maximized model thus far. As we expect to expand our services and increase the number of campaigns we will conduct for our corporate sponsors, the future expense levels of our business will be based largely on estimates of planned operations and future revenue. It is difficult to accurately forecast future revenue because both our business and our business models are new to the market and are still developing. If our forecasts prove incorrect, the business, operating results, and financial condition of the Company may be materially and adversely affected. Moreover, we may be unable to adjust our spending in a timely manner to compensate for any unanticipated reduction in revenue. As a result, any significant reduction in planned or actual revenue may immediately and adversely affect our business, financial condition, and operating results.

3

We may need additional financing to execute our business plan and fund operations, which additional financing may not be available on reasonable terms or at all.

As of March 31, 2023, we had total assets of JPY266,560 thousand (approximately $2,008 thousand) and a working capital deficit of JPY156,354 thousand (approximately $1,178 thousand). As of the date of this annual report, we believe we need a minimum of JPY951,985 thousand (approximately $7,171 thousand) in order to fund our presently forecasted working capital requirements over the next 12 months. We believe that the net proceeds of our initial public offering will be sufficient to fund our presently forecasted business plan and scale-up operations over, at least, the 12 months following the date of this annual report. However, as a result of certain factors presently unforeseen, we may require additional capital over the next 12 months, the receipt of which there can be no assurance. In addition, unless we are able to successfully scale our operations and achieve meaningful cash flow from operations, we will require additional capital in order to fund the continued development of our trinity business model following the 12-month period after the date of this annual report. We will endeavor to acquire any additional required funds through various financing sources, including borrowings under our existing loans from financial institutions, the private and public sale of our equity and debt securities, and other third-party financings. In addition, we will consider alternatives to our current business plan that may enable us to achieve meaningful cash flow from operations with a smaller amount of capital. However, there can be no guaranty that such funds will be available on commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further pursue our business plan and we may be unable to continue operations.

We have incurred losses from operations during the fiscal years ended March 31, 2022 and 2021. Our ability to continue as a going concern depends on our being able to generate revenue significant enough to result in operating profitability.

We have a history of recurring losses, including a loss from operations of JPY89,842 thousand (approximately $677 thousand) and JPY27,754 thousand (approximately $209 thousand) for the fiscal years ended March 31, 2022 and 2021, respectively. This operating loss has resulted in an accumulated deficit of JPY470,605 thousand (approximately $3,545 thousand), JPY511,908 thousand (approximately $3,856 thousand), and JPY414,828 thousand (approximately $3,125 thousand) as of March 31, 2023, 2022, and 2021, respectively.

If we are unable to generate enough revenue to result in operating profitability in the future, there may be substantial doubt about our ability to continue as a going concern and, therefore, investors or other financing sources may be unwilling to provide funding to us on commercially reasonable terms, or at all. Further, if we are unable to continue as a going concern, we may have to discontinue operations and liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, which could cause our investors to lose all or part of their investment.

We face intense competition in the field of marketing, advertising, and market research services, which is likely to intensify further as existing competitors devote additional resources to, and new participants enter, the market. If we cannot compete successfully, we may be unable to increase our revenue or sustain profitability.

We face significant competition from providers of advertising, marketing, and market research services, including market data analysis service providers such as online sentiment and survey companies, product analytics companies, marketing analytics companies, point solution vendors offering usability research tools, research services firms, and panel aggregators, many of whom have significantly more resources than we do. Competition is based on, among other things, rates, availability of markets, quality of products and services provided and their effectiveness, audience coverage, and other factors. The development of new devices and technologies, as well as higher consumer engagement with other forms of digital media, such as online and mobile social networking, are increasing the number of media choices and formats available to audiences, resulting in audience fragmentation and increased competition. Our current and potential competitors may develop and market new technologies, products, or services that render our existing or future services less competitive or obsolete.

4

Most of our competitors have longer operating histories, larger customer bases, greater brand recognition and market penetration, higher margins on their products and services, and substantially greater financial, technological, and research and development resources and selling and marketing capabilities. As a result, they may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion, and sale of their products and services than we do, or sell their products and services at prices designed to win significant levels of market share. We may not be able to compete effectively against these organizations. In addition, for cost-saving or other reasons, our customers, which are often large consumer goods manufacturers, may decide to conduct directed marketing or market data research in-house. Increased competition and cost-saving initiatives on the part of corporate sponsors are likely to result in pricing pressures, which could harm our sales, profitability, or ability to gain market share.

We had a limited number of customers accounting for a substantial portion of our revenue in fiscal years ended March 31, 2023, 2022, and 2021, respectively. We have not generated revenue from any customer on a recurring basis, and our efforts in expanding our customer base, increasing average contract value, and generating recurring revenue may not be successful, which makes us vulnerable to a near-term severe financial loss.

We have derived a substantial portion of our revenue from a limited number of customers. For the fiscal year ended March 31, 2021, more than 80% of the consolidated revenue was derived from two customers. In the fiscal year ended March 31, 2022, we received revenue from one corporate sponsor, Paygene Co., Ltd. (“Paygene”), a sales agency for medical devices. In May 2022, we acquired three new corporate sponsors, Beauken Co., Ltd. (“Beauken”), Connect Plus Co., Ltd. (“Connect Plus”), and Y’s Inc. We completed the marketing campaigns for Beauken and Connect Plus in May 2023 and completed the marketing campaign for Y’s Inc. in November 2023. There are inherent risks whenever a large percentage of total revenue is concentrated with a limited number of customers. We have not yet established a recurring customer base that provides us with an ongoing sustainable source of revenue sufficient to cover our operating expenses, which makes us vulnerable to the risk of a near-term severe financial impact if we are unable to secure new revenue generating customer contracts. We will need to develop new campaigns and engage new customers to maintain or increase our service revenue, and there is no assurance that we can do so at a cost-effective manner. In addition, our customers have been concentrated in certain market sectors, such as durables, non-prescription medical treatments and devices, and supplements. If our customers or prospective customers reduce their marketing expenditure because they experience declining or delayed revenue due to market, economic, or competitive conditions, or for other reasons, we could be pressured to reduce the prices we charge for our services or we may not be able to efficiently expand our customer base, which could have an adverse effect on our profit margins and financial position, and could negatively affect our revenue and results of operations and/or trading price of the ADSs.

As our sponsored marketing or market research services have been primarily provided on a campaign basis, revenue from our customers has fluctuated based on the number of the campaigns we may be engaged to conduct for corporate sponsors and the average contract value, which represents the average sponsorship amount from campaigns, during a reporting period, which may be affected by our corporate sponsors’ needs, market conditions, or other factors, some of which may be outside of our control. Our bargaining leverage is often limited with our large manufacturer customers, and we may not be able to obtain the pricing and other terms favorable to us when entering into service contracts with them.

We have not generated recurring revenue from any customer after a campaign designed for such customer has been completed. While we plan to increase our services and revenue by developing and conducting more campaigns for new customers, expanding our service to customers in various industries and markets, increasing campaigns in the market sectors where sponsors are willing to pay a higher fee, and leveraging the relationships we established with our past customers to market additional services to them, there is no guarantee that such efforts to maintain and increase our revenue will be successful or that we can grow our business and revenue cost effectively.

We are not a licensed insurer and depend on third-party insurance companies to provide product insurance or other insurance necessary for our campaigns. Although we have been able to obtain insurance policies used in our past campaigns from multiple providers on competitive terms, there is no guarantee that we may not become dependent on one or a few insurance companies for any special policies needed for our future campaigns.

We are not a licensed insurer and do not provide any insurance that requires a regulatory license. In order to avoid the requirement to obtain an insurance license in Japan, we typically offer to participant users insurance coverage of no more than JPY100,000 (approximately $753). We have used insurance companies to provide certain product insurance and medical insurance policies to cover our business or the participant users in our campaigns. Although we have been able to obtain insurance policies from multiple sources on competitive terms in the past, there may be only a limited number of insurance companies providing the types of insurance policies we may need to use in our future campaigns. In such cases, we may have only limited bargain power and may not be able to obtain our needed insurance policies at an acceptable price, which could limit our ability to increase our profit margin in those campaigns.

5

If we fail to retain our Chief Executive Officer or attract and retain additional qualified personnel, we may not be able to pursue our growth strategy.

Our future success will depend upon the continued service of our Chief Executive Officer, Mr. Yusuke Shono. We have leveraged his relationships in our business development activities and in obtaining financing for our operations. See “—As a controlled company, we have relied on our Chief Executive Officer to provide guarantees for our corporate loans from financial institutions and for the lease of our corporate headquarters. We have also historically received short-term loans from our Chief Executive Officer and his wholly owned companies to fund our working capital needs. We may not be able to find alternative financing sources on terms equal to or better than those obtained from our Chief Executive Officer, which could adversely impact our ability to secure necessary financing in the future.” The loss of his services could have a material adverse effect on our business, operations, revenue, or prospects. We do not currently maintain key man life insurance on the life of our Chief Executive Officer. In order to implement our growth plans and continue to grow our business, we also need to recruit additional qualified personnel, such as marketing and sales personnel. If we are not able to recruit such qualified personnel as and when needed, or if the labor costs for such additional personnel exceed the additional revenue we can generate, our growth prospects and profit margins will be harmed.

Our success greatly depends upon our ability to generate and maintain goodwill with the public so that potential customers of our corporate sponsors will be willing to participate in the campaigns we design for our corporate sponsors. If we or our corporate sponsors fail to provide satisfactory products and services to our participant users, our brand image may be tarnished and our financial results and prospects for growth may be adversely affected, and we could also incur liability for recommending our sponsors’ products.

Our ability to provide our marketing campaign services to our corporate sponsors greatly depends on our ability to attract an adequate number of users who are within our corporate sponsors’ target customer base to provide data to us or participate in trials or meetings facilitating the sale of our corporate sponsors’ products or services. We sometimes access these users through third-party partners, such as clinics, for our corporate sponsors in the commercial healthcare vertical arena. While most of the corporate sponsors we work with are large reputable manufacturers in Japan, we cannot guarantee that any products and services they provide to the users who participate in our campaigns are free of defect or error or will meet the participant users’ satisfaction each time. In our past campaign for a supplement supplier, we recommended our sponsor’s preventative care supplements to participant users whose gene test results suggested they may need certain micronutrients. We may also make recommendations of our sponsors’ products in future campaigns we design and conduct for other corporate sponsors. We could incur liability in these campaigns and legal costs in defending litigation if our sponsors’ products cause any negative effect on the participant users.

We have developed and offered the Warrantee app that can be installed and used on a mobile phone to streamline the process for users who participate in certain of our campaigns in the durables vertical to provide data to us and to claim product repair service or replacement. Enhancements to our app may not be introduced in a timely or cost-effective manner, may contain errors or defects, and may have interoperability difficulties with users’ devices. If our participant users believe that utilizing our app to participate in our campaigns or claim product repair service or replacement would be overly time-consuming, confusing, or technically challenging, then our ability to use the app to facilitate our campaigns would be substantially harmed.

If we are not able to provide a positive experience and create value to our participant users, we may not be able to establish goodwill among users to attract an adequate number of users targeted by our corporate sponsors to participate in our campaigns or to promote sales of our sponsors’ products in such campaigns, and thus limiting our ability to market our services to corporate sponsors and expand our revenue.

6

We rely on a combination of patent, trademark, trade secret, and other intellectual property rights and measures to protect our intellectual property. Our patents may expire and may not be extended, our patent applications may not be granted, and our patent rights may be contested, circumvented, invalidated, or limited in scope. As a result, our patent rights may not protect us effectively. In particular, we may not be able to prevent others from developing and deploying competing technologies, which could have a material and adverse effect on our business, financial condition, results of operations, and prospects.

To establish and protect our proprietary rights, we rely on a combination of patents, trademarks, confidentiality policies and procedures, non-disclosure agreements with third parties, employee non-disclosure agreements, and other contractual and implicit rights worldwide. As of the date of this annual report, we have three registered patents for the system underlying our business model for us to serve as an intermediary between sponsors, insurance companies, and users and in such role, providing insurance for the users upon terms agreed by the sponsors, and nine registered trademarks and other names and logos used by our Company as trademarks with the Japan Patent Office. Such patents and trademarks are not registered in any other jurisdiction except that Warrantee has been registered in the European Union, the United Kingdom, and Singapore. The success of our business strategy depends on our continued ability to use our existing intellectual property to increase brand awareness and develop our branded services. If our efforts to protect our intellectual property are not adequate or if any third-party misappropriates or infringes on our intellectual property, whether in print, on the Internet, or through other media, the value of our brands may be harmed, which could have a material adverse effect on our business, including the failure of our brands and branded services to achieve and maintain market acceptance. There can be no assurance that all of the steps we have taken to protect our intellectual property in Japan or outside Japan in relevant foreign countries will be adequate. In addition, in light of our intention to expand internationally, the laws of some foreign countries do not protect intellectual property rights to the same extent as do the laws of Japan. If any of our patents, trademarks, trade secrets, or other intellectual property are infringed, our business, financial condition, and results of operations could be materially adversely affected.

In addition, third parties may assert infringement or misappropriation claims against us, or assert claims that our rights in our trademarks, and other intellectual property assets are invalid or unenforceable. Any such claims could have a material adverse effect on us if such claims were to be decided against us. If our rights in any intellectual property were invalidated or deemed unenforceable, it could permit competing uses of intellectual property which, in turn, could lead to a decline in business and other revenue. If the intellectual property became subject to third-party infringement, misappropriation, or other claims, and such claims were decided against us, we may be forced to pay damages, be required to develop or adopt non-infringing intellectual property, or be obligated to acquire a license to the intellectual property that is the subject of the asserted claim. There could be significant expenses associated with the defense of any infringement, misappropriation, or other third-party claims.

We rely on information technology, and any material failure, weakness, interruption, or breach of security could prevent us from effectively operating our business.

We rely significantly on information systems, including the collection of participant user data and processing of product insurance claims on our Warrantee app. Our ability to efficiently and effectively manage our business depends significantly on the reliability and capacity of the information systems. Failures of these systems to operate effectively, maintenance problems, or a breach in security of these systems could result in delays in user service and reduce efficiency in our operations.

We collect, store, process, and use personal information and other user data, which subjects us to governmental regulation and other legal obligations related to privacy, information security, and data protection, and any security breaches or our actual or perceived failure to comply with such legal obligations could harm our business.

We collect, store, process, and use personal information and other data of users participating in our campaigns via electronic means or manually, and we may use third parties that are not directly under our control to do so. In our campaigns we may gather participant users’ personal data, including, among other information, names, addresses, phone numbers, email addresses, payment account information, height, weight, and information such as heart rates, sleeping patterns, and activity patterns. Due to the types of the personal information and data we collect and the nature of our services, our data safety measures and the security features of our app and information systems are critical. If our security measures, some of which we manage using third-party solutions, are breached or fail, unauthorized persons may be able to obtain access to or acquire our participant users’ data. Furthermore, if third-party service providers that host participant users’ data on our behalf experience security breaches or violate applicable laws, agreements, or their policies, such events may also put our participant users’ information at risk and could in turn have an adverse effect on our business. Additionally, if we or any third party, including third-party service providers, were to experience a breach of systems compromising our participant users’ personal data, our brand and reputation could be adversely affected, use of our services could decrease, and we could be exposed to a risk of loss, litigation, and regulatory proceedings.

7

Depending on the nature of the information compromised, in the event of a data breach or other unauthorized access to or acquisition of our participant users’ data, we may also have obligations to notify participant users about the incident and we may need to provide some form of remedy, such as a subscription to a credit monitoring service, for the individuals affected by the incident. A growing number of legislative and regulatory bodies have adopted user notification requirements in the event of unauthorized access to or acquisition of certain types of personal data. Such breach notification laws continue to evolve in Japan. Complying with these obligations could cause us to incur substantial costs and could increase negative publicity surrounding any incident that compromises participant users’ data. Given the limited amount of user data we have collected, we do not currently carry insurance coverage that is designed to address aspects of cyber risks, and we will have to pay for all losses or all types of claims that may arise in the event we experience a security breach. In addition, any such security breaches may result in negative publicity, adversely affect our brand, decrease demand for our services, and adversely affect our operating results and financial condition.

Failure to comply with relevant laws and regulations, including those relating to the processing, safekeeping, and use of personal data and the insurance licensing requirements could harm our business, financial condition, or results of operations, and any change in laws and regulations may adversely affect our ability to grow our business.

We are subject to various laws and government regulations, including those relating to the processing, safekeeping, and use of personal data and the Insurance Business Act of Japan (Act No. 105 of 1995, as amended) (the “Insurance Business Act”), in respect of each of which the relevant regulators in Japan have a broad discretion to interpret the relevant laws and regulations. Although we have implemented policies and procedures and business models designed to comply with these laws, there can be no assurance that our employees, contractors, agents, or other third parties will not take actions in violation of our policies or applicable law. Any such violations or suspected violations could subject us to civil or criminal penalties, including substantial fines and significant investigation costs, and could also materially damage our reputation, brands, international expansion efforts, and growth prospects, business, financial condition, and results of operations. Publicity relating to any noncompliance or alleged noncompliance as well as interpretation of such laws and regulations by the relevant regulators could also harm our reputation and adversely affect our business, financial condition, or results of operations. Any change in the laws and regulations as well as interpretation of such laws and regulations by the relevant regulators applicable to us may also adversely affect our ability to grow our business, including by greatly increasing the costs for ensuring compliance with the new laws and regulations.

In addition to the expenses and risk of regulatory compliance, certain government regulations may inhibit our ability to develop and pursue certain corporate sponsorships. For example, we are subject to Japan’s insurance regulations. In our campaigns, if we enter into an insurance contract with a licensed insurer where the participant users are insured and the participant users directly receive insurance proceeds from the licensed insurer, we are not subject to any coverage amount limitation since our activities would not be regarded as “insurance business.” However, if we enter into an insurance contract with the licensed insurer where we are insured and we receive the insurance proceeds from the licensed insurer (which are distributed to the participant users from us), we may be required to obtain an insurance business license, since our activities would be regarded as “insurance business” pursuant to the Insurance Business Act, as interpreted by the Financial Services Agency of Japan. In such case, we would incur the resulting costs and burdens of the additional regulatory compliance, unless we limit the maximum amount of insurance coverage we may provide to a participant user in such campaigns to be no more than JPY100,000 (approximately $753). In addition, as the Financial Services Agency of Japan has broad discretion as to the interpretation of the Insurance Business Act, it may amend the detailed requirements under the interpretation (including the amount of the minimum coverage) in the future. Such amendment may require us to adjust our business model, which may harm our revenue prospectus or increase our compliance costs.

All of our revenue has been generated in Japan, but an increase of our international presence could expose us to fluctuations in foreign currency exchange rates, or a change in monetary policy may harm our financial results.

Our functional currency and reporting currency is the Japanese yen. All of our revenue has been generated in Japan, but an increase in our international presence could expose us to fluctuations in foreign currency exchange rates. We are subject to the effects of exchange rate fluctuations with respect to any of these currencies which, among other factors, may be influenced by governmental policies and domestic and international economic and political developments. If our non-Japanese revenue increases substantially in the future, any significant change in the value of the currencies of the countries in which we do business against the Japanese yen could adversely affect our financial condition and results of operations due to translational and transactional differences in exchange rates.

8

Moreover, we do not take actions to manage our foreign currency exposure, such as entering into hedging transactions.We cannot predict the effects of exchange rate fluctuations upon our future operating results because of the number of currencies involved, the amount of our revenue that will be generated in other countries, the variability of currency exposures, and the potential volatility of currency exchange rates.

Our long-term success depends, in part, on our ability to expand our services to customers located outside of Japan and our future expansion of our international operations exposes us to risks that could have a material adverse effect on our business, operating results, and financial condition.

We have not provided any service or generated any revenue from customers located outside Japan but expect to do so as part of our growth strategy. We intend to focus our international expansion initially on other Asian countries, particularly Taiwan and Singapore. Our ability to manage our business and conduct our operations internationally requires considerable management attention and resources and is subject to the particular challenges of supporting a business in an environment of multiple cultures, customs, legal systems, regulatory systems, and commercial infrastructures. International expansion will require us to invest significant funds and other resources. Our operations in international markets may not develop at a rate that supports our level of investment. Expanding internationally may subject us to new risks that we have not faced before or increase risks that we currently face, including risks associated with:

● recruiting and retaining talented and capable employees in foreign countries;

● increased exposure to public health issues, such as the COVID-19 pandemic;

● promoting our business models to customers and users from different cultures, which may require us to adapt to sales and service practices necessary to effectively serve the local market;

● compliance with the laws of numerous taxing jurisdictions, both foreign and domestic, in which we conduct business, potential double taxation of our international earnings, and potentially adverse tax consequences due to changes in applicable Japanese and foreign tax laws;

● compliance with privacy, data protection, encryption, and information security laws, such as the Singapore Personal Data Protection Act of 2012;

● credit risk and higher levels of payment fraud;

● weaker intellectual property protection in some countries;

● compliance with anti-bribery laws;

● currency exchange rate fluctuations;

● tariffs, export, and import restrictions, restrictions on foreign investments, sanctions, and other trade barriers or protection measures;

● foreign exchange controls that might prevent us from repatriating cash earned outside Japan;

● economic or political instability in countries where we may operate;

● increased costs to establish and maintain effective controls at foreign locations; and

● overall higher costs of doing business internationally.

9

Our international operations may be subject to foreign governmental laws and regulations, which vary substantially from country to country. Further, we may be unable to keep up to date with changes in government laws and regulations as they change over time. Failure to comply with these laws and regulations could result in adverse effects to our business. Although we have implemented policies and procedures designed to ensure compliance with these laws and regulations and our internal policies, there can be no assurance that all of our employees, contractors, partners, and agents will comply with these laws and regulations or our internal policies. Violations of laws or regulations by our employees, contractors, partners, or agents could result in litigation, regulatory action, costs of investigation, delays in revenue recognition, delays in financial reporting, financial reporting misstatements, fines, or penalties, any of which could have an adverse effect on our business, operating results, and financial condition.

As a controlled company, we have relied on our Chief Executive Officer to provide guarantees for our corporate loans from financial institutions and for the lease of our corporate headquarters. We have also historically received short-term loans from our Chief Executive Officer and his wholly owned companies to fund our working capital needs. We may not be able to find alternative financing sources on terms equal to or better than those obtained from our Chief Executive Officer, which could adversely impact our ability to secure necessary financing in the future.

As a controlled company, we have relied on our Chief Executive Officer’s business relationships and financial support in our operations. Mr. Shono is the guarantor of all our outstanding corporate loans from financial institutions and our lease for our corporate headquarters. We have also historically received short-term loans from our Chief Executive Officer and his wholly owned companies to fund our working capital needs. See “Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Transactions with Our Chief Executive Officer and His Wholly-Owned Companies.” If Mr. Shono’s ownership interest in us declines significantly in the future, we may not be able to receive the same level of financial support from Mr. Shono. See “—Our Chief Executive Officer has entered into an agreement with another shareholder that may obligate our Chief Executive Officer to effect a transaction that may be unfavorable to our shareholders and our Company.” Although we expect Mr. Shono to continue to support our growth and development through his role with our Company, Mr. Shono does not have any contractual obligation to provide any operational, financial, or other support to us other than those under the existing guarantees. Our inability to secure additional financing in the future on equal or better terms could be limited and, in such event, could adversely affect our business and operations.

Our Chief Executive Officer has entered into an agreement with another shareholder that may obligate our Chief Executive Officer to effect a transaction that may be unfavorable to our shareholders and our Company.

A share pledge agreement (the “Share Pledge Agreement”) was executed on February 19, 2020, among Hack Osaka Investment Limited Partnership (“Hack”), our Chief Executive Officer, Mr. Shono, and ZENY Inc. (“ZENY”), a company wholly owned and controlled by Mr. Shono, in connection with a pledge to Hack of an aggregate of 1,737,000 Common Shares held by ZENY and Mr. Shono. The pledge was established as security for the joint and several liability of ZENY and Mr. Shono to pay for the repurchase of the Common Shares acquired by Hack under a share purchase agreement executed among Hack, ZENY, and Mr. Shono on March 29, 2019. The Share Pledge Agreement was supplemented on March 31, 2020 and further amended on March 31, 2022. ZENY was dissolved and liquidated in 2021 and is no longer a party to the Share Pledge Agreement, as supplemented and amended.

Under the terms of the Share Pledge Agreement, as supplemented and amended, the outstanding balance due to Hack as of March 31, 2022 was confirmed as JPY193,390,450 (approximately $1,456,802) as the aggregate principal balance. To release the pledge, Mr. Shono is required, to pay (a) by March 31, 2023, the outstanding aggregate principal balance of JPY193,390,450 (approximately $1,456,802) in a lump sum payment, and (b) monthly installments (equal monthly installments of JPY2,360,000 (approximately $17,778) from April 30, 2022 to February 28, 2023, and JPY2,275,005 (approximately $17,138) on March 31, 2023. If Mr. Shono fails to make any payment under (a) or (b), he is required to use his best efforts to assist Hack in selling the pledged shares to third parties by means of a public offering of the pledged shares or other means of acquisition. Pursuant to the provisions of the agreement, the aforementioned share pledge has been registered on the shareholder registry of the Company. Mr. Shono and Hack are currently in the process of amending the Share Pledge Agreement to extend the outstanding balance due date to March 31, 2024. See “Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Share Pledge Agreement.”

We have no control over whether Mr. Shono may repay the lump sum payment to Hack on a timely basis. If Mr. Shono fails to make the payment and the pledged shares are required to be sold in a public offering or by other means at a price lower than the prevailing market price, the consequences of such transaction may not be favorable to our other shareholders and may adversely affect the market price of our shares.

10

Our articles of incorporation exculpate our directors and corporate auditors from certain liability to us or our shareholders.

Our articles of incorporation include limitation of liability provisions, pursuant to which we can exempt, by resolution of our board of directors, our directors and corporate auditors from liabilities arising in connection with any failure to execute their respective duties in good faith or due to simple negligence (excluding gross negligence and willful misconduct), within the limits stipulated by applicable Japanese laws and regulations. We have also entered into a limitation of liability agreement with each of our directors and corporate auditors, except our Chief Executive Officer and Chief Financial Officer. With certain exceptions, these agreements provide for indemnification for related expenses, including attorneys’ fees, judgments, fines, and settlement amounts incurred by any of these directors and corporate auditors in connection with any action, proceeding, or investigation in those capacities. We have not entered into any limitation of liability agreement with our Chief Executive Officer or Chief Financial Officer, as Article 427 of the Companies Act of Japan (the “Companies Act”) does not allow companies to enter into limitation of liability agreements with executive directors (gyomu-shikko-torishimariyaku).

The limitation on liability provided by our articles of incorporation and the limitation of liability agreements with our non-executive directors and corporate auditors may reduce the likelihood of derivative litigation against directors and corporate auditors and may discourage or deter our shareholders from suing them based upon breaches of their duties to us. Successful claims for indemnification by our non-executive directors and corporate auditors may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Risks Relating to Our Common Shares and the Trading Market

The sale or availability for sale of substantial amounts of the ADSs could adversely affect their market price.

Sales of substantial amounts of the ADSs in the public market, or the perception that these sales could occur, could adversely affect the market price of the ADSs and could materially impair our ability to raise capital through equity offerings in the future. As of the date of this annual report, 22,404,000 of our Common Shares are issued and outstanding. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder or the availability of these securities for future sale will have on the market price of the ADSs.

Our board of directors may determine the number of Common Shares to be issued as equity compensation from time to time, and the future issuance of additional Common Shares in connection with such issuances or in other transactions may adversely affect the market of the ADSs.

We from time to time may grant equity-based compensation in the form of stock options or other equity incentives to our directors, internal corporate auditors, employees, and external consultants. The number of Common Shares to be issued for such purpose may be determined by our board of directors without any further action or approval of our shareholders, subject to certain exceptions. As of March 31, 2023, 2,073,000 Common Shares were issuable upon exercise of outstanding stock options at a weighted average exercise price of JPY55.20 per share. If and when these options are exercised for our Common Shares, the number of Common Shares outstanding will increase. Such an increase in our outstanding securities, and any sales of such shares, could have a material adverse effect on the market for the ADSs, and the market price of the ADSs.

We currently plan to continue granting stock options and other incentives so that we can continue to secure talented personnel in the future. Any Common Shares to be issued as equity-based compensation, the exercise of outstanding stock options, or in other transactions, including future financing transactions, would dilute the percentage ownership held by our current shareholders.

If securities or industry analysts do not publish research or reports about our business, or if they publish a negative report regarding the ADSs, the price of the ADSs and trading volume could decline.

Any trading market for the ADSs may depend in part on the research and reports that industry or securities analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade us, the price of the ADSs would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause the price of the ADSs and the trading volume to decline.

11

The market price of the ADSs may be volatile or may decline regardless of our operating performance.

From the listing of the ADSs on Nasdaq on July 25, 2023 to the date of this annual report, the closing price of the ADSs has ranged from $0.26 to $4.30 per ADS. The trading price of the ADSs is likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry factors, including the performance and fluctuation of the market prices of other companies with business operations located mainly in Japan that have listed their securities in the United States.

In addition to market and industry factors, the price and trading volume for the ADSs may be highly volatile for factors specific to our own operations, including the following:

● actual or anticipated fluctuations in our revenue and other operating results;

● the financial projections we may provide to the public, any changes in these projections, or our failure to meet these projections;

● actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our Company, or our failure to meet these estimates or the expectations of investors;

● announcements by us or our competitors of significant services or features, technical innovations, acquisitions, strategic partnerships, joint ventures, or capital commitments;

● price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;

● the trading volume of the ADSs on Nasdaq;

● sales of the ADSs or Common Shares by us, our executive officers and directors, or our shareholders or the anticipation that such sales may occur in the future;

● lawsuits threatened or filed against us; and

● other events or factors, including those resulting from war or incidents of terrorism, or responses to these events.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. Stock prices of many companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business.

12

We have identified deficiencies that could aggregate to a material weakness in our internal control over financial reporting. If our remediation of these deficiencies is not effective, or if we identify additional material weaknesses or control deficiencies in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our Company.

We used to be a private company with limited accounting personnel and other resources with which to address our internal controls and procedures. Our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. However, in preparing our consolidated financial statements as of and for the fiscal year ended March 31, 2023, we have identified certain deficiencies resulting from multiple audit adjustments that could aggregate to a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. A material weakness could result in a misstatement of account balances or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected on a timely basis. Our Chief Executive Officer and Chief Financial Officer concluded that our internal controls over financial reporting were deficient primarily due to (i) a lack of manpower in our accounting department, which may reduce the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP and (ii) failure to timely file our annual reports on Form 20-F for the fiscal years ended March 31, 2023 and 2022. The primary deficiencies related to audit adjustments are due to this shortage of staff within our internal accounting department, in addition to the burdens of reporting under U.S. GAAP. As of March 31, 2023, we did not have an effective internal control in place to monitor the progress of all aspects of our SEC reporting and disclosure requirements to timely identify delays, resulting in us being unable to timely meet our reporting and disclosure requirements with the SEC. We are re-evaluating our internal procedures to reduce delays in our future periodic and current reports and plan to adopt certain remedial measures to this effect, including, but not limited to, adopting formal internal policies and guidance on the monitoring of our SEC reporting and disclosure requirements and holding regular training sessions for our internal accounting staff related to SEC reporting and U.S. GAAP requirements. However, the implementation of these measures may not fully address the material weakness in our internal control over financial reporting. Our failure to correct the material weakness or our failure to discover and address any other material weaknesses or control deficiencies could result in inaccuracies in our financial statements and could also impair our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result, our business, financial condition, results of operations, and prospects, as well as the trading price of the ADSs, may be materially and adversely affected. Moreover, ineffective internal control over financial reporting significantly hinders our ability to prevent fraud.

In addition, once we cease to be an “emerging growth company,” as such term is defined in the Jumpstart Our Business Startups Act of 2012, or the “JOBS Act,” in April 2029, our independent registered public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated, or reviewed, or if it interprets the relevant requirements differently from us. In addition, as a public company, our reporting obligations may place a significant strain on our management, operational, and financial resources and systems for the foreseeable future. We may be unable to complete our evaluation testing and any required remediation in a timely manner.

The requirements of being a public company may strain our resources and divert management’s attention.

As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations. Despite recent reforms made possible by the JOBS Act, compliance with these rules and regulations has nonetheless increased and will continue to increase our legal, accounting, and financial compliance costs and investor relations and public relations costs, make some activities more difficult, time-consuming, or costly, and increase demand on our systems and resources, particularly after we are no longer an “emerging growth company.” The Exchange Act requires, among other things, that we file annual reports and reports of foreign private issuer with respect to our business and operating results as well as proxy statements.

As a result of disclosure of information in the Form 20-F and in filings required of a public company, our business and financial condition are more visible, which we believe may result in an increased likelihood of threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and adversely affect our business, brand and reputation, and results of operations.

13

Being a public company and these new rules and regulations make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors and executive officers.

We were not in compliance with our periodic reporting obligation under the Exchange Act by failing to file our annual reports on Form 20-F for the fiscal years ended March 31, 2023 and 2022 on a timely basis. In the event that we become delinquent with our SEC reporting obligation again, we may not be able to provide up-to-date disclosure to the public market, the ADSs may be considered highly risky or worthless, and the ADSs may be delisted from Nasdaq.

We have become subject to periodic reporting obligations under the Exchange Act since June 30, 2022, when our registration statement on Form F-1, as amended (File No. 333-265511), was declared effective by the SEC. As a reporting company and a foreign private issuer, the prescribed deadline for us to file our annual report on Form 20-F for the fiscal year ended March 31, 2023 was July 31, 2023, which annual report we did not file until January 31, 2024; the prescribed deadline for us to file our annual report on Form 20-F for the fiscal year ended March 31, 2022 was July 31, 2022, which annual report we did not file until June 16, 2023.

Such failure to satisfy our periodic reporting obligation represents a deficiency in our internal controls over financial reporting. See also “—We have identified deficiencies that could aggregate to a material weakness in our internal control over financial reporting. If our remediation of these deficiencies is not effective, or if we identify additional material weaknesses or control deficiencies in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which may adversely affect investor confidence in our Company.”

Further, any failure by us to comply with our SEC reporting obligation in the future may materially and adversely affect investors’ investment in the ADSs. For instance, in the event that we fail to timely file any periodic reports or current reports, we may not be able to provide up-to-date disclosure to the public market, and the ADSs may be considered highly risky or even worthless as a result. Additionally, under Nasdaq Listing Rule 5250(c)(1), a foreign private issuer listed on Nasdaq is required to timely file all required periodic financial reports with the SEC. See “—We are currently not in compliance with the continued listing requirements of Nasdaq. As a result, the ADSs may be delisted, which could negatively impact the price of the ADSs and your ability to sell them.” In the event that the ADSs are delisted from Nasdaq, the value and liquidity of investors’ investment in the ADSs will be materially and adversely affected. Failure to comply with reporting obligation will also render us ineligible to use Form F-3 for registration of securities offered by us.

Our Chief Executive Officer owns a majority of our Common Shares and can exercise significant influence on the Company’s activities, thereby limiting a shareholder’s ability to influence our business and affairs.

Yusuke Shono, our Chief Executive Officer and a director, beneficially owns approximately 76.0% of the outstanding Common Shares. Consequently, Mr. Shono is able to control key corporate decisions, thus limiting the ability of the holders of the ADSs to influence matters affecting our Company. As a shareholder, Mr. Shono may be able to influence the outcome of matters submitted to shareholders for approval, including amendments of our organizational documents, issuance of additional Common Shares, approval of any merger, sale of assets, or other major corporate transactions. This may prevent or discourage unsolicited acquisition proposals or offers for our Common Shares or ADSs that you may feel are in your best interest as one of our shareholders. Circumstances may occur in which the interests of our Chief Executive Officer could be in conflict with your interests or the interests of other shareholders. Accordingly, a shareholder’s ability to fully influence our business and affairs through voting its Common Shares may be limited.

We plan to adopt a related party transaction policy, which will require that all related party transactions that meet the disclosure requirements set forth in Item 404 of Regulation S-K under the Securities Act be disclosed to and approved by all our board of corporate auditors. We expect that, with the adoption of the related party transaction policy and a more active role to be played by our board of auditors in reviewing and monitoring related party transactions, proper controls will be put in place to safeguard the Company’s interests in any related party transactions. However, given the influence of Mr. Shono on our corporate matters, including his ability to control the election of our directors due to his controlling stake in the Company, there is no guarantee that our future related party transactions involving Mr. Shono will be carried out on an arms’ length basis or on terms that are most favorable to us and our shareholders.

14

As a foreign private issuer, we have followed home country practice even though we are considered a “controlled company” under Nasdaq corporate governance rules, which could adversely affect our public shareholders.

Our largest shareholder, Mr. Yusuke Shono, owns more than a majority of the voting power of our outstanding Common Shares. Under the Nasdaq corporate governance rules, a company of which more than 50% of the voting power is held by an individual, group, or another company is a “controlled company” and may elect not to comply with certain Nasdaq corporate governance standards, including the requirements that:

● a majority of its board of directors consist of independent directors;

● its director nominations be made, or recommended to the full board of directors, by its independent directors or by a nominations committee that is comprised entirely of independent directors and that it adopts a written charter or board resolution addressing the nominations process; and

● it has a compensation committee that is composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities.

As a foreign private issuer, however, Nasdaq corporate governance rules allow us to follow corporate governance practice in our home country, Japan, with respect to appointments to our board of directors and committees. We have followed home country practice as permitted by Nasdaq rather than relying on the “controlled company” exception to the corporate governance rules. See “—Because we are a foreign private issuer and have taken advantage of exemptions from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.” Accordingly, you would not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq.

We do not intend to pay dividends on our Common Shares for the foreseeable future.

We currently intend to retain most, if not all, of our available funds and any future earnings to fund the operation, development, and growth of our business and, as a result, we do not expect to declare or pay any dividends in the foreseeable future. Therefore, you should not rely on an investment in the ADSs as a source for any future dividend income. Accordingly, the return on your investment in the ADSs will likely depend entirely upon any future price appreciation of the ADSs. There is no guarantee that the ADSs will appreciate in value or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment in the ADSs and you may even lose your entire investment in the ADSs.

Rights of shareholders under Japanese law may be different from rights of shareholders in other jurisdictions.

Our articles of incorporation and the Companies Act govern our corporate affairs. Legal principles relating to matters such as the validity of corporate procedures, directors’ and executive officers’ fiduciary duties, and obligations and shareholders’ rights under Japanese law may be different from, or less clearly defined than, those that would apply to a company incorporated in any other jurisdiction. Shareholders’ rights under Japanese law may not be as extensive as shareholders’ rights under the law of other countries. For example, under the Companies Act, only holders of 3% or more of our total voting rights or our outstanding shares are entitled to examine our accounting books and records. Furthermore, there is a degree of uncertainty as to what duties the directors of a Japanese company may have in response to an unsolicited takeover bid, and such uncertainty may be more pronounced than that in other jurisdictions.

As holders of ADSs, you may have fewer rights than holders of our Common Shares and must act through the depositary to exercise those rights.

The rights of shareholders under Japanese law to take actions, including voting their shares, receiving dividends and distributions, bringing derivative actions, examining our accounting books and records, and exercising appraisal rights, are available only to shareholders of record. ADS holders are not shareholders of record. The depositary, through its custodian agents, is the record holder of our Common Shares underlying the ADSs. ADS holders will not be able to bring a derivative action, examine our accounting books and records, or exercise appraisal rights through the depositary.

15

Holders of ADSs may exercise their voting rights only in accordance with the provisions of the deposit agreement. If we instruct the depositary to ask for your voting instructions, upon receipt of voting instructions from the ADS holders in the manner set forth in the deposit agreement, the depositary will make efforts to vote the Common Shares underlying the ADSs in accordance with the instructions of the ADS holders. The depositary and its agents may not be able to send voting instructions to ADS holders or carry out their voting instructions in a timely manner. Furthermore, the depositary and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast, or for the effect of any such vote. As a result, holders of ADSs may not be able to exercise their right to vote.

The right of holders of ADSs to participate in any future rights offerings may be limited, which may cause dilution to their holdings and holders of ADSs may not receive cash dividends if it is impractical to make them available to them.

We may, from time to time, distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make any such rights available to the ADS holders in the United States unless we register such rights and the securities to which such rights relate under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit agreement provides that the depositary bank will not make rights available to ADS holders unless the distribution to ADS holders of both the rights and any related securities are either registered under the Securities Act or exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act.

The depositary has agreed to pay ADS holders the cash dividends or other distributions it or the custodian receives on our Common Shares or other deposited securities after deducting its fees and expenses. However, because of these deductions, ADS holders may receive less, on a per share basis with respect to their ADSs than they would if they owned the number of shares or other deposited securities directly. ADSs holders will receive these distributions in proportion to the number of Common Shares the ADSs represent. In addition, the depositary may, at its discretion, decide that it is not lawful or practical to make a distribution available to any holders of ADSs. For example, the depositary may determine that it is not practicable to distribute certain property through the mail, or that the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may decide not to distribute such property and ADS holders will not receive such distribution.

ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.

The deposit agreement governing the ADSs representing our Common Shares provides that, to the fullest extent permitted by applicable law, owners and holders of ADSs irrevocably waive the right to a jury trial for any claim that they may have against us or the depositary arising from or relating to our Common Shares, the ADSs, or the deposit agreement, including any claim under the U.S. federal securities laws.

However, ADS holders will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary’s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. In fact, ADS holders cannot waive our or the depositary’s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. If we or the depositary opposed a demand for jury trial relying on jury trial waiver mentioned above, it is up to the court to determine whether such waiver was enforceable considering the facts and circumstances of that case in accordance with the applicable state and federal law.

16

If this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated by a federal court or by the United States Supreme Court. Nonetheless, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New York, which govern the deposit agreement, or by a federal or state court in the City of New York. In determining whether to enforce a jury trial waiver provision, New York courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in fraud or one which is based upon a creditor’s negligence in failing to liquidate collateral upon a guarantor’s demand, or in the case of an intentional tort claim, none of which we believe are applicable in the case of the deposit agreement or the ADSs. If you or any other owners or holders of ADSs bring a claim against us or the depositary relating to the matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other owner or holder may not have the right to a jury trial regarding such claims, which may limit and discourage lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may have different outcomes compared to that of a jury trial, including results that could be less favorable to the plaintiff(s) in any such action.

Nevertheless, if the jury trial waiver provision is not enforced, to the extent a court action proceeds, it would proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any owner or holder of ADSs or by us or the depositary of compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.

Holders of ADSs may not receive distributions on our Common Shares or any value for them if it is illegal or impractical to make them available to such holders.

Subject to the terms of the deposit agreement, the depositary has agreed to pay holders of ADSs the cash dividends or other distributions it or the custodian for the ADSs receives on the Common Shares or other deposited securities after deducting its fees and expenses and any taxes or other government charges. Holders of ADSs will receive these distributions in proportion to the number of our Common Shares that such ADSs represent. However, the depositary is not responsible for making such payments or distributions if it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are not properly registered or distributed pursuant to an applicable exemption from registration. The depositary is not responsible for making a distribution available to any holders of ADSs if any government approval or registration required for such distribution cannot be obtained after reasonable efforts made by the depositary. We have no obligation to take any other action to permit distributions on our Common Shares to holders of ADSs. This means that holders of ADSs may not receive the distributions we make on our Common Shares if it is illegal or impractical to make them available to such holders. These restrictions may materially reduce the value of the ADSs.

Holders of ADSs may be subject to limitations on transfer of their ADSs.

ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer, or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.

We may amend the deposit agreement without consent from holders of ADSs and, if such holders disagree with our amendments, their choices will be limited to selling the ADSs or cancelling and withdrawing the underlying our Common Shares.

We may agree with the depositary to amend the deposit agreement without consent from holders of ADSs. If an amendment increases fees to be charged to ADS holders or prejudices a substantial existing right of ADS holders, it will not become effective until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, ADS holders are considered, by continuing to hold their ADSs, to have agreed to the amendment and to be bound by the amended deposit agreement. If holders of ADSs do not agree with an amendment to the deposit agreement, their choices will be limited to selling the ADSs or cancelling and withdrawing the underlying our Common Shares. No assurance can be given that a sale of ADSs could be made at a price satisfactory to the holder in such circumstances.

17

We are incorporated in Japan, and it may be more difficult to enforce judgments obtained in courts outside Japan.

We are incorporated in Japan as a joint-stock corporation. All of our directors are non-U.S. residents, and a substantial portion of our assets and the personal assets of our directors and executive officers are located outside the United States. As a result, when compared to a U.S. company, it may be more difficult for investors to effect service of process in the United States upon us or to enforce against us, our directors or executive officers, judgments obtained in U.S. courts predicated upon civil liability provisions of the federal or state securities laws of the U.S. or similar judgments obtained in other courts outside Japan. There is doubt as to the enforceability in Japanese courts, in original actions or in actions for enforcement of judgments of U.S. courts, of civil liabilities predicated solely upon the federal and state securities laws of the United States.

Dividend payments and the amount you may realize upon a sale of our Common Shares or the ADSs that you hold will be affected by fluctuations in the exchange rate between the U.S. dollar and the Japanese yen.

Cash dividends, if any, in respect of our Common Shares represented by the ADSs will be paid to the depositary in Japanese yen and then converted by the depositary or its agents into U.S. dollars, subject to certain conditions and the terms of the deposit agreement. Accordingly, fluctuations in the exchange rate between the Japanese yen and the U.S. dollar will affect, among other things, the amounts a holder of ADSs will receive from the depositary in respect of dividends, the U.S. dollar value of the proceeds that a holder of ADSs would receive upon sale in Japan of our Common Shares obtained upon cancellation and surrender of ADSs and the secondary market price of ADSs. Such fluctuations will also affect the U.S. dollar value of dividends and sales proceeds received by holders of our Common Shares.

If we cease to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and we would incur significant additional legal, accounting, and other expenses that we would not incur as a foreign private issuer.

As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements, and our executive officers, directors, and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States domestic issuers, and we are not required to disclose in our periodic reports all of the information that United States domestic issuers are required to disclose. We may cease to qualify as a foreign private issuer in the future, in which case we would incur significant additional expenses that could have a material adverse effect on our results of operations.

Because we are a foreign private issuer and have taken advantage of exemptions from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.

Nasdaq listing rules require listed companies to have, among other things, a majority of its board members be independent. As a foreign private issuer, however, we are permitted to, and we have followed home country practice in lieu of the above requirements. The corporate governance practice in our home country, Japan, does not require a majority of our board to consist of independent directors. Thus, although a director must act in the best interests of the company, it is possible that fewer board members will be exercising independent judgment and the level of board oversight on the management of our company may decrease as a result. In addition, Nasdaq listing rules also require U.S. domestic issuers to have an audit committee, a compensation committee, and a nominating/corporate governance committee composed entirely of independent directors, and an audit committee with a minimum of three members. We, as a foreign private issuer, are not subject to these requirements. Consistent with corporate governance practices in Japan, we have a three-member board of corporate auditors instead of an audit committee and we do not have a standalone compensation committee or nomination and corporate governance committee of our board.

In addition, we are not required under the Exchange Act to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act and we are generally exempt from filing quarterly reports with the SEC. Also, we are not required to provide the same executive compensation disclosures regarding the annual compensation of our five most highly compensated senior executives on an individual basis as are required of U.S. domestic issuers. As a foreign private issuer, we are permitted to disclose executive compensation on an aggregate basis and need not supply a Compensation Discussion and Analysis, as is required for domestic companies. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD promulgated under the Exchange Act. These exemptions and accommodations will reduce the frequency and scope of information and protections to which you are entitled as an investor.

18

We are currently not in compliance with the continued listing requirements of Nasdaq. As a result, the ADSs may be delisted, which could negatively impact the price of the ADSs and your ability to sell them.

In order to maintain our listing on Nasdaq, we are required to comply with certain rules of Nasdaq, including those regarding minimum stockholders’ equity, minimum share price, minimum market value of publicly held shares, and various additional requirements. On August 18, 2023, we received a notice of non-compliance from the Listing Qualifications Department of Nasdaq stating that, as a result of not having timely filed our annual report on Form 20-F for the fiscal year ended March 31, 2023, we were not in compliance with Nasdaq Listing Rule 5250(c)(1). On October 13, 2023, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that we are not in compliance with the minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided 180 calendar days, or until April 10, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the ADSs must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. In the event we do not regain compliance by April 10, 2024, we may be eligible for additional time to regain compliance or may face delisting. On October 27, 2023, we received a staff determination letter (the “Letter”) from the Listing Qualifications Department of Nasdaq notifying us of the determination from the Nasdaq staff to delist our securities from The Nasdaq Stock Market because we had not filed our Form 20-F for the fiscal year ended March 31, 2023 and we are not in compliance with Nasdaq’s filing requirements for continued inclusion set forth in Nasdaq Listing Rule 5250(c)(1). The delisting action referenced in the Letter has been stayed pending the issuance of a formal decision by the Nasdaq Hearings Panel following a hearing to be held on February 8, 2024.

If Nasdaq subsequently delists the ADSs from trading, we could face significant consequences, including:

● a limited availability for market quotations for the ADSs;

● reduced liquidity with respect to the ADSs;

● a determination that the ADS is a “penny stock,” which will require brokers trading in the ADSs to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for the ADSs;

● limited amount of news and analyst coverage; and

● a decreased ability to issue additional securities or obtain additional financing in the future.

We are an “emerging growth company” within the meaning of the Securities Act, and we have taken advantage of certain exemptions from disclosure requirements available to emerging growth companies, which will make it more difficult to compare our performance with other public companies.

We are an “emerging growth company” within the meaning of the Securities Act, as modified by the JOBS Act. Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This will make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

19

Because we are an “emerging growth company,” we may not be subject to requirements that other public companies are subject to, which could affect investor confidence in us and the ADSs.

For as long as we remain an “emerging growth company,” as defined in the JOBS Act, we will elect to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of shareholder approval of any golden parachute payments not previously approved. Because of these lessened regulatory requirements, our shareholders would be left without information or rights available to shareholders of other public companies. If some investors find the ADSs less attractive as a result, there may be a less active trading market for the ADSs and the ADS price may be more volatile.

If we are classified as a passive foreign investment company, United States taxpayers who own the ADSs or our Common Shares may have adverse United States federal income tax consequences.

A non-U.S. corporation such as ourselves will be classified as a passive foreign investment company, which is known as a PFIC, for any taxable year if, for such year, either:

● At least 75% of our gross income for the year is passive income; or

● The average percentage of our assets (determined at the end of each quarter) during the taxable year which produce passive income or which are held for the production of passive income is at least 50%.

Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business), and gains from the disposition of passive assets.

If we are determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. taxpayer who holds the ADSs or our Common Shares, the U.S. taxpayer may be subject to increased U.S. federal income tax liability and may be subject to additional reporting requirements.

Based on our operations and the composition of our assets, we do not believe we were a PFIC for our 2023 taxable year. However, it is possible that, for our 2024 taxable year or for any subsequent year, more than 50% of our assets may be assets which produce passive income, in which case we would be deemed a PFIC, which could have adverse U.S. federal income tax consequences for U.S. taxpayers who are shareholders. We will make this determination following the end of any particular tax year.

The classification of certain of our income as active or passive, and certain of our assets as producing active or passive income, and hence whether we are or will become a PFIC, depends on the interpretation of certain United States Treasury Regulations as well as certain IRS guidance relating to the classification of assets as producing active or passive income. Such regulations and guidance are potentially subject to different interpretations. If due to different interpretations of such regulations and guidance the percentage of our passive income or the percentage of our assets treated as producing passive income increases, we may be a PFIC in one or more taxable years.

For a more detailed discussion of the application of the PFIC rules to us and the consequences to U.S. taxpayers if we were or are determined to be a PFIC, see “Item 10. Additional Information—E. Taxation—United States Federal Income Taxation—PFIC.”

U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISERS ABOUT THE PFIC RULES, THE POTENTIAL APPLICABILITY OF THESE RULES TO THE COMPANY CURRENTLY AND IN THE FUTURE, AND THEIR FILING OBLIGATIONS IF THE COMPANY IS A PFIC.

20

Direct acquisition of our Common Shares, in lieu of ADSs, is subject to a prior filing requirement under the amendments in 2019 to the Japanese Foreign Exchange and Foreign Trade Act of Japan and related regulations.

Under the amendments in 2019 to the Foreign Exchange and Foreign Trade Act of Japan (Act No. 228 of 1949, as amended) (“FEFTA”) and related regulations, direct acquisition of our Common Shares, in lieu of ADSs, by a Foreign Investor (as defined herein under “Item 10. Additional Information—D. Exchange Controls”) could be subject to the prior filing requirement under FEFTA, regardless of the amount of shares to be acquired. A Foreign Investor wishing to acquire direct ownership of our Common Shares, rather than ADSs, will be required to make a prior filing with the relevant governmental authorities through the Bank of Japan and wait until clearance for the acquisition is granted by the applicable governmental authorities, which approval may take up to 30 days and could be subject to further extension. Without such clearance, the Foreign Investor will not be permitted to acquire our Common Shares directly.

A prior filing requirement as set forth above is not triggered for acquiring or trading the ADSs since the depositary received clearance for the acquisition of our Common Shares underlying the ADS in June 2022. In addition, any Foreign Investor expecting to receive delivery of our Common Shares upon surrender of ADSs must also obtain pre-clearance from the applicable Japanese governmental authority prior to accepting delivery, which approval may take up to 30 days and could be subject to further extension. Although such prior filing requirement is not triggered for trading the ADSs once the depositary receives clearance for the deposit of the underlying Common Shares, we cannot assure you that there will not be delays for additional Foreign Investors who wish to acquire our Common Shares or for holders of the ADSs who are Foreign Investors and who wish to surrender their ADSs and acquire the underlying Common Shares. In addition, we cannot assure you that the applicable Japanese governmental authorities will grant such clearance in a timely manner or at all.

The discussion above is not exhaustive of all possible foreign exchange controls requirements that may apply to a particular investor, and potential investors are advised to satisfy themselves as to the overall foreign exchange controls consequences of the acquisition, ownership and disposition of our Common Shares or the ADSs by consulting their own advisors. For a more detailed discussion on the requirements and procedures regarding the prior notifications under the Foreign Exchange Regulations, see “Item 10. Additional Information—D. Exchange Controls.”

Item 4. INFORMATION ON THE COMPANY

A. History and Development of the Company

Corporate History and Structure

We began our operations through Warrantee, a joint-stock corporation organized under the laws of Japan on October 21, 2013. On July 12, 2019, Warrantee incorporated a wholly owned subsidiary, Warrantee Pte. Ltd., in Singapore as a private company limited by shares.

On July 25, 2023, the ADSs began trading on the Nasdaq Capital Market under the symbol “WRNT.” On July 27, 2023, we closed our initial public offering of 2,400,000 ADSs at a public offering price of $4.00 per ADS.

Corporate Information

Our principal executive offices are located at 1103 Kitahama Craft, 2-4-1 Doshomachi, Chuo-ku, Osaka City, Osaka 541-0045, Japan, and our phone number is+81(0) 6-6227-8775. Our website address is https://warrantee.com/. The information contained in, or accessible from, our website or any other website does not constitute a part of this annual report. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168.

The SEC maintains a website at www.sec.gov that contains reports, proxy, and information statements, and other information regarding issuers that file electronically with the SEC using its EDGAR system.

For information regarding our principal capital expenditures, see “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources.”

21

B. Business Overview

Overview

We are a Japanese marketing and market research technology company that helps corporate sponsors unlock value through targeted marketing campaigns, while providing our corporate sponsors’ potential customers who participate in our campaigns with extended warranty coverage on durables or certain healthcare benefits sponsored by our corporate sponsors.

Our Company was founded in Japan in 2013. Beginning in 2018, we have focused on developing a suite of specialized marketing and market research services through campaigns for enterprises, which we refer to as our corporate sponsors or sponsors in our campaigns. These services are designed to collect and leverage targeted and specialty data of our corporate sponsors’ potential customers to provide proprietary market insights to our corporate sponsors and promote the sales of their products. In addition to our Chief Executive Officer and Chief Financial Officer, we operate our business with one full-time employee in charge of accounting matters and one part-time employee in charge of sales matters in Japan. We have a limited operating history with our campaign services, including a limited number of corporate sponsors (three in the fiscal year ended March 31, 2021, one in the fiscal year ended March 31, 2022, and four in the fiscal year ended March 31, 2023), on whom our business has been substantially dependent. We cannot guarantee that, with our current limited resources, we can adequately grow our business, increase our sponsor base, or manage our operations as a publicly traded company in the United States. In addition, the loss of any corporate sponsor in the absence of securing new business would have a material adverse effect on our operations and financial condition.

At the core of our current business of providing marketing campaign services is our trinity model, which connects three stakeholders: corporate sponsors, campaign participants, whom we also refer to as users, and Warrantee, and is designed to benefit all three stakeholders. This model is exemplified by our sponsored product insurance model used in our durables vertical. Under the sponsored product insurance model, we provide product insurance in the form of a limited extended warranty for appliances to users participating in our marketing campaigns, in exchange for their personal, purchase, or other data needed by our corporate sponsors, which we provide to our corporate sponsors for a sponsorship fee. We typically provide to participant users no more than JPY100,000 (approximately $753) of insurance coverage in order to comply with Japanese insurance regulations. Our collected user data enables our corporate sponsors to gain insights on their potential customers’ purchase patterns and inform our sponsors’ formulation of marketing strategies. In each campaign, within the covered period, if a participant user’s registered appliance breaks down, the user may elect to use the insurance coverage to pay for repair services or a replacement. Should a participant user make a claim for a replacement, we will only use the insurance coverage to subsidize a purchase of our corporate sponsor’s product. In this way, our campaigns can potentially increase sales of our sponsors’ products. We use the sponsorship fees to cover our operational costs, including purchasing product insurance from licensed insurers for participant users.

22

In 2020, we expanded our marketing campaign services to corporate sponsors in the commercial healthcare vertical. Based on our trinity model, we have designed and conducted campaigns for corporate sponsors in the commercial healthcare vertical, which use sponsorship fees to provide certain types of medical insurance or other healthcare benefits in exchange for user data. Such model has the potential of increasing sales of such corporate sponsors’ products by means of such marketing. In June 2022, we further expanded our marketing campaign services by initiating a sponsor campaign for an employment agency, pursuant to which we will provide to the sponsor’s labor pool members a limited amount of unemployment insurance in exchange for their personal data.

For the fiscal years ended March 31, 2023, 2022, and 2021, we generated total revenue of JPY243,218 thousand (approximately $1,832 thousand), JPY224,727 thousand (approximately $1,693 thousand), and JPY212,000 thousand (approximately $1,597 thousand), respectively, and generated net income of JPY41,303 thousand (approximately $311 thousand) and incurred net losses of JPY97,080 thousand (approximately $731 thousand), and JPY25,798 thousand (approximately $194 thousand), respectively. We have had only 11 customers and associated marketing campaigns to date, including one currently ongoing sponsor contract with Paygene, which will expire on December 31, 2023, one sponsor contract with Y’s Inc. that expired on May 26, 2023, which we are in the process of extending to December 2023, and two customers, Beauken and Connect Plus for which we completed marketing campaigns in May 2023. We have not yet established a recurring customer base that provides an ongoing sustainable source of revenue sufficient to cover our operating expenses. If we are unable to develop new sponsor contracts or other revenue sources, we may not be able to sustain our operations.

We believe our trinity model creates value for both our corporate sponsors and participant users. We expect to design and conduct more campaigns based on our trinity model in our two existing verticals, as well as in other market verticals as part of our growth strategy.

Sponsored Marketing and Market Research Services

We are focused on offering marketing campaign services, which may help drive revenue growth for our corporate sponsors through demand and behavior analysis and direct incremental sales. We believe that our marketing campaign services provide manufacturers and suppliers greater clarity on aspects of product purchases, such as stock-keeping unit, price, quantity, and timing by their customers or potential customers. We collect relevant granular sales data points and provide to our corporate sponsors organized user data that may be used for retargeting or marketing activities.

To facilitate our data collection and to provide convenience to participant users, we have developed and provided a mobile app for our campaigns for certain of our campaigns in the durables vertical, which allows participant users to input data and make claims for repair services or replacements through the app. Our app is available through the iTunes Store and Google Play in Japan. For cost efficiency or to accommodate less tech savvy participant users, we also utilize a manual process of data collection. All user data collected are owned by Warrantee, and we impose contractual limitations on use periods and purposes to our sponsors or obtain a confirmation letter stating that our sponsors have discarded all user data provided by Warrantee.

Currently, we primarily provide our marketing and market research services to corporate sponsors on a campaign-by-campaign basis, and our campaigns are customized for each corporate sponsor based on our trinity model. We also provide traditional marketing consultancy and related services to corporate sponsors. We have focused on developing customers in the durables vertical and the commercial healthcare vertical thus far and are also actively exploring opportunities to provide services to customers in other market verticals.

Durables Vertical

We primarily apply our sponsored product insurance model in organizing our campaigns for our corporate sponsors in the durables vertical, which include manufacturers, suppliers, and agencies marketing or selling household appliances and other durables. Our campaigns in this vertical provide extended warranty coverage on durables for participant users. Our participant users may be consumers or business entities. As of the date of this annual report, we have served a total of seven sponsors in this vertical, including two appliance manufacturers in the fiscal year ended March 31, 2021, a medical device sales agency, Paygene, for which we are conducting a marketing campaign as of the date of this annual report, and a real estate management firm, Connect Plus, for which we completed a marketing campaign in May 2023 directed to the existing tenants at the sponsor’s properties.

23

In a typical campaign, in partnership with our corporate sponsor or an advertising agency, we access and recruit participant users via flyers, email, social media, phone calls, or through person-to-person outreach. After signing our consent form to participate in the campaign, a participant user is requested to provide personal or other identification data, such as a name and contact information, answer questions designed to gather targeted and relevant information for our sponsor, and register all appliances the user owns that are of the same type as sold by our sponsor. For participant users who use our mobile app, and if we have a campaign launched on the app, participant users can provide requested information and register their products on the app.

In exchange for the requested data, we provide to each participant user one year of product insurance coverage of up to JPY100,000 (approximately $753) for the user’s registered appliances. The coverage can be used to pay for repair services or replacements if a registered appliance breaks down, regardless of whether such appliance is still within the warranty period provided by the manufacturer. If the user chooses a replacement, our coverage can only be used to purchase the replacement product from our sponsor.

After we collect the user data, we organize the data and provide it to our sponsor. In return for the information, the sponsor pays a sponsorship fee to us, which we use to cover our operating costs, including purchasing product insurance from licensed insurers to provide coverage to the participant users.

We believe our sponsored product insurance model benefits both our corporate sponsors and participant users. This model enables participant users to receive product insurance coverage without paying any cash premium and enables our corporate sponsors to receive targeted and relevant user data in a cost-efficient manner to inform their business and marketing decisions. As we effectively subsidize our participant users’ purchase costs if their registered products break down and if they elect to use our coverage to purchase replacements from our sponsors, we expect our participant users to be incentivized to purchase replacements from our sponsors instead of repairing broken products. We believe this can potentially generate new sales for our sponsors.

Commercial Healthcare Vertical

We entered the commercial healthcare vertical in 2020 by adapting our trinity model for the design and conduct of customized campaigns for corporate sponsors in this vertical, which include manufacturers, suppliers, and agencies marketing or selling health care related goods or services. Our campaigns in this vertical allow participant users who are generally consumers to receive complimentary examinations or treatments for ailments and procedures that are usually not covered by Japan’s “universal” coverage program. In our campaigns, we use sponsorship fees to pay the costs to enable these complimentary examinations or treatments to be available for participant users in exchange for their health and other data needed by our sponsors. As of the date of this annual report, we have served a total of three sponsors in this vertical, including one supplement supplier in the fiscal year ended March 31, 2021 and a manufacturer of health food products, Beauken, for which we completed a marketing campaign in May 2023.

The healthcare system in Japan requires that all residents maintain health insurance coverage. The country has a statutory health insurance system that subsidizes citizens who are not covered under an employment-based or private health insurance plan with a blanket “universal” coverage program. While this system helps maintain baseline coverage, the statutory and employer-based programs are often rigid. For example, employer-based programs typically do not allow employees the flexibility of selecting end healthcare providers, and there are often specific health and medical applications that are excluded from coverage. These restrictions have led to the growth of the Japanese private health insurance market, which range from critical quality of life functions tied to cancer or cardiac outcomes to more cosmetic oriented procedures, such as orthodontics or plastic surgery, usually for a high premium.

Within this vertical, we have two primary types of corporate sponsors. The first type is medical device manufacturers which provide medical devices that are generally not covered under Japan’s government-run universal medical insurance program. In the campaign we conducted for a medical device manufacturer in the fiscal year ended March 31, 2020, we subsidized the insurance costs for participant users to enable them to test use certain knee regenerative treatment devices of our sponsor in exchange for their personal and use data. In this campaign, we used sponsorship fees to purchase special commercial medical insurance policies for participant users providing coverage up to JPY100,000 (approximately $753) per participant user, which enabled the participant users to receive certain regenerative treatments not covered by the “universal” coverage program and test use our sponsor’s devices. In addition to receiving the target user data, upon the conclusion of our campaign, more than half of the participant users purchased our sponsor’s devices.

24

Our other type of customer is a manufacturer and/or supplier of supplement and health food products. In the campaign we conducted for a supplement manufacturer in the fiscal year ended March 31, 2021 and our recently completed campaign for Beauken, we used sponsorship fees to purchase and provided gene testing kits that help test potential metabolic and genetic traits of disease to participant users in exchange for their health data. In providing the test results for participant users, we also made recommendations of our sponsor’s preventative care supplements and health food products to participant users whose test results suggested they may need certain micronutrients. For participant users who decided to purchase our sponsor’s products, they were directed to make orders with our sponsor. We believe by promoting users’ awareness of our sponsor’s supplements through our campaign, we could increase sales of our sponsor’s supplements.

Additional Verticals

Our strategy includes, among other things, the development of and entry into other industry verticals. For example, in May 2022, we were engaged by Y’s, Inc., a Kyoto, Japan based employment agency, to design and launch a campaign directed at persons placed by Y’s placement services, pursuant to which users receive a limited amount of unemployment insurance, up to JPY100,000 (approximately $753), in exchange for their personal data. We believe that campaigns on behalf of corporate sponsors that offer users limited unemployment insurance will be attractive in times of macroeconomic uncertainty, such as those experienced by our addressable markets as of the date of this annual report.

Customers

Our primary source of revenue is derived from corporate sponsorship contracts for our campaigns. We have also generated revenue from miscellaneous services, including advertising, licensing fees, and system development services from time to time, though we do not expect to engage in any significant activity or incur significant revenue or expenses with regard to miscellaneous services going forward. Our customers include both established companies, such as Daikin Industries, Ltd., and growth companies. Our customers for our campaign services have been concentrated in the durables and commercial healthcare verticals, and we plan to expand our services to potential customers in other market verticals.

In the fiscal year ended March 31, 2023 and 2022, we generated 88% and 100% of our total revenue, respectively, from one corporate sponsor, Paygene, in the durables vertical. Paygene is a sales agency for medical devices. Pursuant to the sponsor contract with Paygene, as amended, we will provide to Paygene certain requested information of 40 hospitals or clinics (the “Required Delivery Number”) each month for a monthly fee of ¥16,000 thousand (approximately $121 thousand) from January 1, 2021 to December 31, 2023, provided that, if we deliver information for a number of participant hospitals and clinics (the “Actually Delivered Number”) that is greater than the Required Delivery Number, Paygene will pay us an additional fee equal to a per billing unit price of ¥400 thousand (approximately $3 thousand) (the “Per Billing Unit Price”) multiplied by the difference by which the Actually Delivered Number exceeds the Required Delivery Number, and if we fail to deliver information for the Required Delivery Number, our fee will be reduced by an amount equal to the Per Billing Unit Price multiplied by the difference by which the Required Delivery Number exceeds the Actually Delivered Number. This sponsor contract automatically renews for successive one-year terms unless either party gives the other party termination notice one month before the expiration date. Either Paygene or we may terminate this contract if (i) the other party commits a breach and fails to cure such breach in 30 days after notice, (ii) if the other party commences certain liquidation or bankruptcy proceedings, or (iii) if the other party commits fraud or other similarly improper acts and the parties fail to resolve the issue.

Under this sponsor contract, we are requested to provide purchase and use data of certain medical devices and contact information of doctors at the participant hospitals and clinics as well as an opportunity for Paygene to conduct pitch meetings with the participant hospitals and clinics. We have leveraged our Chief Executive Officer’s relationships with certain hospitals and clinics in gathering and delivering the requested information and arranging the meetings. We have used our sponsored product insurance model to incentivize other hospitals and clinics with which we do not have relationships to participate in our campaign by providing product insurance coverage for their medical devices in exchange for their consents to provide the requested information and attend pitch meetings with Paygene. We can provide coverage above JPY100,000 (approximately $753) for each participant clinic or hospital without obtaining an insurance business license as the participant hospitals and clinics will be directly insured by the policies we purchase for them. As of March 31, 2023, our Actually Delivered Number had met or exceeded the Required Delivery Number each month. There is no guarantee that we can continue to successfully deliver the requested information and arrange pitch meetings for Paygene. If we fail to meet the Required Delivery Number, our monthly fee from this contract may be substantially reduced.

25

For the fiscal years ended March 31, 2023, 2022, and 2021, two customers, one customer, and two customers, respectively, accounted for 100%, 100%, and 84%, respectively, of our total revenue. Revenue, which was related to sales in Japan, from those customers totaled JPY243,218 thousand (approximately $1,832 thousand), JPY224,727 thousand (approximately $1,693 thousand), and JPY177,000 thousand (approximately $1,333 thousand) of the total revenue of JPY243,218 thousand (approximately $1,832 thousand), JPY224,727 thousand (approximately $1,693 thousand), and JPY212,000 thousand (approximately $1,597 thousand) for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. Our revenue from miscellaneous system development services constituted, less than 10% of our total revenue in the fiscal year ended March 31, 2021, and decreased to zero in the fiscal years ended March 31, 2022 and 2023, as we continuously transitioned to focusing on our marketing campaign services and reduced those miscellaneous services. The following represents revenue attributable to each of these customers as a percentage of total revenue for each respective year.

	Fiscal Year Ended
	March 31,
	2023		2022		2021
Customer A(1)	88	%	100	%	—
Customer B(2)	—		—	%	51	%
Customer C(1)	12	%	—	%	33	%

(1) Durables

(2) Commercial healthcare, including supplements

Our sponsorship fee for each campaign is often a fixed amount paid in advance, which is calculated based on a per user rate and an estimated participant number. Contract value varies depending on sponsors. We anticipate our average contract value to increase as we continue to expand sponsor relationships in the commercial healthcare vertical, where our experience indicates that customers tend to agree to pay a higher rate for each user engaged in our campaigns.

Recent Development

In May 2022, we entered into corporate sponsorship contracts with Beauken, Connect Plus, and Y’s Inc. We completed the marketing campaigns for Beauken and Connect Plus in May 2023 and completed the marketing campaign for Y’s Inc. in November 2023.

● Beauken manufactures and sells health food products. Pursuant to the corporate sponsorship contract, we provided to Beauken’s existing and potential customers free genetic testing in exchange for their personal data. Beauken has agreed to pay us JPY10,000 (approximately $75) for each set of personal data, subject to a maximum of 20,000 sets of personal data, for a maximum potential contract value of $1.6 million. Our corporate sponsorship contract had a term of one year and ended on May 29, 2023.

● Connect Plus is a financial advisory and real property management firm. Pursuant to the corporate sponsorship contract, we provided to the tenants of the properties managed by Connect Plus a warranty for repair or replacement of air conditioners and other equipment installed on the property up to JPY100,000 (approximately $753), in exchange for the tenants’ personal data. Connect Plus agreed to pay us ¥10,000 (approximately $75) for each set of personal data, subject to a maximum of 10,000 sets of personal data, for a maximum potential contract value of $820,000. Our corporate sponsorship contract had a term of one year and ended on May 29, 2023.

● Y’s, Inc. is an employment agency. Pursuant to the corporate sponsorship contract, we provided to persons placed by Y’s a limited amount of unemployment insurance, up to JPY100,000 (approximately $753), in exchange for their personal data. Y’s, Inc. agreed to pay us ¥10,000 (approximately $75) for each set of personal data, subject to a maximum of 10,000 sets of personal data, for a maximum potential contract value of $820,000. Our corporate sponsorship contract had a term of one year ended May 26, 2023.

26

Market

We operate in the competitive marketing and market research technology industry in Japan. Our sponsors generally view our services as a substitute to other means of advertising and marketing, including social media marketing, direct response marketing, TV or radio ads, and other advertising. In contrast to traditional advertising media, we believe our services provide sponsors an effective, differentiated targeted marketing program that generates actionable customer insights, including specific consumer information and purchase data and potential increase of revenue through new sales.

Our Growth Strategy

Domestically, we strive to continue our growth through demonstrated track records on return on investment for sponsors and increased branding with their potential customers. By demonstrating tangible return on investment for sponsors and growing usage by their potential customers, we believe we will continue to be able to increase adoption from both stakeholders as we scale the business across more corporate sponsors. Additionally, we plan to leverage outbound marketing—including through an expansion of agency network referrals, recruitment of internal sales staff, and general advertising and promotion—to attract new corporate sponsors.

Our focus domestically will be to expand the number of corporate sponsors for whom we provide marketing and market research services, increase the frequency of campaigns for sponsors, increase the average rate charged per participant user in our campaigns, and enter into other industry verticals. Our strategy is to monetize the higher per user pricing often associated with the commercial healthcare vertical and other verticals we identify and pursue, which we expect will help improve our contract value and core business growth and profitability. We believe our trinity model is widely applicable across many traditional industries and new growth industries, given the benefits we provide to our sponsors’ potential customers with no cash payment required.

Our primary focus in the near term is to continue to grow our business based on the trinity model, where we believe we deliver quantifiable campaign results for our sponsors and value to the participant consumers. We currently do not have any international operations. We intend to expand our business internationally with an initial focus on other Asian countries, particularly Taiwan and Singapore. Our international growth strategy is expected to rely on a hub and spoke model, whereby we plan to leverage parent company relationships with multinational Japanese companies to target their international subsidiaries and their local campaigns outside Japan.

Competition

We view our core service offerings to corporate sponsors as a form of targeted marketing—one which offers higher tangible return on marketing spend and both quantitative and qualitative feedback that directly impact product offerings. Our business model overlaps with the broad mass media and advertising industry which, in Japan, is dominated by the large advertising giants, such as Dentsu, Hakuhodo, CyberAgent, Asatsu-Dk, and others.

By comparison, according to Dentsu, overall advertising expenditures in Japan increased 1.9% year-over-year to JPY6,938.1 billion in 2019, while Internet advertising continued to replace traditional television and radio advertisements. We believe our services fall within the intersection of Internet marketing and the niche of “newly established categories,” including events, exhibitions, screen displays, and live advertisements, which has also experienced solid growth at the expense of traditional advertising.

Our Competitive Strengths

We believe our competitive strengths in the targeted marketing service space include:

● Combination of Targeted Marketing and Market Research Services for Sponsors: As corporate sponsors increasingly search for data intelligence to predict and monetize customer trends, our campaigns can provide insights into customer behavior with incremental revenue generated from related sales.

● Building Goodwill with Potential Customers: When we conduct campaigns for our sponsors, we will disclose our sponsors’ sponsorship. As we use sponsorship fees to provide tangible benefits to participant users with no cash payment required, we believe our campaigns can help our corporate sponsors build goodwill with their potential customers.

27

● Patent Protection of the System Underlying Our Sponsored Product Insurance Model: The system underlying our sponsored product insurance model, which is for us to serve as an intermediary between sponsors, insurance companies, and users and in such role, providing insurance for the users upon terms agreed by the sponsors, is patent protected in Japan. We believe this prevents other marketing agencies from adopting a similar model of using sponsored insurance to solicit user data in the durable vertical, which is one of the major verticals for our current customers and targeted customers.

Human Capital

We currently operate with a very limited staff and use mostly third-party providers to provide the services required by each campaign on an as-needed basis. All business critical functions are decided by our Chief Executive Officer and Chief Financial Officer, with the day-to-day administrative functions outsourced to professional vendors. As part of our development strategy, we have strived for continued growth while managing our operating expenses, including labor costs. We plan to maintain this approach as we seek to increase our employee base to accelerate expansion of our business and support the infrastructure of a public company. As of the date of this annual report, in addition to our Chief Executive Officer and Chief Financial Officer, we have one full-time employee in charge of accounting matters and one part-time employee in charge of sales matters. We will need to increase our staff substantially in order to operate as a public company and grow our business. We have allocated a portion of the net proceeds of our initial public offering towards the hiring of additional employees, including sales and marketing personnel and accounting and financial reporting personnel. However, there can be no assurance that we will be able to hire and retain experienced and qualified employees in the near term, which could adversely impact our ability to operate as a public company and to grow our business. Our Company is not required by law to be unionized and, to date, has not been unionized. As such, we are not required to engage in collective bargaining procedures with any unions under Japanese labor laws.

Insurance

We do not maintain directors’ and officers’ liability insurance, property insurance, business interruption insurance, or general third-party liability insurance. We believe the insurance coverage we maintain is in line with the industry.

Property and Equipment

We do not own any real property. We entered into a lease with Daiwa k. Co., Ltd. on February 3, 2014 for 494.5 square feet of office space, which is used as our headquarters in Osaka City, Osaka, Japan. The monthly rent for this lease is JPY148 thousand (approximately $1.1 thousand). The current lease term expires on February 27, 2024 and is automatically renewable for two-year terms, unless a notice is provided from the landlord at least six months prior to the last day of the then-current term. Mr. Shono, our Chief Executive Officer, is a guarantor of this lease.

In addition, we lease five office seats in Tokyo, Japan from Mitsui Fudosan Co., Ltd for a monthly rent of JPY575 thousand (approximately $4.33 thousand). The current lease term is from July 1, 2023 to June 30, 2024 and is automatically renewable for one-month terms, unless a notice is provided from the landlord at least two months prior to the last day of the then-current term.

28

Intellectual Property

To establish and protect our proprietary rights, we rely on a combination of patents, trademarks, confidentiality policies and procedures, non-disclosure agreements with third parties, employee non-disclosure agreements, and other contractual and implicit rights worldwide. As of the date of this annual report, we have three registered patents protecting the intellectual property of the system underlying our sponsored product insurance model, which enables us to serve as an intermediary—helping facilitate data in exchange for insurance benefits—among sponsors, insurance companies, and users. We also have nine registered trademarks, including our names and marks, Warrantee, Warrantee Now, Free Insurance, our logo, and the Warrantee Now logo, with the Japan Patent Office. Our patents have a term of 20 years. Our patents and trademarks are not currently registered in any other jurisdiction, except that Warrantee has been registered in Australia, Brazil, China, the European Union, India, the United Kingdom, and Singapore. The success of our business strategy depends on our continued ability to use our existing intellectual property in order to increase brand awareness and develop our branded services. If our efforts to protect our intellectual property are not adequate, or if any third-party misappropriates or infringes on our intellectual property, whether in print, on the Internet or through other media, the value of our brands may be harmed, which could have a material adverse effect on our business, including the failure of our brands and branded services to achieve and maintain market acceptance. There can be no assurance that all of the steps we have taken to protect our intellectual property in Japan or outside Japan in relevant foreign countries, such as Taiwan and Singapore, will be adequate. In addition, in light of our intention to expand internationally, the laws of some foreign countries do not protect intellectual property rights to the same extent as do the laws of Japan. If any of our patents, trademarks, trade secrets, or other intellectual property are infringed, our business, financial condition, and results of operations could be materially adversely affected.

In addition, third parties may assert infringement or misappropriation claims against us, or assert claims that our rights in our trademarks, patents, and other intellectual property assets are invalid or unenforceable. Any such claims could have a material adverse effect on us if such claims were to be decided against us. If our rights in any intellectual property were invalidated or deemed unenforceable, it could permit competing uses of our intellectual property which, in turn, could lead to a decline in business and our revenue. If the intellectual property became subject to third-party infringement, misappropriation or other claims, and such claims were decided against us, we may be forced to pay damages, be required to develop or adopt non-infringing intellectual property or be obligated to acquire a license to the intellectual property that is the subject of the asserted claim. There could be significant expenses associated with the defense of any infringement, misappropriation, or other third-party claims.

Seasonality

Our business is not subject to seasonal fluctuations.

Regulations

Personal Information Protection

In Japan, the Act on the Protection of Personal Information (the “APPI”) and its related guidelines impose various requirements on businesses, including us, that use databases containing personal information. Under the APPI, we are required to lawfully use personal information we have obtained within the purpose of use we have specified and taken appropriate measures to maintain the security of such personal information. We are also restricted from providing the personal information of a person (the “principal”) to third parties without the consent of the principal. The APPI also includes regulations relating to the handling of sensitive personal data and anonymous personal data and the transfer of personal information to foreign countries. A Personal Information Handling Business Operator (as defined below) shall not transfer a person’s personal data to third parties, including its affiliated entities without the prior consent of the principal unless an exception applies (Article 27, Paragraph 1 of the APPI).

A “Personal Information Handling Business Operator” is defined as a person (including a judicial person and excluding any administrative organizations) providing a personal information database for use in business (Article 16, Paragraph 2). Our business utilizes the personal information obtained from participant users, thereby subjecting our Company to the provisions applicable to the Personal Information Handling Business Operator. Under the APPI, the prior consent of the principal to a transfer of such person’s personal data (including Sensitive Information (as defined below)) is not required if the transfer:

(a) is specifically required or authorized by any laws or regulation;

(b) the amount of which are reasonably law based on common sense means JPY100,000 or less (the “Threshold”);

29

(c) is necessary for improving public health and sanitation, or promoting the sound upbringing of children, and the consent of the principal is difficult to obtain; or

(d) is made in a case where there is a need to cooperate in regard to a central government organization or a local government, or a person entrusted by them performing affairs prescribed by laws and regulations, and when there is a possibility that obtaining the principal’s consent would interfere with the performance of the said affairs.

Furthermore, the Personal Information Handling Business Operator shall, unless an exception listed above applies, not acquire Sensitive Information (such as personal information relating to physical or mental disabilities, medical records, and medical and pharmacological treatment) without obtaining prior consent from the principal (Article 2, Paragraph 3 and Article 20, Paragraph 2 of the APPI).

We gather personal information from participant users and transfer them to our corporate sponsors in conducting our campaigns for our corporate sponsors. Therefore, we are required to obtain consents from the participant users prior to the transfer of their information to our corporate sponsors. Some of the information we collect could fall under the category of sensitive personal data under the APPI. In addition, we gather personal information including diagnosis records, which is understood to typically fall under the Sensitive Information,  from participant users in our campaigns for corporate sponsors in the healthcare industry. Therefore, we are required to obtain prior consent from the participant users to obtain the Sensitive Information.

When storing personal information, it is necessary to manage it safely so that it will not be leaked and the database storing the information is not breached. For the safe management, the APPI requires the Personal Information Handling Business Operator to establish an information security system. It includes establishment of the fundamental rule of personal information management, appointment of personnel responsible for personal information management, provisions of regular training courses on privacy and security breach, and physical security control. As for the fundamental rules, we have two internal rules, “Rules on Personal Information Protection” and “Basic Policy on Handling of Personal Information,” which govern personal information protection. Under the Rules on Personal Information Protection, we appointed our Chief Executive Officer, as the person who is responsible for personal information management. We provide a copy of our privacy policy and relevant contact information on our website.

The Insurance Business Act

The Insurance Business Act prohibits any person from conducting insurance business without obtaining an insurance business license. Under Article 2, Paragraph 1 of the Insurance Business Act, the term “insurance business” is defined to generally include (i) the business of underwriting insurance for which premiums are received in exchange for an agreement to pay a fixed amount of insurance proceeds in connection with the life or death of an individual, (ii) insurance for which premiums are received in exchange for an agreement to compensate for damage caused by specific and accidental events, and (iii) other insurances known as so-called life insurance or non-life insurance, with certain exceptions. We do not hold an insurance business license under the Insurance Business Act though we use the term “Free Insurance” as a trademark in conducting our business in Japan.

The Financial Services Agency of Japan (“JFSA”) publishes the Guideline related to Insurance Companies (for insurance companies that provide small size/short-term insurances) (the “Guideline”) in connection with interpretations of the Insurance Business Act. Among others, the Guideline provides the JFSA’s interpretation of Article 2, Paragraph 1 of the Insurance Business Act as follows:

● “premiums received” does not include premiums the amount of which are reasonably low based on common sense; and

● the amount of which are reasonably low based on common sense means the Threshold.

Other factors that regulators are required to consider in determining whether an insurance business license is required include: the contents of the agreement to provide for the subject service, the person who provides the service, the manner in which the service is provided (such as whether the service is relevant to the primary business of the service provider), whether the service has traditionally been perceived as different from an insurance transaction, and the purpose of the regulations under the Insurance Business Act.

We have and will continue to conduct our business in a manner that does not require us to comply with such licensing requirement for an insurance business under the Insurance Business Act. See “Item 3. Key Information—D. Risk Factors—Risks Related to Our Company and Our Business—Failure to comply with relevant laws and regulations including those relating to the processing, safekeeping, and use of personal data and the insurance licensing requirements could harm our business, financial condition, or results of operations, and any change in laws and regulations may adversely affect our ability to grow our business.”

30

C. Organizational Structure

See “—A. History and Development of the Company.”

D. Property, Plants and Equipment

See “—B. Business Overview—Property and Equipment.”

Item 4A. UNRESOLVED STAFF COMMENTS

Not applicable.

Item 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

The following discussion of our financial condition and results of operations is based upon and should be read in conjunction with our consolidated financial statements and their related notes included in this annual report. This report contains forward-looking statements. In evaluating our business, you should carefully consider the information provided under the caption “Item 3. Key Information—D. Risk Factors” in this annual report. We caution you that our businesses and financial performance are subject to substantial risks and uncertainties.

Key Financial Definitions

Revenue. Our primary source of revenue comes from customer billings in sponsor contracts. We have also generated revenue from miscellaneous services, including advertising, licensing fees, and system development services from time to time, though we do not expect to engage in any significant activity or incur significant revenue or expenses with regard to miscellaneous services going forward.

Cost of revenue. Cost of revenue includes the direct cost to develop software products, depreciation, personnel-related expenses, insurance costs, repair and replacement costs, genetic testing costs, and participant user recruiting costs for our sponsored marketing and market research services.

Selling, general, and administrative expenses. Our selling, general, and administrative expenses (“SG&A”) are primarily composed of operating expenses related to sales and marketing, technology development, miscellaneous insurance expenses for our Company, and other general and administrative expenses, such as expenses related to our initial public offering.

Other income (expense). From time to time we have non-recurring, non-operating gains and losses, which are reflected through other income/expense.

Non-GAAP Measures

To supplement our consolidated financial statements presented in accordance with U.S. GAAP, we also provide Non-GAAP EBITDA and its ratio to revenue, Non-GAAP EBITDA %, each of which are financial measures that are not based on any standardized methodology prescribed by U.S. GAAP. Management considers Non-GAAP EBITDA and Non-GAAP EBITDA Margin to be measures of performance which provide useful information to both management and investors as an additional tool to use in evaluating our ongoing operating results and trends and in comparing our financial measures with those of comparable companies, which may present similar non-GAAP financial measures to investors. We also believe that Non-GAAP EBITDA and Non-GAAP EBITDA Margin are used by some investors as a way to measure a company’s ability to incur and service debt, make capital expenditures, and meet working capital requirements. However, you should be aware that non-GAAP financial measures are not a substitute for U.S. GAAP measures; they should be read and used in conjunction with our U.S. GAAP financial information. Our non-GAAP measures may not be comparable to similar non-GAAP information which may be presented by other companies. In all cases, it should be understood that non-GAAP operating measures do not depict amounts that accrue directly to the benefit of shareholders.

31

Non-GAAP EBITDA. We define Non-GAAP EBITDA as net income plus other income, other loss, interest expenses, share-based compensation, and depreciation and amortization expenses. Non-GAAP EBITDA should not be considered an alternative to net income or other measures under GAAP. Non-GAAP EBITDA is not calculated identically by all companies and, therefore, our measures of Non-GAAP EBITDA may not be comparable to similarly titled measures reported by other companies.

Non-GAAP EBITDA Margin. We define Non-GAAP EBITDA Margin as the percentage derived from dividing Non-GAAP EBITDA for a period by total revenue for the same period.

A. Operating Results

Comparison of Results of Operations for the Fiscal Years Ended March 31, 2023 and 2022

(in thousands)	Fiscal years ended March 31,
	2023 ($)		2023 (¥)		2022 (¥)		2021 (¥)		Change (¥)		% Change
Statement of Income Information
Revenue	$	1,832	¥	243,218	¥	224,727	¥	212,000	¥	18,491	8	%
Cost of revenue		16		2,097		2,516		25,146		(419)	(17)	%
Gross profit		1,816		241,121		222,211		186,854		18,910	9	%
Operating expenses:
Selling, general, and administrative expenses		1,420		188,528		312,053		214,608		(123,525)	(40)	%
Income (Loss) from operations		396		52,593		(89,842)		(27,754)		142,435	159	%
Other (expense) income, net		(58)		(7,692)		(4,254)		5,380		(1,843)	43	%
Interest expenses		(27)		(3,598)		(2,984)		(3,424)		(614)	21	%
Total other (expenses) income, net		(85)		(11,280)		(7,238)		1,956		(2,457)	34	%
Net income (loss)	$	311	¥	41,303	¥	(97,080)	¥	(25,798)	¥	139,978	144	%
Non-GAAP EBITDA	$	541	¥	71,806	¥	(5,004)	¥	84,045	¥	76,810	1,535	%

Revenue

Revenue increased by 8% year-over-year in the fiscal year ended March 31, 2023 to JPY243,218 thousand ($1,832 thousand) because we mainly focused on one significant market campaign service in the durables vertical during the fiscal year ended March 31, 2023 which comprises 88% of the revenue of the fiscal year ended March 31, 2023. We transitioned to focusing on our marketing campaign services and reduced the offering of miscellaneous services compared to previous years.

Cost of Revenue

Cost of revenue decreased by 17% year-over-year to JPY2,097 thousand ($16 thousand) in the fiscal year ended March 31, 2023, mainly due to the decrease in variable costs, which are primarily comprised of insurance premiums paid for participant users in campaigns and system development costs in the fiscal year ended March 31, 2022. As we focused on a few significant projects during the fiscal year ended March 31, 2023, insurance costs and labor costs were lower in the fiscal year ended March 31, 2023.

Gross profit grew by 9% year-over-year to JPY18,910 thousand ($142 thousand) and gross profit margin was 99.1% in the fiscal year ended March 31, 2023.

SG&A

SG&A decreased by 40% year-over-year to JPY188,528 thousand ($1,420 thousand) in the fiscal year ended March 31, 2023, primarily due to a decrease in stock compensation expenses and professional fees.

Other (Expenses) Income

We recorded other expenses of JPY7,692 thousand ($58 thousand) in the fiscal year ended March 31, 2023, primarily due to increases in foreign currency losses due to the depreciation of the Japanese yen against the U.S. dollars and the increase in foreign currency remittances compared to the prior fiscal years. This was partially offset by interest income.

32

Net Income (Loss) and Non-GAAP EBITDA

Net income increased to JPY41,303 thousand ($311 thousand) in the fiscal year ended March 31, 2023 from a net loss of JPY97,080 thousand ($731 thousand) in the prior fiscal year, primarily due to the increase in revenue and significant decrease in SG&A.

Non-GAAP EBITDA increased to JPY71,806 thousand ($541 thousand) in the fiscal year ended March 31, 2023 from a loss of JPY5,004 thousand ($38 thousand) in the prior fiscal year due to the increase in revenue, significant decreased in SG&A and increase in depreciation and amortization expense which was added back to net income to calculate Non-GAAP EBITDA.

Comparison of Results of Operations for the Fiscal Years Ended March 31, 2022 and 2021

(in thousands)	Fiscal years ended March 31,
	2022 ($)		2022 (¥)		2021 (¥)		¥ Change		% Change
Statement of Income Information
Revenue	$	1,553	¥	224,727	¥	212,000	¥	12,727	6	%
Cost of revenue		17		2,516		25,146		(22,630)	(90)	%
Gross profit		1,536		222,211		186,854		35,357	19	%
Operating expenses:
Selling, general, and administrative expenses		2,157		312,053		214,608		97,445	45	%
(Loss) from operations		(621)		(89,842)		(27,754)		(62,088)	224	%
Other (expense) income, net		(28)		(4,254)		5,380		(9,634)	(179)	%
Interest expenses		(21)		(2,984)		(3,424)		440	(13)	%
Total other (expenses) income, net		(49)		(7,238)		1,956		(9,194)	(470)	%
Net loss	$	(670)	¥	(97,080)	¥	(25,798)	¥	(71,282)	276	%
Non-GAAP EBITDA	$	(35)	¥	(5,004)	¥	84,045	¥	(89,049)	(106)	%

Revenue

Revenue increased by 6% year-over-year in the fiscal year ended March 31, 2022 to JPY224,727 thousand ($1,553 thousand) because we focused on one significant market campaign service in the durables vertical during the current year, which contributed more than all the prior year’s market campaign services. We transitioned to focusing on our marketing campaign services and reduced prior miscellaneous services.

Cost of Revenue

Cost of revenue decreased by 90% year-over-year to JPY2,516 thousand ($17 thousand) in the fiscal year ended March 31, 2022, due to the decrease in variable costs, which was primarily comprised of insurance premiums paid for participant users in campaigns and system development costs in the prior year, which were not incurred in the current year because we focused on one significant project during the current year, which resulted in a decrease in system development costs, insurance costs, and labor costs. As a result, gross profit grew 19% year-over-year to JPY222,211 thousand ($1,536 thousand) and gross profit margin increased year-over-year to 98.9% in the fiscal year ended March 31, 2022.

SG&A

SG&A increased by 45% year-over-year to JPY312,053 thousand ($2,157 thousand) in the fiscal year ended March 31, 2022, primarily due to increased stock compensation expenses associated with our fourth series stock option grant.

Other (Expenses) Income

We recorded other expenses of JPY4,254 thousand ($28 thousand) in the fiscal year ended March 31, 2022, primarily due to increases in foreign currency losses due to the depreciation of the Japanese yen against the U.S. dollars and the increase in foreign currency remittances compared to the prior fiscal year. This was partially offset by interest income and a Singapore government grant.

33

Net Loss and Non-GAAP EBITDA

Net loss increased to JPY97,080 thousand ($670 thousand) in the fiscal year ended March 31, 2022 from a net loss of JPY25,798 thousand ($212 thousand) in the prior fiscal year, primarily due to the increase in SG&A and the increase in other expenses.

Non-GAAP EBITDA decreased to a loss of JPY5,004 thousand ($35 thousand) in the fiscal year ended March 31, 2022 from a profit of JPY84,045 thousand ($692 thousand) in the prior fiscal year due to the increased SG&A, increase in other expenses.

B. Liquidity and Capital Resources

Liquidity is a measure of our ability to meet potential cash requirements. We generally fund our operations with cash flow from operations and, when needed, with borrowings from Japanese financial institutions, our Chief Executive Officer or its affiliates. As of the date of this annual report, we believe we need a minimum of JPY1,050,553 thousand ($7,914 thousand) in order to fund our presently forecasted working capital requirements over the next 12 months. On July 26, 2023, we closed our initial public offering of 2,400,000 ADSs at a public offering price of $4.00 per ADS. Gross proceeds of our initial public offering totaled $9.6 million, before deducting underwriting discounts and other related expenses. Net proceeds of our initial public offering were approximately $7.19 million. We believe that the net proceeds of the offering will be sufficient to fund our presently forecasted working capital requirements over, at least, the 12 months following the date of this annual report. However, as a result of certain factors presently unforeseen, we may require additional capital over the next 12 months, the receipt of which there can be no assurance. In addition, unless we are able to successfully scale our operations and achieve meaningful cash flow from operations, we will require additional capital in order to fund our continued development of our trinity business model following the 12-month period following the date of this annual report. We will endeavor to acquire any additional required funds through various financing sources, including borrowings under our existing loans from financial institutions, the private and public sale of our equity and debt securities and other third-party financings. In addition, we will consider alternatives to our current business plan that may enable us to achieve meaningful cash flow from operations with a smaller amount of capital. However, there can be no guarantees that such funds will be available on commercially reasonable terms, if at all. If such financing is not available on satisfactory terms, we may be unable to further pursue our business plan and we may be unable to continue operations.

Cash Flows for the Fiscal Years Ended March 31, 2023 and 2022

	Fiscal years ended March 31,
(in thousands)	2023 ($)		2023 (¥)		2022 (¥)
Consolidated Statements of Cash Flows Data:
Cash flow from operating activities:	$	314	¥	41,662	¥	79,565
Cash flow from investing activities:	$	(65)	¥	(8,670)	¥	(20,841)
Cash flow from financing activities:	$	(349)	¥	(46,374)	¥	(60,099)

Operating Activities. Cash flow generated from operations was JPY41,662 thousand ($314 thousand) in the fiscal year ended March 31, 2023, compared to cash generated from operations of JPY79,565 thousand ($599 thousand) in the prior fiscal year, mainly due to the decrease in accrued liabilities and other current liabilities balance and stock compensation expenses, which was partially offset by the increase in net income.

Investing Activities. Cash flow used in investing activities was JPY8,670 thousand ($65 thousand) in the fiscal year ended March 31, 2023, compared to cash used in investing activities of JPY20,841 thousand ($157 thousand) in the fiscal year ended March 31, 2022. The decrease in cash outflow from investing activities was primarily due to fewer investments in capitalized software during the fiscal year ended March 31, 2023.

Financing Activities. Cash flow used in financing activities was JPY46,374 thousand ($349 thousand) in the fiscal year ended March 31, 2023, compared to cash used in financing activities of JPY60,099 thousand ($453 thousand) in the prior fiscal year, primarily due to the decreased payments of deferred offering costs.

34

Cash Flows for the Fiscal Years Ended March 31, 2022 and 2021

The following table sets forth a summary of our cash flows for the fiscal years indicated.

	Fiscal years ended March 31,
(in thousands)	2022 ($)		2022 (¥)		2021 (¥)
Consolidated Statements of Cash Flows Data:
Cash flow from operating activities:	$	655	¥	79,565	¥	2,043
Cash flow from investing activities:	$	(172)	¥	(20,841)	¥	—
Cash flow from financing activities:	$	(495)	¥	(60,099)	¥	(12,554)

Operating Activities. Cash flow from operations was a source of JPY79,565 thousand ($655 thousand) in the fiscal year ended March 31, 2022, compared to a source of JPY2,043 thousand ($17 thousand) in the prior fiscal year, mainly due to a decrease in net income, partially increased due to an increase in trade receivables and deferred revenue.

Investing Activities. Cash flow from investing activities was a use of JPY20,841 thousand ($172 thousand) in the fiscal year ended March 31, 2022, due to investments in capitalized software. There were no cash flows from investing activities during the fiscal year ended March 31, 2022.

Financing Activities. Cash flow from financing activities was a use of cash of JPY60,099 thousand ($495 thousand) in the fiscal year ended March 31, 2022, compared to a use of cash of JPY12,554 thousand ($103 thousand) in the prior fiscal year, primarily due to increased payments of deferred offering costs, and less receipts related to long term debt in comparison to the prior fiscal year.

Outstanding Loans from Financial Institutions

As of March 31, 2023, the Company had outstanding loans from three Japanese financial institutions: SBI Estate Finance Co., Ltd., Resona Bank, Limited, and Japan Finance Corporation. The main purpose of obtaining these loans has been to expand the Company’s business lines and develop more services. Mr. Shono, our Chief Executive Officer, is a guarantor of the Company’s obligations under the loan agreements with SBI Estate Finance Co., Ltd., Resona Bank, Limited, and Japan Finance Corporation.

On August 31, 2017, the Company obtained a loan in the principal amount of JPY52,000 thousand ($392 thousand) from SBI Estate Finance Co., Ltd., which matures on September 5, 2037, and accrues interest at a rate of 6.00% per annum. This loan is guaranteed by Mr. Shono, our Chief Executive Officer. Principal and interest are payable monthly; the outstanding balance as of March 31, 2023 and 2022 was JPY43,187 thousand ($325 thousand) and JPY45,011 thousand ($339 thousand), respectively.

On December 18, 2020, the Company obtained a loan from Resona Bank in the principal amount of JPY25,000 thousand ($188 thousand), which matures on November 30, 2030. No interest is payable or accrues prior to December 17, 2023. Thereafter, interest accrues at a rate of 1.200% per annum until the earlier of repayment in full or maturity. This loan is guaranteed by Credit Guarantee Corporation of Osaka and Mr. Shono, our Chief Executive Officer. Principal and, if applicable, interest are payable monthly; the outstanding balance as of March 31, 2023 and 2022 was JPY24,220 thousand ($182 thousand) and JPY25,000 thousand ($188 thousand), respectively.

35

On September 3, 2014, the Company obtained a loan from Japan Finance Corporation in the principal amount of JPY15,000 thousand ($113 thousand), which matured on September 30, 2021 (the “Prior Term Loan”). On September 30, 2021, the Company refinanced the Prior Term Loan with Japan Finance Corporation to extend the maturity date to August 31, 2026. The Company also used JPY15,000 thousand ($113 thousand) out of JPY15,500 thousand ($117 thousand) of the proceeds from the new loan to repay all outstanding principal balance under the Prior Term Loan. The interest rate per annum on the new term loan is 0.36% per annum from September 30, 2021 to September 30, 2024, and 1.26% per annum from October 1, 2024 to the maturity date. Under the new loan, the Company is required to make monthly repayments of principal beginning September 30, 2022 and monthly repayments of interest beginning October 30, 2021. This loan is guaranteed by Mr. Shono, our Chief Executive Officer. The outstanding balance as of March 31, 2023 and 2022 was JPY13,975 thousand ($105 thousand) and JPY15,500 thousand ($117 thousand), respectively.

Contractual Obligations

Payments of contractual obligations and commitments will require considerable resources. In our ordinary course of business, we routinely enter into commercial commitments and financial obligations for various aspects of our operations.

The following table sets forth the amount of our contractual obligations as of March 31, 2023.

	As of March 31, 2023
Yen in thousands	Payments due by period:
	Total		Less than 1 year		1 – 3 years		4 – 5 years		More than 5 years
Long-term debt principal payments	¥	81,382	¥	9,860	¥	18,278	¥	12,637	¥	40,607
Long-term debt interest payments		22,924		2,697		5,457		4,535		10,235
Total	¥	104,306	¥	12,557	¥	23,735	¥	17,172	¥	50,842

Off-Balance Sheet Arrangements

As of March 31, 2023, 2022, and 2021, we were not party to any material off-balance sheet financial arrangements that are reasonably likely to have a current or future effect on our financial condition or operating results. We do not have any relationship with unconsolidated entities or financial partnerships for the purpose of facilitating off-balance sheet arrangements or for other contractually narrow or limited purposes.

C. Research and Development, Patents and Licenses, etc.

See “Item 4. Information on the Company—B. Business Overview—Intellectual Property.”

D. Trend Information

Other than as disclosed below and elsewhere in this annual report on Form 20-F, we are not aware of any trends, uncertainties, demands, commitments, or events for the period from April 1, 2022 to March 31, 2023 that are reasonably likely to have a material adverse effect on our net revenue, income, profitability, liquidity, or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial condition.

Factors and Trends Affecting Our Results of Operations

We believe that the growth and future success of our business depends on many factors. While each of these factors presents significant opportunities for our business, they also pose important challenges that we plan to successfully address in order to sustain our growth and improve our results of operations.

36

Acquiring New Sponsors and Campaign Opportunities. Our revenue and costs are primarily affected by the volume of campaign services, as well as the mix of sponsors of these services, which vary from period to period. Although we hope to develop repeated service opportunities with existing sponsors, we have not been successful in doing so to date under our business model and we intend to focus on incremental revenue opportunities through development of new sponsors. We plan to use our initial public offering proceeds to invest in sales and marketing, including hiring more staff to drive sponsor acquisition and to conduct more campaigns. We believe our investments in these areas will allow us to market our services to the needs of enterprises in the durables vertical and the commercial healthcare vertical which comprise our existing sponsor base, while unlocking opportunities to expand our sponsor base and to conduct campaigns in other verticals and markets. If our investments in sponsor acquisition are not successful, our operating results would be adversely impacted.

Ability to Manage Costs Associated with Implementing Our Growth Strategy. Managing our costs to maintain or increase our profit margin associated with performing our campaign services has been our long-time strategic objective. We have been thinly staffed and have leveraged third-party services to support the operations of our business. In order to acquire more sponsors and campaign opportunities, we intend to invest in sales and marketing and increase hiring. In addition, management expects to adopt automation software where appropriate to maintain or increase efficiency, including increasing the use of our app in conducting campaigns. If we fail to manage the costs and expenses associated with our growth strategy effectively, our profit margin would be harmed.

Business Environment. Product manufacturers and suppliers have always had the need for their potential customers’ information to optimize their sales and marketing funnels. We believe our services address their needs for targeted user data and our trinity model, which is designed to provide a tangible benefit to participant users in exchange for their data, can facilitate obtaining such data efficiently. We believe our patents in Japan also provide certain protection to us in hindering others from serving in a similar intermediary role and adopting the same sponsored product insurance model in Japan. As a relatively new business model, we rely on our patents and the current regulatory framework to allow for this model to be applied for campaigns for sponsors in various verticals. We intend to continue to tap the needs of our sponsors and potential sponsors for user data and new sales channels while any challenge to our patents or change to the current regulatory framework applicable to our business model may adversely affect our business and increase our costs.

Impact of COVID-19

On March 11, 2020, the World Health Organization designated the outbreak of COVID-19 as a pandemic. Given that our marketing campaigns did not depend on face-to-face interactions with sponsors or participant users, we did not observe significant impacts on our business or results of operations for the fiscal years ended March 31, 2023, 2022, and 2021. We applied for the COVID-19 subsidy program for sustaining businesses provided by the Japanese government. For the fiscal year ended March 31, 2021, we received a one-time grant of JPY2,000 thousand ($15 thousand) from the subsidy program. While the extent to which COVID-19 may impact our future results cannot be known at this time, there is no guarantee that the pandemic and associated economic impacts will not result in a negative impact to our future financial condition, results of operations, and cash flows.

E. Critical Accounting Estimates

Our consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. As events continue to evolve, our estimates may change materially in future periods.

In many cases, the accounting treatment of a particular transaction is specifically dictated by U.S. GAAP and does not require management’s judgment in its application, while in other cases, management’s judgment is required in selecting among available alternative accounting standards that allow different accounting treatment for similar transactions. We believe that the accounting policies discussed below are the most critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

37

Revenue Recognition

We apply ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) for all periods presented in the consolidated financial statements. To determine the appropriate amount of revenue to be recognized in accordance with ASC 606, we follow a five-step model as follows:

1 — Identification of the contract with a customer;

2 — Identification of the performance obligation in the contract;

3 — Determination of the transaction price;

4 — Allocation of the transaction price to the performance obligation in the contract; and

5 — Recognition of revenue when, or as, a performance obligation is satisfied.

Our revenue is primarily derived from the durables vertical and the commercial healthcare vertical. Our services are marketed and sold directly to the customers. We assess the contract term as the period in which the parties to the contract have enforceable rights and obligations. The actual contract term may differ from the stated term in contracts with certain termination or renewal rights, depending on whether there are substantive penalties associated with those rights. Customer contracts are generally standardized and noncancellable for the duration of the stated contract term. Consumption taxes collected and remitted to tax authorities are excluded from revenue. We may use third-party vendors to provide certain goods or services to our customers. We evaluate those relationships to determine whether revenue should be reported gross or net. We recognize revenue on a gross basis where we act as principal and control the goods and services used to fulfill the performance obligations to the customer and on a net basis where we act as an agent. We have not acted as an agent during the fiscal years ended March 31,2023, 2022, and 2021.

Durables Vertical:

Performance Obligations

Revenue from the durables vertical is primarily comprised of sponsorship fees from corporate sponsors in exchange for participant users’ personal or other identification information. During the sponsorship campaigns, we aggregate personal information, organize that data, and then provide it to corporate sponsors. We have identified one performance obligation, the delivery of participant users’ personal information. All other immaterial deliverables occur prior to this but revenue is not recognized until the delivery of the participant users’ personal information, which is the performance obligation. Accordingly, we recognize revenue at a point in time when the personal information is provided to corporate sponsors upon satisfying our single distinct performance obligation.

When we conduct the market research or marketing planning proposal services for the customers in the preliminary stages of the durables vertical contract, the single performance obligation is satisfied and revenue is recognized when the services are completed and accepted by the customers and we have no further obligations.

Contractual Consideration

The transaction price is generally fixed at contract inception. However, our contracts with corporate sponsors within the durables vertical may include a specified quantity, which entitles the customer to refunds, when defined quantity levels are not met at the end of the provision period. These arrangements represent a form of variable consideration, which is estimated using the most likely amount method to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of the applicable periods.

Commercial Healthcare Vertical:

Performance Obligations

Revenue from the commercial healthcare vertical is primarily comprised of sponsorship fees from corporate sponsors in exchange for healthcare-related promotional campaigns. During healthcare-related promotional campaigns targeted to participant users based on results of their free genetic test kits, we have the stand-ready obligation to provide promotional services for the duration of the campaign promotion period. Accordingly, revenue is recognized ratably based on the time-elapsed method over the contractual term with the corporate sponsors.

38

When we conduct a campaign sponsored by the corporate sponsors and provide them the personal information we have collected from the participant users in exchange for complimentary examinations, we have identified one performance obligation, which is the delivery of participant users’ personal information, with other promises being immaterial in the context of the contract. Therefore, we recognize revenue at a point in time when the personal information is provided to the corporate sponsors.

Contractual Consideration

The transaction price may be fixed at contract inception within the commercial healthcare vertical in a form of non-refundable minimum guarantee but may also have a component of variable consideration, such as sales incentives, which are calculated by multiplying the amount of work accomplished by a fixed unit price of remuneration. Due to the variable consideration being entirely constrained, the sales incentive is excluded from the transaction price until the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of the applicable period.

Miscellaneous revenue, such as revenue from advertising, licensing, and system development, is recognized ratably over time or at the point of time depending on the type of deliverables and duration of the sponsor contract.

Transaction Price

The transaction price is the amount of consideration to which we expect to be entitled for transferring goods and services to the customer.

Payments from the customers are often made in advance before satisfaction of the performance obligations. When payments are not due in advance, they are due within 30 days of delivery of the goods or service. In instances where the timing of revenue recognition differs from the timing of the right to invoice, we have determined that a significant financing component generally does not exist. Additionally, we have elected the practical expedient that permits an entity not to recognize a significant financing component if the time between the transfer of a good or service and payment is one year or less.

Share-Based Compensation

We apply the provisions of ASC Topic 718, Compensation—Stock Compensation. We measure the cost of employee and non-employee services received in exchange for awards of equity instruments at the fair value of the award on the grant date and recognize the cost over the requisite service period which the employee and non-employee are required to provide services in exchange for the award. Compensation costs are recognized on a straight-line basis over the requisite service period of the awards which are expected to vest. Recognition of compensation cost will be deferred until the liquidity event occurs. For awards with performance conditions, compensation cost is recognized when the condition is probable of being achieved, or in the case of a liquidity event, when the liquidity event occurs. We use option pricing methods that require the input of subjective assumptions, including the expected term, expected volatility, dividend yield, and risk-free interest rate. For awards with market conditions, we use a hybrid method between a discounted cash flow method and Monte Carlo simulation models to value the awards. We have elected to recognize forfeitures as they occur.

Trade Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable primarily consist of amounts billed and currently due from customers, net of an allowance for doubtful accounts, if recorded. When we have an unconditional right to payment, subject only to the passage of time, the right is treated as a receivable. Fees billed in advance of the related contractual term represent contract liabilities and are presented as deferred revenue. Typical payment terms provide for customer payment within 30 days of the contract date.

Trade accounts receivable are subject to collection risk. We perform evaluations of our customers’ financial positions and generally extend credit on account, without collateral. We determine the need for an allowance for doubtful accounts based upon various factors, including credit quality of the customer, age of the receivable balance, and current economic conditions.

There were no bad debt expenses or allowance for doubtful accounts recorded as of and for the fiscal years ended March 31, 2023, 2022, and 2021.

39

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the differences between the financial statement and tax bases of assets, liabilities, and net operating loss by using enacted tax rate in effect for the year in which the differences are expected to reverse. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that these assets are believed to be more likely than not to be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are more likely than not expected to be realized. In making such a determination, all available positive and negative evidence is considered, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.

Warrantee and its subsidiary file tax returns in the tax jurisdictions of Japan and Singapore. Tax benefits for uncertain tax positions are based upon management’s evaluation of the information available at the reporting date. To be recognized in the consolidated financial statements, a tax benefit must be at least more likely than not of being sustained based on technical merits. The benefit for positions meeting the recognition threshold is measured as the largest benefit more likely than not of being realized upon settlement with a taxing authority that has full knowledge of all relevant information.

Recently Issued Accounting Pronouncements

As an emerging growth company, the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. We have elected to delay adoption of certain new or revised accounting standards. As a result, our consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies.

Financial Instruments — Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which is intended to provide more decision-useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. ASU 2016-13 revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to accounts receivable. This standard is effective for annual reporting periods beginning after December 15, 2022 for non-public entities, including interim periods within that reporting period. Early adoption is permitted. We adopted this standard effective April 1, 2023 and the adoption did not have a material effect on our consolidated financial statements.

40

Item 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A. Directors and Senior Management

The following table sets forth the names, ages, and positions of our executive officers and members of our board of directors and of our board of corporate auditors as of the date of this annual report. The business address of all of persons identified below is 1103 Kitahama Craft, 2-4-1 Doshomachi, Chuo-ku, Osaka City, Osaka 541-0045, Japan.

Name	Age	Position(s)
Yusuke Shono	37	Chief Executive Officer and Director
Yumi Matsudaira	40	Chief Financial Officer and Director
Hideto Nakamura	46	Independent Director
Ryo Matsutani*	36	Corporate Auditor
Rimi Takahashi*	31	Corporate Auditor
Taeko Horiguchi*	58	Corporate Auditor

* Members of our statutory board of corporate auditors are not members of our board of directors.

Biographical Information

The following is a summary of certain biographical information concerning our executive officers, directors, and corporate auditors.

Yusuke Shono. Mr. Shono is our founder and has served as our Chief Executive Officer and our representative director since October 2013 as well as the representative director of our Singapore subsidiary, Warrantee Pte. Ltd. Mr. Shono has expertise in data marketing and programming. Mr. Shono has served as a member of the Medical Point Promotion Council of the Ministry of International Affairs and Communications since 2012. He received a Bachelor of Arts degree in Economics from Kyoto University in 2013.

Yumi Matsudaira. Ms. Matsudaira has served as our director since June 2023 and our Chief Financial Officer since April 2023. Prior to joining our Company, Ms. Matsudaira was an audit manager at PricewaterhouseCoopers where she obtained her U.S. CPA license. She worked at PricewaterhouseCoopers Michigan office and Singapore office for a total seven years from October 2010 to October 2017. Ms. Matsudaira also worked at Canadian Education College in Singapore as a General Manager from October 2017 to April 2023. Ms. Matsudaira received her Bachelor of Business Administration degree in Finance from University of Hawaii in 2007 and her Master of Business Administration from Hawaii Pacific University in 2010.

Hideto Nakamura. Mr. Nakamura is an independent director and has served on our board of directors since June 2023. Mr. Nakamura has served as a Director at Leong Hum Engineering Pte Ltd., where he oversees the accounting and administration department, since April 2019. Mr. Nakamura has served as the Managing Director at Singapore Biken Pte Ltd., where he oversees operations of the entire company, since January 2013. Mr. Nakamura served as a Director at Aquatic Maintenance Services Pte Ltd., where he oversaw the entire company operations, from January 2017 to June 2019. Mr. Nakamura obtained his Bachelor’s degree in Economics from Kyushu International University in 1999.

Ryo Matsutani. Mr. Matsutani has served as a corporate auditor of the Company since June 2023. Mr. Ryo Matsutani has served as a Director at One Asia Lawyers Vietnam Co., Ltd since October 2019. He worked as an in-house Legal Officer at Nitto Denko Corporation from October 2016 to September 2019 and as an in-house Legal Officer at Yahoo Japan Corporation from January 2014 to September 2016. He obtained his Bachelor’s degree in Law from Sophia University in Japan in 2010 and his Juris Doctor degree from Chuo Law School in Japan in 2013.

41

Rimi Takahashi. Ms. Takahashi has served as a corporate auditor of the Company since October 2021. Ms. Takahashi is a free-lance consultant providing services including business planning, financial strategy planning, management planning, and developing competence for small and medium enterprises and executives. Prior to her consulting role, she served as an account executive at Aoyama Sogo Accounting Firm Co., Ltd. from September 2020 to September 2021. From April 2014 to August 2020, she worked in the corporate planning and trade operations department at Itoham Foods Inc. where she analyzed the company’s internal and external performance and developed its corporate strategy. Ms. Takahashi received a Bachelor of Science degree in Chemistry from Nara Women’s University in 2014.

Taeko Horiguchi. Ms. Horiguchi has served as a corporate auditor of the Company since October 2021. Ms. Horiguchi is a principal tax accountant at Taeko Horiguchi Tax Accountant Office (“Taeko”) where she has provided tax representation, tax returns and financial consulting services since October 2009. Prior to Taeko, Ms. Horiguchi held various positions at Ernst & Young LLP’s Japan office providing business advisory services, including M&A consulting, financial due diligence, and corporate valuation. In addition, Ms. Horiguchi worked at Deloitte LLP’s Japan office providing various tax due diligence and consulting services. Ms. Horiguchi received a Bachelor of Arts degree in Business from Tokyo Keizai University in 1987.

There is no family relationship among any of the directors, corporate auditors, and officers. There is no arrangement or understanding among any of our directors and corporate auditors or any other person pursuant to which our directors and corporate auditors are appointed.

Board Diversity

The table below provides certain information regarding the diversity of our board of directors as of the date of this annual report.

Board Diversity Matrix
Country of Principal Executive Offices:	Japan
Foreign Private Issuer	Yes
Disclosure Prohibited under Home Country Law	No
Total Number of Directors	3
	Female	Male	Non- Binary	Did Not Disclose Gender
Part I: Gender Identity
Directors	1	2	0	0
Part II: Demographic Background
Underrepresented Individual in Home Country Jurisdiction	0
LGBTQ+	0
Did Not Disclose Demographic Background	0

42

Controlled Company

Yusuke Shono, our Chief Executive Officer and a director, owns a majority of our outstanding Common Shares and consequently has effective veto rights over certain significant corporate actions, which may limit a shareholder’s ability to influence our business and affairs. As a result, we are a “controlled company” for purposes of the Nasdaq listing rules. As a controlled company, we are permitted to elect to rely on certain exemptions from the obligation to comply with certain corporate governance requirements, including the requirement that:

● our director nominees be selected or recommended solely by independent directors; and

● the requirement that we have a nominating and corporate governance committee and a compensation committee that are composed entirely of independent directors with a written charter addressing the purposes and responsibilities of the committees.

As a foreign private issuer, however, Nasdaq corporate governance rules allow us to follow corporate governance practice in our home country, Japan, with respect to appointments to our board of directors and committees. We follow home country practice as permitted by Nasdaq rather than rely on the “controlled company” exception to the corporate governance rules. See “Item 3. Key Information—D. Risk Factors— Risks Relating to Our Common Shares and the Trading Market—Because we are a foreign private issuer and have taken advantage of exemptions from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.” Accordingly, you would not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq.

B. Compensation

In accordance with the Companies Act and our articles of incorporation, the amount of compensation for our directors and corporate auditors is decided by first setting the maximum amount of total compensation for all of our directors and corporate auditors through a resolution adopted by our shareholders at a shareholders meeting. The representative director authorized by our board of directors and our board of directors then decide on the amount of compensation for each director based on certain criteria established by our Company.

The following table summarizes the total amount of cash remuneration paid to each category of our directors and corporate auditors in the fiscal year ended March 31, 2023, including by the type of remuneration and the number of persons in each category.

(in thousands, except					Number of
number of persons in category)	Total amount of				persons in
Category of directors and corporate auditor	remuneration		Base compensation		category
Executive directors(1)	¥	15,396	¥	15,396		2
Outside directors(2)	¥	720	¥	720		3
Outside corporate auditors(3)	¥	2,520	¥	2,520		3

(1) Consisted of Yusuke Shono and Hiromitsu Tsuga. Hiromitsu Tsuga ceased to be our Chief Financial Officer and Director in April 2023.

(2) Consisted of Takashi Kanazawa, Takashi Kato, and Takeshi Todoroki. Takashi Kanazawa received no payments in the fiscal year ended March 31, 2023 and ceased to be our director in November 2023. Takashi Kato ceased to be our director in June 2023. Takeshi Todoroki ceased to be our director in November 2023.

(3) Consisted of Tomotake Hasumi, Rimi Takahashi, and Taeko Horiguchi. Tomotake Hasumi ceased to be our corporate auditor in June 2023.

43

Stock Options

We granted stock options to purchase our Common Shares, as authorized by our shareholders in June 2016, March 2017, January 2021, and March 2021. The purpose of these grants is to enable our directors, corporate auditors, employees, and advisors to share in our success and to reinforce a corporate culture that aligns interests with those of our shareholders. Our stock option grants generally prohibit transfers of the options. A stock option holder generally forfeits such stock options if they are no longer a director, corporate auditor, employee, or advisor of our Company, except under limited circumstances or as otherwise determined by our board of directors. The following table summarizes the stock options we have issued which are still outstanding.

					Number of
			Exercise Price		Common Shares
Name of Issuance	Issuance Date	Expiration Date	(per share)		to be Granted(2)
Second Series	06/26/2016	06/26/2026	¥	19	45,000
Third Series	03/31/2017	02/28/2027	¥	56	9,000
Fourth Series(1)	01/29/2021	02/02/2031	¥	56	1,146,000
Fourth Series(1)	03/31/2021	02/02/2031	¥	56	873,000

(1) The options may not be exercised and will lapse if: (i) the Company’s Common Shares are issued at a price of less than JPY55.66, (ii) if stock options are issued with an exercise price less than JPY55.66 or other securities with a price less than JPY55.66 per share are paid in exchange for the delivery of one Common Share, (iii) in the event of any sale, purchase, or other disposition transaction of all of the Company’s Common Shares at a price less than JPY55.66 per share, or (iv) if the Common Shares are listed on any stock exchange in Japan or elsewhere and the closing price falls below JPY55.66 per share.

For additional details, see Note 8 to our audited consolidated financial statements as of and for the fiscal years ended March 31, 2023, 2022, and 2021 appearing elsewhere in this annual report.

The following table summarizes the outstanding stock options with respect to our Common Shares that we have granted to our directors and corporate auditors:

							Total Number of
				Exercise		Total Number of	Common Shares
		Beginning of	End of	Price		Stock Options	Underlying
Name	Grant Date	Exercise Period	Exercise Period	(per share)		Granted	Stock Options
Yusuke Shono	03/31/2021	02/03/2021	02/02/2031	¥	56	261	783,000
Hiromitsu Tsuga	06/26/2016	06/27/2016	06/26/2026	¥	19	15	45,000
Hiromitsu Tsuga	03/31/2017	04/01/2017	02/28/2027	¥	56	3	9,000
Hiromitsu Tsuga	02/03/2021	02/03/2021	02/02/2031	¥	56	10	30,000

C. Board Practices

Board of Directors

Our board of directors has the ultimate responsibility for the administration of our affairs. Our board of directors meets no less than once a month. Under the Companies Act, our Company must have at least three directors on our board of directors. Our board of directors is currently comprised of three directors. Directors are typically nominated at the board level and are elected at general meetings of the shareholders. The normal term of office of any director expires at the close of the ordinary general meeting of shareholders held with respect to the last fiscal year ended within two years after such director’s election to office. Our directors may, however, serve any number of consecutive terms.

Our board of directors appoints from among its members one or more representative directors, who serve as head administrator(s) over our Company’s affairs and represent our Company in accordance with the resolutions of our board of directors. Mr. Yusuke Shono, our Chief Executive Officer and a director, is currently the sole representative director of our Company. Our board of directors may appoint from among its members a chairman, a president, or one or more deputy presidents, senior managing directors, or managing directors.

44

Under our Company’s current corporate structure, the Companies Act does not require our board of directors to have any independent directors. Our board of directors is currently comprised of three directors, one of which (Mr. Nakamura) is considered “independent,” as determined in accordance with the applicable Nasdaq rules.

Board of Corporate Auditors

As permitted under the Companies Act, we have elected to structure our corporate governance system as a company with a separate board of corporate auditors instead of an audit committee of our board of directors. Our articles of incorporation provide for not more than five corporate auditors. Corporate auditors are typically nominated at the board level and are elected at general meetings of shareholders by a majority of shareholders entitled to vote, where a quorum is established by shareholders holding one-third or more of the voting rights of those who are entitled to vote are present at the shareholders’ meeting. The normal term of office of any corporate auditor expires at the close of the annual general meeting of shareholders held with respect to the last fiscal year ended within four years after such corporate auditor’s election to office. Our corporate auditors may, however, serve any number of consecutive terms. A corporate auditor may be removed by a special resolution of a general meeting of shareholders.

Our corporate auditors are not required to be certified public accountants. Our corporate auditors may not concurrently serve as directors, employees, or accounting advisors (kaikei sanyo) of our Company or any of our subsidiaries or serve as corporate officers of our subsidiaries. Under the Companies Act, at least one-half of the corporate auditors of a company must be persons who satisfy the requirements for an outside corporate auditor under the Companies Act, and at least one of the corporate auditors must be a full-time corporate auditor.

The function of our board of corporate auditors and each corporate auditor is similar to that of independent directors, including those who are members of the audit committee of a U.S. public company. Each corporate auditor has a statutory duty to supervise the administration by the directors of our affairs, to examine our financial statements and business reports to be submitted by a representative director at the general meetings of shareholders, and to prepare an audit report. Our corporate auditors are obligated to participate in meetings of our board of directors and, if necessary, to express their opinion at such meetings, but are not entitled to vote. Our corporate auditors must inspect the proposals, documents, and any other materials to be submitted by our board of directors to the shareholders at the shareholders’ meeting. If a corporate auditor finds a violation of statutory regulations or our articles of incorporation, or another significant improper matter, such auditor must report those findings to the shareholders at the shareholders’ meeting.

Furthermore, if a corporate auditor believes that a director has engaged in, or is likely to engage in, misconduct or acts that are significantly improper, or that there has been a violation of statutory regulations or our articles of incorporation, the corporate auditor: (i) must report that fact to our board of directors; (ii) can demand that a director convene a meeting of our board of directors; and (iii) if no such meeting is convened in response to the demand, can convene the meeting under the corporate auditor’s own authority. If a director engages in, or is likely to engage in, an activity outside the scope of the objectives of our Company or otherwise in violation of laws or regulations or our articles of incorporation, and such act is likely to cause significant damage to our Company, then a corporate auditor can demand that the director cease such activity.

Our board of corporate auditors has a statutory duty to prepare an audit report based on the audit reports issued by the individual corporate auditors and submit such audit reports to a relevant director and, in the case of audit reports related to financial statements, the independent auditors of our Company each year. A corporate auditor may note an opinion in an audit report issued by our board of corporate auditors, if the opinion expressed in such corporate auditor’s individual audit report is different from the opinion expressed in the audit report issued by our board of corporate auditors. Our board of corporate auditors is empowered to establish the audit principles, the method of examination by our corporate auditors of our affairs and financial position, and any other matters relating to the performance of our corporate auditors’ duties.

Additionally, our corporate auditors must represent our Company in: (i) any litigation between our Company and a director; (ii) dealing with shareholders’ demands seeking a director’s liability to our Company; and (iii) dealing with notices of litigation and settlement in a derivative suit seeking a director’s liability to our Company. A corporate auditor can file court actions relating to our Company within the authority of our corporate auditors, such as an action to nullify the incorporation of our Company, the issuance of shares, or a merger, or to cancel a resolution at a shareholders’ meeting.

45

Risk Management

One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole. Our board of directors is responsible for monitoring and assessing strategic risk exposure, including risks associated with cybersecurity and data protection. In addition, our board of corporate auditors is responsible for overseeing and evaluating our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our board of corporate auditors also reviews legal, regulatory, and compliance matters that could have a significant impact on our financial statements.

Limitation of Liability of Directors and Corporate Auditors

In accordance with Articles 25 and 34 of our articles of incorporation, and pursuant to the provisions of Article 427 of the Companies Act, we are authorized to enter into agreements with our non-executive directors and corporate auditors, respectively, to limit their liability to our Company for any losses or damages arising from the conduct specified under Article 423 of the Companies Act; provided that the amount of such limited liability is either: (i) an amount determined in advance by the Company within the scope specified in our articles of incorporation or (ii) the amount stipulated in applicable laws and regulations, whichever is higher. Mr. Nakamura is considered a non-executive director within the meaning of the Companies Act. We have executed customary limitation of liability agreements with our corporate auditors, Mses. Horiguchi, Takahashi, and Matsutani, and our independent director, Mr. Nakamura. We have not entered into any limitation of liability agreement with our Chief Executive Officer or Chief Financial Officer, as Article 427 of the Companies Act does not allow companies to enter into limitation of liability agreements with executive directors.

Our articles of incorporation include limitation of liability provisions for our directors and corporate auditors, pursuant to which our board of directors can authorize the Company to exempt our directors and corporate auditors from liabilities arising in connection with any failure to execute their respective duties in good faith and due to simple negligence (excluding gross negligence and willful misconduct), within the limits stipulated by applicable laws and regulations, including Article 426, Paragraph 1 of the Companies Act.

D. Employees

See “Item 4. Information on the Company—B. Business Overview—Human Capital.”

E. Share Ownership

The following table sets forth information with respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our Common Shares as of the date of this annual report for:

● each of our named executive officers, directors, and corporate auditors;

● all our named executive officers, directors, and corporate auditors as a group; and

● each person or entity (or group of affiliated persons or entities) known by us to be the beneficial owner of 5% or more of our Common Shares.

Beneficial ownership includes voting or investment power with respect to the Common Shares. Except as indicated below, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all Common Shares shown as beneficially owned by them. Percentage of beneficial ownership of each listed person is based on 22,404,000 Common Shares outstanding as of the date of this annual report.

46

Information with respect to beneficial ownership has been furnished by each named executive officer, director, corporate auditor, or beneficial owner of 5% or more of our Common Shares. Beneficial ownership is determined in accordance with the rules of the SEC and generally requires that such person have voting or investment power with respect to securities. In computing the number of Common Shares beneficially owned by a person listed below and the percentage ownership of such person, Common Shares underlying options, warrants, or convertible securities held by each such person that are exercisable or convertible within 60 days of the date of this annual report are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of any other person.

	Common Shares
	Beneficially Owned
	Number	Percent
Named executive officers, directors, and corporate auditors(1) :
Yusuke Shono(2)	17,618,916	76.0	%
Yumi Matsudaira	—	—
Hideto Nakamura	30,000	*
Ryo Matsutani	—	—
Rimi Takahashi	—	*
Taeko Horiguchi	—	*
All named executive officers, directors, and corporate auditors as a group (six individuals):	17,705,916	76.4	%
5% shareholders:
Yusuke Shono(2)	17,618,916	76.0	%

* Represents less than 1% of the number of Common Shares outstanding.

(1) Unless otherwise indicated, the business address of each of the individuals is c/o Warrantee Inc., 1103 Kitahama Craft, 2-4-1 Doshomachi, Chuo-ku, Osaka City, Osaka 541-0045, Japan.

(2) The aggregate number of Common Shares beneficially owned by Mr. Shono constitutes (i) 16,835,916 Common Shares, and (ii) an aggregate of 783,000 Common Shares that may be issued upon exercise of stock options held by Mr. Shono. 1,737,000 shares owned by Mr. Shono and to which he holds a voting right (including shares previously owned by ZENY and already transferred to Mr. Shono) are subject to a pledge. See “Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Share Pledge Agreement.”

To our knowledge, the Company is not directly or indirectly owned or controlled by another corporation(s), by any foreign government, or by any other natural or legal person(s) severally or jointly.

As of the date of this annual report, none of our issued and outstanding Common Shares are held in the United States.

We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company.

F. Disclosure of a registrant’s action to recover erroneously awarded compensation

Not applicable.

Item 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A. Major Shareholders

See “Item 6. Directors, Senior Management and Employees—E. Share Ownership.”

47

B. Related Party Transactions

The following includes summaries of transactions or agreements, since April 1, 2021, to which we have been a party, in which any of our directors, corporate auditors, executive officers, or beneficial owners of more than 5% of our capital shares, affiliates of our directors, corporate auditors, executive officers, and holders of more than 5% of our voting securities or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control, and other similar arrangements, which are described under “Item 6. Directors, Senior Management and Employees—A. Directors and Senior Management.”

Transactions with Our Chief Executive Officer and His Wholly-Owned Companies

On August 1, 2023, we entered into a term loan agreement with Mr. Shono for $2,700 thousand with a maturity date of March 31, 2024. The interest rate of the term loan is 6.00% per annum. As of the date of this annual report, $2,700 thousand of the principal is outstanding.

Mr. Shono is a guarantor for all our outstanding loans from financial institutions. See a description of these loans under “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Outstanding Loans from Financial Institutions.” Mr. Shono is also a guarantor for the lease of our corporate headquarters. See a description of the lease terms under “Item 4. Information on the Company—B. Business Overview—Property and Equipment.”

Mr. Shono is also a party to a Share Pledge Agreement discussed below, which may cause our Company to be involved in facilitating a sale of the pledged shares.

Share Pledge Agreement

A Share Pledge Agreement was executed on February 19, 2020, among Hack, Mr. Shono, and ZENY, in connection with a pledge to Hack of an aggregate of 1,737,000 Common Shares held by ZENY and Mr. Shono. The pledge was established as security for the joint and several liability of ZENY and Mr. Shono, individually, to pay for the repurchase of the Common Shares acquired by Hack under a share purchase agreement executed among Hack, ZENY, and Mr. Shono on March 29, 2019. The Share Pledge Agreement was supplemented on March 31, 2020 and further amended on March 31, 2022 and January 31, 2024. ZENY was dissolved and liquidated in 2021 and is no longer a party to the Share Pledge Agreement, as supplemented and amended.

Under the terms of the Share Pledge Agreement, as supplemented and amended, the outstanding principal balance due to Hack as of January 31, 2024 was confirmed as JPY193,390,450 (approximately $1,456,802) as the aggregate principal balance. To release the pledge, Mr. Shono is required, to pay (a) by February 29, 2024, the outstanding aggregate principal balance of JPY193,390,450 (approximately $1,456,802) in a lump sum payment, (b) monthly installments (equal monthly installments of JPY17,400,000 (approximately $131,073) from March 31, 2024 to December 31, 2024. If Mr. Shono fails to make any payment under (a) or (b), he is required to use his best efforts to assist Hack in selling the pledged shares to third parties by means of a public offering of the pledged shares or other means of acquisition. Pursuant to the provisions of the agreement, the aforementioned share pledge has been registered on the shareholder registry of our Company.

Investment Agreement with Hack

On March 30, 2018, the Company entered into an investment agreement with Hack for the purchase by Hack of 1,737,000 Common Shares. As of December 31, 2021, Hack’s shareholding was reduced to 57,000 Common Shares, or 0.3% of our outstanding Common Shares.

Under the terms of the investment agreement, Hack is entitled to designate one director to the Company’s board of directors or, in the alternative, to send an observer to meetings of the Company’s board of directors. In the latter case, such observer would not have voting rights. Hack currently does not have a director designee on the Company’s board of directors. In addition, in the event that the Company issues, disposes of, or grants stock options, bonds with stock options, or any other rights to acquire Common Shares, Hack is entitled to subscribe for such rights on a pro-rata basis. The agreement has been terminated in accordance with its terms upon consummation of our initial public offering.

48

Agreement with Lotus Wise Associates Co., Ltd.

On December 23, 2018, we entered in a Capital Alliance Agreement with Lotus Wise Associates Co., Ltd. for the purchase of 1,737,000 Common Shares from Mr. Shono, our Chief Executive Officer. Under the terms of the agreement, Lotus Wise Associates Co., Ltd. is entitled to a board observer at meetings of our board of directors; however, such observer is not entitled to voting rights. Tomotake Hasumi, who served as a director of our Company until February 26, 2021, was appointed on such date to serve as our corporate auditor. Mr. Hasumi is the Chief Executive Officer and representative director of Lotus Wise Associates Co., Ltd., a company wholly owned and controlled by Mr. Hasumi, and certain of its affiliates. In addition, the Company and/or Mr. Shono has a right of first refusal to purchase any of our Common Shares held by Lotus Wise Associates Co., Ltd. The agreement has been terminated in accordance with its terms upon consummation of our initial public offering.

Policies and Procedures for Related Party Transactions

Our board of corporate auditors, as a group, is responsible for establishing a related person transaction policy, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers any transaction, arrangement, or relationship, or any series of similar transactions, arrangements, or relationships that meets the disclosure requirements set forth in Item 404 of Regulation S-K under the Securities Act, or Item 404, in which we were, are or are to be a participant, and in which a “related person,” as defined in Item 404, had, has, or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness, and employment by us of a related person. In reviewing and approving any such transactions, our board of corporate auditors is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s-length transaction and the extent of the related person’s interest in the transaction. Under the approval policy, the board of corporate auditors similarly oversees approval of transactions and arrangements between us and our subsidiaries, on the one hand, and between principal shareholders, directors, and officers to the extent involving amounts in excess of $120,000, on the other hand.

C. Interests of Experts and Counsel

Not applicable.

Item 8. FINANCIAL INFORMATION

A. Consolidated Statements and Other Financial Information

We have appended consolidated financial statements filed as part of this annual report. See “Item 18. Financial Statements.”

Legal Proceedings

We are currently not a party to any material legal or administrative proceedings, other than disclosed below. We are from time to time subject to various legal or administrative claims and proceedings arising in the ordinary course of our business. Any litigation or other legal or administrative proceedings, regardless of the outcome, are likely to result in substantial costs and a diversion of our resources, including our management’s time and attention.

A lawsuit filed by Freude Inc., as the complainant, and our Company as the defendant, relating to the payment of a fee for software development is currently pending in Fukuoka District Court. In this case, Freude Corporation sought recovery of JPY13,027,025 (approximately $98,132) and related late fees from our Company. We intend to vigorously defend the lawsuit.

49

Dividend Policy

We currently intend to retain any future earnings to finance the development and expansion of our businesses and, therefore, do not intend to pay any cash dividends in the foreseeable future. Since our inception, we have not declared or paid any cash dividends on our Common Shares. Any decision to pay dividends in the future will be subject to a number of factors, including our financial condition, results of operations, the level of our retained earnings, capital demands, general business conditions, and other factors our board of directors may deem relevant. Accordingly, we cannot give any assurance that any dividends may be declared and paid in the future.

If declared, holders of outstanding Common Shares on a dividend record date will be entitled to the full dividend declared without regard to the date of issuance of the Common Shares or any transfer of the Common Shares subsequent to the dividend payment date. Payment of declared annual dividends in respect of a particular year, if any, will be made in the following year after approval by our shareholders at the annual general meeting of shareholders, subject to certain provisions of our articles of incorporation. Any dividend we declare will be paid by the depositary bank to the holders of ADSs, subject to the terms of the deposit agreement, to the same extent as holders of our Common Shares, to the extent permitted by applicable law and regulations, less the fees and expenses payable under the deposit agreement.

B. Significant Changes

Except as disclosed elsewhere in this annual report, we have not experienced any significant changes since the date of our audited consolidated financial statements included in this annual report.

Item 9. THE OFFER AND LISTING

A. Offer and Listing Details.

The ADSs have been listed on the Nasdaq Capital Market since July 25, 2023 under the symbol “WRNT.”

B. Plan of Distribution

Not applicable.

C. Markets

The ADSs have been listed on the Nasdaq Capital Market since July 25, 2023 under the symbol “WRNT.”

D. Selling Shareholders

Not applicable.

E. Dilution

Not applicable.

F. Expenses of the Issue

Not applicable.

Item 10. ADDITIONAL INFORMATION

A. Share Capital

Not applicable.

50

B. Memorandum and Articles of Association

We incorporate by reference into this annual report our amended and restated articles of association, which are filed as Exhibit 1.1 to this annual report, and the description of differences in corporate laws contained in our registration statement on Form F-1 (File No. 333-272367), as amended, initially filed with the SEC on June 2, 2023.

C. Material Contracts

We have not entered into any material contracts other than in the ordinary course of business and other than those described in “Item 4. Information on the Company” or elsewhere in this annual report.

D. Exchange Controls

Foreign Exchange Regulations

FEFTA and related regulations regulate certain transactions involving a “Non-Resident of Japan” or a “Foreign Investor,” including “inward direct investments” by Foreign Investors, and payments from Japan to foreign countries or by residents of Japan to Non-Residents of Japan.

“Non-Residents of Japan” are defined as individuals who are not residents in Japan and corporations whose principal offices are located outside of Japan. Generally, branches and other offices of Japanese corporations which are located outside of Japan are regarded as Non-Residents of Japan, and branches and other offices of non-resident corporations which are located within Japan are regarded as residents of Japan.

“Foreign Investors” are defined as:

(i) individuals who are Non-Residents of Japan;

(ii) entities which are organized under the laws of foreign countries or whose principal offices are located outside of Japan;

(iii) companies of which 50% or more of their voting rights are held by individuals who are Non-Residents of Japan and/or corporations which are organized under the laws of foreign countries or whose principal offices are located outside of Japan;

(iv) partnerships engaging in investment activities and investment limited partnerships (including partnerships formed under the laws of foreign countries) which satisfy one of the following conditions:

(a)50% or more of contributions to the partnership were made by (i) individuals who are Non-Residents of Japan, (ii) entities which are organized under the laws of foreign countries or whose principal offices are located outside of Japan, (iii) companies of which 50% or more of their voting rights are held by individuals who are Non-Residents of Japan and/or corporations which are organized under the laws of foreign countries or whose principal offices are located outside of Japan, (iv) entities a majority of whose officers, or officers having the power of representation, are individuals who are Non-Residents of Japan, or (v) partnerships a majority of whose executive partners fall within items (i) through (iv) above; and

(b)a majority of the executive partners of the partnership are (A) any persons or entities who fall within items (i) through (v) above, (B) any partnerships to which 50% or more of contribution were made by persons or entities who fall within items (i) through (v) above, or (C) limited partnerships a majority of whose executive partners fall within Non-Residents of Japan, persons or entities who fall within (A) or (B), or any officers of entities which fall within (A) or (B); and

(v) entities, a majority of whose officers are individuals who are Non-Residents of Japan.

Under FEFTA and related regulations, dividends paid on, and the proceeds of sales in Japan of, shares held by Non-Residents of Japan may in general be converted into any foreign currency and repatriated abroad.

51

Under FEFTA, among other triggering events, a Foreign Investor who desires to acquire shares in a Japanese company which is not listed on any stock exchange in Japan, is subject to a prior filing requirement, regardless of the acquired amount of shares, if such Japanese company engages any business in certain industries related to the national security. Such industries include, among other things, manufacturing in relation to weapons, aircraft, space, and nuclear power, as well as agriculture, fishery, mining, and utility service. Additionally, due to today’s growing awareness of cybersecurity, the recent amendment to FEFTA expanded the scope of the prior filing requirement, broadly covering industries related to data processing businesses and information and communication technologies service. Since our services provided in the commercial healthcare vertical could potentially involve the processing of data by collecting, processing, and retaining customers’ health information, direct acquisition of our Common Shares, rather than ADSs, by a Foreign Investor could be subject to the prior filing requirement under FEFTA.

A Foreign Investor wishing to acquire or hold our Common Shares directly will be required to make a prior filing with the relevant government authorities through the Bank of Japan and wait until clearance for the acquisition is granted by the applicable governmental authorities. Without such clearance, the Foreign Investor will not be permitted to acquire or hold our Common Shares directly. Once clearance is obtained, the Foreign Investor may acquire shares in the amount indicated in the filing any time within six months of the filing. While the standard waiting period to obtain clearance is 30 days, the waiting period could be expedited to two weeks, at the discretion of the applicable governmental authorities, depending on the level of potential impact to national security.

In addition to the prior filing requirement above, when a Foreign Investor who completed a prior filing and received clearance has acquired shares in accordance with the filed information, such Foreign Investor will be required to make a post-acquisition notice filing to report the completed acquisition. Such post-acquisition notice filing must be made no later than 45 days after the acquisition of the shares.

Under FEFTA, in each case where a resident of Japan receives a single payment of more than JPY30 million from a Non-Resident of Japan for a transfer of shares in a Japanese company, such resident of Japan is required to report each receipt of payment to the Minister of Finance of Japan.

E. Taxation

Japanese Taxation

The following is a general summary of the principal Japanese tax consequences (limited to national tax) to owners of our Common Shares, in the form of Common Shares or ADSs, who are non-resident individuals of Japan or who are non-Japanese corporations without a permanent establishment in Japan, collectively referred to in this section as “Non-Resident Holders.” The statements below regarding Japanese tax laws are based on the laws and treaties in force and as interpreted by the Japanese tax authorities as of the date of this annual report, and are subject to changes in applicable Japanese laws, tax treaties, conventions, or agreements, or in the interpretation of them, occurring after that date. This summary is not exhaustive of all possible tax considerations that may apply to a particular investor, and potential investors are advised to satisfy themselves as to the overall tax consequences of the acquisition, ownership, and disposition of our Common Shares, including, specifically, the tax consequences under Japanese law, under the laws of the jurisdiction of which they are resident and under any tax treaty, convention, or agreement between Japan and their country of residence, by consulting their own tax advisors.

For the purpose of Japanese tax law and the tax treaty between the United States and Japan, a U.S. holder of ADSs will generally be treated as the owner of the Common Shares underlying the ADSs evidenced by the ADRs.

Generally, a Non-Resident Holder is subject to Japanese withholding tax on dividends paid by Japanese corporations. Share splits are not subject to Japanese income tax. A conversion of retained earnings or legal reserve (but not additional paid-in capital, in general) into stated capital (whether made in connection with a share split or otherwise) is not treated as a deemed dividend payment to shareholders for Japanese tax purposes. Thus, such a conversion does not trigger Japanese withholding taxation (Article 25 of the Japanese Income Tax Law).

52

Pursuant to the Convention Between the Government of the United States of America and the Government of Japan for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income (the “Treaty”), dividend payments made by a Japanese corporation to a U.S. resident or entity, unless the recipient of the dividend has a “permanent establishment” in Japan, and the Common Shares or ADSs with respect to which such dividends are paid are effectively connected with such “permanent establishment,” are generally subject to a withholding tax at rate of: (i) 10% for portfolio investors who are qualified U.S. residents eligible for benefits of the Treaty; and (ii) 0% (i.e., no withholding) for pension funds which are qualified U.S. residents eligible for benefits of the Treaty, provided that the dividends are not derived from the carrying on of a business, directly or indirectly, by such pension funds. Japan is a party to a number of income tax treaties, conventions, and agreements (collectively, the “Tax Treaties”), whereby the maximum withholding tax rate for dividend payments is set at, in most cases, 15% for portfolio investors who are Non-Resident Holders. Specific countries with which such Tax Treaties have been entered into include Canada, Denmark, Finland, Germany, Ireland, Italy, Luxembourg, New Zealand, Norway, Republic of Singapore, and Spain. Japan also has Tax Treaties with, among others, Australia, Belgium, France, the Netherlands, Sweden, Switzerland and the United Kingdom whereby the withholding tax rate on dividends is reduced to 10% for portfolio investors.

On the other hand, unless one of the applicable Tax Treaties reducing the maximum rate of withholding tax applies, the standard tax rate applicable to dividends paid to Non-Resident Holders is generally 20.42% (or 20% for dividends due and payable on or after January 1, 2038) under the Japanese Income Tax Law. However, with respect to dividends paid on listed shares issued by a Japanese corporation to non-resident holders, other than any individual shareholder who holds 3% or more of the total issued shares (to whom the aforementioned withholding tax rate still applies), the aforementioned withholding tax rate is reduced to 15.315% (or 15% for dividends due and payable on or after January 1, 2038) (Article 213, Paragraph 1, Item 1 of the Japanese Income Tax Law and Article 9-3, Item 1 of the Japanese Special Tax Measures Law). On December 2, 2011, the “Special measures act to secure the financial resources required to implement policy on restoration of the East Japan Earthquake” (Act No. 117 of 2011) was promulgated and special surtax measures on income tax and withholding tax were introduced thereafter to fund the restoration effort for the earthquake. Income tax and withholding taxpayers need to pay a surtax, calculated by multiplying the standard tax rate by 2.1% for 25 years starting from January 1, 2013 (“Surtax”). The withholding tax rates described above include this Surtax.

The treaty rate normally overrides the domestic rate, but due to the so-called “preservation doctrine” under Article 1(2) of the Treaty, and/or due to Article 3-2 of the Special Measures Law for the Income Tax Law, Corporation Tax Law and Local Taxes Law with respect to the Implementation of Tax Treaties, if the tax rate under the domestic tax law is lower than that promulgated under the applicable income tax treaty, then the domestic tax rate is still applicable. Currently, the tax rate under the applicable tax treaty is lower than that under the domestic tax law and thus the treaty override treatment applies. As such, the tax rate under the Treaty applies for most holders of shares or ADSs who are U.S. residents or entities. In the case where the treaty rate is applicable, no Surtax is imposed. In order to enjoy treaty benefits, Non-Resident Holders who are entitled to a reduced treaty rate of Japanese withholding tax on any dividends on Common Shares or ADSs, in general, are required to submit a treaty application form, through our Company (or the relevant withholding agent), to the relevant tax authority prior to the payment of dividends. With respect to ADSs, in order for ADS holders to enjoy treaty benefits, the depositary or its agent must submit two treaty application forms (“Application Form for Income Tax Convention regarding Extension of Time for Withholding of Tax on Dividends with respect to Foreign Depositary Receipt” must be submitted before the payment of dividends and “Application Form for Income Tax Convention regarding Relief from Japanese Income Tax and Special Income Tax for Reconstruction on Dividends with respect to Foreign Depositary Receipt” must be submitted within eight months after the record date concerning such payment of dividends) together with certain other documents, through our Company, to the relevant tax authority. To claim the reduced rate, the ADSs holders are required to file a proof of taxpayer status, residence, and beneficial ownership, as applicable, and provide other information or documents as may be required by the depositary. Gains derived from the sale of a Japanese corporation’s Common Shares or ADSs by Non-Resident Holders without a permanent establishment in Japan as a portfolio investor, are, in general, not subject to Japanese income or corporation taxes. Japanese inheritance and gift taxes at progressive rates may by payable by an individual who has acquired a Japanese corporation’s Common Shares or ADS’s as a legatee, heir, or donee, even if the individual is not a Japanese resident.

United States Federal Income Taxation

The following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of our Common Shares or ADSs by a U.S. holder (as defined below). This summary is for general information purposes only and does not purport to be a complete discussion of all potential tax considerations that may be relevant to a particular person’s decision to acquire Common Shares or ADSs.

53

This summary is based on the U.S. Internal Revenue Code of 1986, as amended (the “Code”), the regulations promulgated under the Code (the “U.S. Treasury Regulations”), the Treaty, published rulings of the U.S. Internal Revenue Service (the “IRS”), published administrative positions of the IRS, and U.S. court decisions that are applicable and, in each case, as in effect and available, as of the date hereof. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis which could affect the U.S. federal income tax considerations described in this summary. We have not requested a ruling from the IRS with respect to any of the U.S. federal income tax considerations described below and, as a result, the IRS could disagree with portions of this discussion.

For purposes of this discussion, a “U.S. holder” is a beneficial owner of the Common Shares or ADSs that is, for U.S. federal income tax purposes:

● an individual who is a citizen or resident of the United States;

● a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;

● an estate the income of which is includable in gross income for U.S. federal income tax purposes regardless of its source; or

● a trust (i) the administration of which is subject to the primary supervision of a court within the United States and which has one or more U.S. persons who have the authority to control all substantial decisions of the trust, or (ii) that has validly elected to be treated as a U.S. person under the Code.

If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds the Common Shares or ADSs, the U.S. federal income tax consequences to such partnership and its partners of the ownership and disposition of the Common Shares or ADSs generally will depend in part on the activities of the partnership and the status of such partners. This summary does not address the tax consequences to any such partner or partnership. Partners of entities or arrangements that are classified as partnerships for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences of the ownership and disposition of the Common Shares or ADSs.

This discussion applies only to a U.S. holder that holds Common Shares or ADSs as “capital assets” under the Code (generally, property held for investment). Unless otherwise provided, this summary does not discuss reporting requirements. In addition, this discussion does not address any tax consequences other than U.S. federal income tax consequences, such as U.S. state and local tax consequences, U.S. estate and gift tax consequences, and non-U.S. tax consequences, and does not describe all of the U.S. federal income tax consequences that may be relevant in light of a U.S. holder’s particular circumstances, including alternative minimum tax consequences, the Medicare tax on certain net investment income, and tax consequences to holders that are subject to special provisions under the Code, including, but not limited to, holders that:

● are tax exempt organizations, qualified retirement plans, individual retirement accounts, or other tax deferred accounts;

● are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies;

● are brokers or dealers in securities or currencies or holders that are traders in securities that elect to apply a mark-to-market accounting method;

● have a “functional currency” for U.S. federal income tax purposes that is not the U.S. dollar;

● own Common Shares or ADSs as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position;

● acquire Common Shares or ADSs in connection with the exercise of employee stock options or otherwise as compensation for services;

54

● are partnerships or other pass-through entities for U.S. federal income tax purposes (or investors in such partnerships and entities);

● are required to accelerate the recognition of any item of gross income with respect to the Common Shares or ADSs as a result of such income being recognized on an applicable financial statement;

● own or will own (directly, indirectly, or constructively) 10% or more of our total combined voting power or value;

● hold the Common Shares or ADSs in connection with trade or business conducted outside of the United States or in connection with a permanent establishment or other fixed place of business outside of the United States; or

● are former U.S. citizens or former long-term residents of the United States.

Each U.S. holder is urged to consult its tax advisor regarding the application of U.S. federal taxation to its particular circumstances, and the state, local, non-U.S., and other tax considerations of the ownership and disposition of our Common Shares or the ADSs.

Treatment of ADSs

For U.S. federal income tax purposes, a U.S. holder of ADSs generally will be treated as the beneficial owner of the underlying shares represented by the ADSs. The remainder of this discussion assumes that a U.S. holder of the ADSs will be treated in this manner. Accordingly, deposits or withdrawals of Common Shares for ADSs generally will not be subject to U.S. federal income tax.

PFIC Considerations

A non-U.S. corporation, such as our Company, is classified as a PFIC for any taxable year in which, after applying relevant look-through rules with respect to the income and assets of its subsidiaries, either: (i) 50% or more of the value of the corporation’s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets; or (ii) at least 75% of the corporation’s gross income is passive income. “Passive income” generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions. In determining the value and composition of our assets, the cash we raised in our initial public offering will generally be considered to be held for the production of passive income and thus will be considered a passive asset.

Based upon our operations and the valuation of our assets, including goodwill, we do not believe we were a PFIC for our 2023 taxable year. However, the determination of whether any corporation was, or will be, a PFIC for a taxable year depends, in part, on the application of complex U.S. federal income tax rules that are subject to differing interpretations. In addition, because the determination of whether a corporation will be a PFIC for any taxable year can only be made after the close of such taxable year, there can be no assurance that we will not be a PFIC for our current taxable year or any future taxable year. Our PFIC status will depend, in part, on how quickly we utilize the cash we raised in our initial public offering in our business. Furthermore, because we may value our goodwill based on the market price of the ADSs, a decrease in the market price of the ADSs may also cause us to be classified as a PFIC for the current or any future taxable year.

We must make a separate determination each year as to whether we are a PFIC. As a result, our PFIC status may change. If we are a PFIC for any year during which you hold the Common Shares or ADSs, we will generally continue to be treated as a PFIC for all succeeding years during which you hold such Common Shares or ADSs. However, if we cease to be a PFIC, provided that you have not made a mark-to-market election, as described below, you may avoid some of the adverse effects of the PFIC regime by making a deemed sale election with respect to the Common Shares or ADSs, as applicable.

The discussion below under “— Distributions on the Common Shares or ADSs” and “— Sale or Other Disposition of the Common Shares or ADSs” is written on the basis that we will not be classified as a PFIC for U.S. federal income tax purposes. The U.S. federal income tax rules that generally would apply if we are treated as a PFIC are discussed below under “— PFIC Rules.”

55

Distributions on the Common Shares or ADSs

Subject to the PFIC rules discussed below, the gross amount of any distributions paid on our Common Shares or ADSs will generally be included in the gross income of a U.S. holder as dividend income on the date actually or constructively received by the U.S. holder, in the case of Common Shares, or by the depositary, in the case of ADSs, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (computed on the basis of U.S. federal income tax principles). Because we do not intend to determine our earnings and profits on the basis of U.S. federal income tax principles, we expect that distributions will generally be reported to U.S. holders as dividends. Dividends received on our Common Shares or ADSs will not be eligible for the dividends received deduction allowed to corporations in respect of dividends received from U.S. corporations.

Subject to the PFIC rules discussed below, individuals and other non-corporate U.S. holders will be subject to tax on any such dividends at the lower capital gains tax rate applicable to “qualified dividend income,” provided that certain conditions are satisfied, including that (i) the Common Shares or ADSs on which the dividends are paid are readily tradable on an established securities market in the United States or we are eligible for the benefits of the Treaty, (ii) we are not a PFIC nor treated as such with respect to a U.S. holder (as discussed below) for either our taxable year in which the dividend was paid or for the preceding taxable year, and (iii) certain holding period requirements are met. For this purpose, ADSs listed on Nasdaq will generally be considered to be readily tradable on an established securities market in the United States. You should consult your tax advisor regarding the availability of the lower rate for dividends paid with respect to our Common Shares or ADSs. There is a tax treaty by and between the U.S. and Japan.

For U.S. foreign tax credit purposes, dividends paid on our Common Shares or ADSs generally will be treated as foreign source income and generally will constitute passive category income. The amount of a dividend will include any amounts withheld by us in respect of Japanese income taxes. Subject to applicable limitations, some of which vary depending upon the U.S. holder’s particular circumstances, Japanese income taxes withheld from dividends on the Common Shares or ADSs, at a rate not exceeding any reduced rate pursuant to the Treaty, will be creditable against the U.S. holder’s U.S. federal income tax liability. In lieu of claiming a foreign tax credit, U.S. holders may, at their election, deduct foreign taxes, including any Japanese income taxes, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. The rules governing foreign tax credits are complex and U.S. holders should consult their tax advisers regarding the creditability or deductibility of foreign taxes in their particular circumstances.

The amount of any dividend paid in Japanese yen will equal the U.S. dollar value of the Japanese yen received, calculated by reference to the exchange rate in effect on the date the dividend is received by you, in the case of Common Shares, or by the depositary, in the case of ADSs, regardless of whether the Japanese yen are converted into U.S. dollars. If the Japanese yen received as a dividend are converted into U.S. dollars on the date of receipt, a U.S. holder generally will not be required to recognize foreign currency gain or loss in respect of the dividend income. If the Japanese yen received as a dividend are not converted into U.S. dollars on the date of receipt, a U.S. holder will have a basis in the Japanese yen equal to their U.S. dollar value on the date of receipt. Any gain or loss realized on a subsequent conversion or other disposition of the Japanese yen will be treated as U.S. source ordinary income or loss.

Sale or Other Disposition of the Common Shares or ADSs

A U.S. holder will recognize gain or loss on the sale or other disposition of a Common Share or ADS equal to the difference between the amount realized for the Common Share or ADS and the holder’s tax basis in the Common Share or ADS. Subject to the PFIC rules discussed below, such gain or loss will generally be capital gain or loss and will be long-term capital gain or loss if the U.S. holder’s holding period for such Common Share or ADS was more than one year as of the date of the sale or other disposition. Long-term capital gain recognized by a non-corporate U.S. holder is subject to U.S. federal income tax at rates lower than the rates applicable to ordinary income and short-term capital gains, while short-term capital gains are subject to U.S. federal income tax at the rates applicable to ordinary income. The deductibility of capital losses is subject to various limitations. Any gain or loss recognized will generally be U.S. source gain or loss for foreign tax credit purposes. Consequently, a U.S. holder may not be able to use the foreign tax credit arising from any Japanese tax imposed on the disposition of the Common Share or ADS unless such credit can be applied (subject to applicable limitations) against tax due on other income treated as derived from non-U.S. sources.

56

PFIC Rules

If we are a PFIC for any taxable year during which you hold our Common Shares or ADSs, you will be subject to special tax rules with respect to any “excess distribution” that you receive and any gain you realize from a sale or other disposition (including a pledge) of the Common Shares or ADSs, unless you make a mark-to-market election as discussed below. Distributions you receive from us in a taxable year that are greater than 125% of the average annual distributions you received from us during the shorter of the three preceding taxable years or your holding period for the Common Shares or ADSs will be treated as an excess distribution. Under these special tax rules:

● the excess distribution or gain will be allocated ratably over your holding period for the Common Shares or ADSs,

● the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income, and

● the amount allocated to each of the other taxable years will be subject to tax at the highest rate of tax in effect for you for such year and will be increased by an additional tax calculated as an interest charge on the resulting tax deemed deferred with respect to each such other taxable year at the rates generally applicable to underpayments of tax payable in those years.

If we are a PFIC for any taxable year during which a U.S. holder holds our Common Shares or ADSs and any of our subsidiaries or other corporate entities in which we own equity interests is also a PFIC, such U.S. holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules. U.S. holders are urged to consult their tax advisors regarding the application of the PFIC rules to any of our subsidiaries.

As an alternative to the foregoing rules, a U.S. holder may make a mark-to-market election with respect to our Common Shares or ADSs, provided such Common Shares or ADSs are treated as “marketable stock.” The Common Shares or ADSs generally will be treated as marketable stock if the Common Shares or ADSs are regularly traded on a “qualified exchange or other market,” as defined in applicable U.S. Treasury Regulations. The ADSs will be marketable stock as long as they remain listed on Nasdaq, which is a qualified exchange for this purpose, and are regularly traded. We anticipate that the ADSs should qualify as being regularly traded but no assurances can be given in this regard. Only the ADSs and not the Common Shares will be listed on Nasdaq. Consequently, a U.S. holder of Common Shares that are not represented by ADSs generally will not be eligible to make the mark-to-market election.

If a U.S. holder makes a valid mark-to-market election with respect to the ADSs, the holder generally will (i) include as ordinary income for each taxable year that we are a PFIC the excess, if any, of the fair market value of ADSs held at the end of the taxable year over the adjusted tax basis of such ADSs and (ii) deduct as an ordinary loss in each such taxable year the excess, if any, of the adjusted tax basis of the ADSs over the fair market value of such ADSs held at the end of the taxable year, but such deduction will only be allowed to the extent of the net amount previously included in income as a result of the mark-to-market election. The U.S. holder’s adjusted tax basis in the ADSs would be adjusted to reflect any income or loss resulting from the mark-to-market election. If a U.S. holder makes a mark-to-market election in respect of the ADSs and we cease to be classified as a PFIC, the holder will not be required to take into account the gain or loss described above during any period that we are not classified as a PFIC. If a U.S. holder makes a mark-to-market election, any gain such U.S. holder recognizes upon the sale or other disposition of the ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary loss to the extent of the net amount previously included in income as a result of the mark-to-market election.

Because a mark-to-market election cannot be made for any lower-tier PFICs that we may own, a U.S. holder may continue to be subject to the general PFIC rules described above with respect to such U.S. holder’s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes.

We do not intend to provide information necessary for U.S. holders to make “qualified electing fund” elections which, if available, would result in tax treatment different from (and generally less adverse than) the general tax treatment for PFICs described above.

If a U.S. holder owns Common Shares or ADSs during any year in which we are a PFIC, the holder generally must file an annual report containing such information as the U.S. Treasury may require on IRS Form 8621 (or any successor form). A failure to file this report generally will suspend the statute of limitations with respect to any tax return, event, or period to which such report relates (potentially including with respect to items that do not relate to a U.S. holder’s investment in Common Shares or ADSs).

57

The PFIC rules are complex, and each U.S. holder should consult its own tax advisor regarding the PFIC rules, the elections which may be available to it, and how the PFIC rules may affect the U.S. federal income tax consequences relating to the ownership and disposition of Common Shares or ADSs.

Information Reporting and Backup Withholding

Payments of dividends or sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries may be subject to information reporting and backup withholding, unless (i) the U.S. holder is a corporation or other exempt recipient, or (ii) in the case of backup withholding, the U.S. holder provides a correct U.S. taxpayer identification number and certifies that it is not subject to backup withholding.

Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding rules will be allowed as a credit against a U.S. holder’s U.S. federal income tax liability, if any, or will be refunded, if such U.S. holder furnishes required information to the IRS in a timely manner. Each U.S. holder should consult its own tax advisor regarding the information reporting and backup withholding rules in its particular circumstances and the availability of and procedures for obtaining an exemption from backup withholding.

Reporting Obligations for Certain Owners of Foreign Financial Assets

Certain U.S. holders may be required to file information returns with respect to their investment in Common Shares or ADSs. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. holders that hold certain specified foreign financial assets in excess of certain thresholds. The definition of “specified foreign financial assets” includes not only financial accounts maintained in non-U.S. financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person, and any interest in a non-U.S. entity. U.S. holders may be subject to these reporting requirements unless their Common Shares or ADSs are held in an account at certain financial institutions.

The discussion of reporting obligations set forth above is not intended to constitute an exhaustive description of all reporting obligations that may apply to a U.S. holder. A failure to satisfy certain reporting obligations may result in an extension of the period during which the IRS can assess a tax, and under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting obligation. Penalties for failure to comply with these reporting obligations are substantial. U.S. holders should consult with their own tax advisors regarding their reporting obligations under these rules, including the requirement to file an IRS Form 8938.

The foregoing discussion of certain U.S. federal income tax considerations is for general information only and is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our Common Shares or the ADSs. U.S. Holders should consult their own tax advisors concerning the tax consequences applicable to their particular situations.

F. Dividends and Paying Agents

Not applicable.

G. Statement by Experts

Not applicable.

H. Documents on Display

We have previously filed with the SEC our registration statements on Form F-1 (File No. 333-265511), as amended, and on Form F-1 (File No. 333-272367), as amended.

58

We are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we are required to file reports and other information with the SEC. Specifically, we are required to file annually a Form 20-F within four months after the end of each fiscal year. However, we did not timely file our annual report on Form 20-F for the fiscal year ended March 31, 2022. See “Item 3. Key Information—D. Risk Factors—Risks Relating to Our Common Shares and the Trading Market—We were not in compliance with our periodic reporting obligation under the Exchange Act by failing to file our annual report on Form 20-F for the fiscal year ended March 31, 2022 on a timely basis. In the event that we become delinquent with our SEC reporting obligation again, we may not be able to provide up-to-date disclosure to the public market, the ADSs may be considered highly risky or worthless, and the ADSs may be delisted from Nasdaq.” The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing, among other things, the furnishing and content of proxy statements to shareholders, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.

I. Subsidiary Information

For information about our subsidiary, see “Item 4. Information on the Company—A. History and Development of the Company.”

J. Annual Report to Security Holders

Not applicable.

Item 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in foreign currency. We do not hold or issue financial instruments for trading purposes.

Foreign Currency Risk

Our functional currency is the Japanese Yen, whereas our foreign operating expenses incurred by our wholly-owned subsidiary in Singapore are denominated in Singapore dollars. Our consolidated results of operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. A hypothetical 10% change in foreign currency exchange rates may result in a material impact on our consolidated financial statements. To date, we have not had a formal hedging program with respect to foreign currencies, but we may do so in the future if our exposure to foreign currencies should become more significant.

Item 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

A. Debt Securities

Not applicable.

B. Warrants and Rights

Not applicable.

C. Other Securities

Not applicable.

59

D. American Depositary Shares

The Bank of New York Mellon, as depositary, registers and delivers ADSs. Each ADS represents one Common Share (or a right to receive one Common Share) deposited with MUFG Bank Ltd., as custodian for the depositary in Japan. Each ADS also represents any other securities, cash, or other property that may be held by the depositary. The deposited shares together with any other securities, cash, or other property held by the depositary are referred to as the deposited securities. The depositary’s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.

The form of deposit agreement for the ADSs and the form of ADRs that represents an ADS have been incorporated by reference as exhibits to this annual report.

Fees and Expenses

Persons depositing or withdrawing shares or ADS holders must pay:	For:
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)	Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
$0.05 (or less) per ADS	Any cash distribution to ADS holders
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs	Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders
$0.05 (or less) per ADS per calendar year	Depositary services
Registration or transfer fees	Transfer and registration of our Common Shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares
Expenses of the depositary	Cable (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement) Converting foreign currency to U.S. dollars
Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes	As necessary
Any charges incurred by the depositary or its agents for servicing the deposited securities	As necessary

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

60

From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary, or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers, or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads, or commissions.

The depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker, or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligation to act without negligence or bad faith. The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from us in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.

Payment of Taxes

You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.

61

Part II

Item 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

Item 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

See “Item 10. Additional Information” for a description of the rights of securities holders, which remain unchanged.

Use of Proceeds

The following “Use of Proceeds” information relates to the registration statement on Form F-1, as amended (File Number 333-272367) for our initial public offering, which was declared effective by the SEC on June 30, 2022. In July 2023, we completed our initial public offering in which we issued and sold an aggregate 2,400,000 ADSs at a price of $4.00 per ADS for $9.6 million. Prime Number Capital LLC was the representative of the underwriters of our initial public offering.

We incurred approximately $2.78 million in expenses in connection with our initial public offering, which included approximately $864,000 in expenses paid to or for underwriters and approximately $1.92 million in other expenses. None of the transaction expenses included payments to directors or officers of our company or their associates, persons owning more than 10% or more of our equity securities, or our affiliates. None of the net proceeds we received from the initial public offering were paid, directly or indirectly, to any of our directors or officers or their associates, persons owning 10% or more of our equity securities or our affiliates.

The net proceeds raised from the initial public offering were $7.19 million after deducting underwriting discounts and the offering expenses payable by us. As of January 29, 2024, we had used $10,000 for recruitment, $100,000 for system development, and $2,000,000 for working capital and other general corporate purposes. We intend to use the remaining proceeds from our initial public offering in the manner disclosed in our registration statement on Form F-1, as amended (File Number 333-272367).

Item 15. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, we carried out an evaluation of the effectiveness of our disclosure controls and procedures, which is defined in Rules 13a-15(e) of the Exchange Act, as of March 31, 2023.

Based on that evaluation, our management has concluded that, due to the material weaknesses described below, as of March 31, 2023, our disclosure controls and procedures were not effective. Our conclusion is based on the fact that we do not have sufficient manpower in our accounting department which may reduce the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management is currently in the process of evaluating the steps necessary to remediate the ineffectiveness, such as (i) hiring more qualified accounting personnel with relevant U.S. GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function and to set up a financial and system control framework, and (ii) implementing regular and continuous U.S. GAAP accounting and financial reporting training programs for our accounting and financial reporting personnel.

62

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of March 31, 2023. The assessment was based on criteria established in the framework Internal Control—Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management concluded that our internal control over financial reporting was not effective as of March 31, 2023. Our management identified a material weakness in our internal control over financial reporting due to (i) a lack of manpower in our accounting department, which may reduce the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP and (ii) failure to timely file our annual report on Form 20-F for the fiscal years ended March 31, 2023 and 2022.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or because the degree of compliance with policies or procedures may deteriorate.

Attestation Report of the Registered Public Accounting Firm

This annual report on Form 20-F does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC where domestic and foreign registrants that are non-accelerated filers, which we are, and “emerging growth companies,” which we also are, are not required to provide the auditor attestation report.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this annual report on Form 20-F that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 16. [RESERVED]

Item 16A. AUDIT COMMITTEE FINANCIAL EXPERT

Under the Companies Act, we have elected to structure our corporate governance system as a company with a separate board of corporate auditors and therefore do not have an audit committee. The function of our board of corporate auditors and each corporate auditor is similar to that of independent directors, including those who are members of the audit committee of a U.S. public company. Our board of corporate auditors is comprised of three corporate auditors, each of which satisfies the requirements of Rule 10A-3 under the Exchange Act.

Item 16B. CODE OF ETHICS

Our board of directors has adopted a written code of business conduct that applies to our directors, corporate auditors, officers, employees (including our principal executive officer, principal financial officer, principal accounting officer or controller, and other persons performing similar functions), and our agents.

63

Item 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered and billed by Assentsure PAC, our independent registered public accounting firm since November 8, 2023, and BF Borgers CPA PC, our independent registered public accounting firm before November 8, 2023.

	For the Fiscal Years Ended March 31,
	2023		2022		2021
Audit fees(1)	$	255,000	$	438,000	$	90,000
Audit-Related fees		—		—		—
Tax fees		—		—		—
All other fees		—		—		—
Total	$	255,000	$	438,000	$	90,000

(1) Audit fees include the aggregate fees billed for each of the fiscal years for professional services rendered by our independent registered public accounting firm for the audit of our annual financial statements or for the audits of our financial statements and review of the interim financial statements in connection with our initial public offering.

The policy of our audit committee is to pre-approve all audit and non-audit services provided by our independent registered public accounting firm, including audit services, audit-related services, tax services, and other services as described above.

Item 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Please refer to “Item 3. Key Information—D. Risk Factors—Risks Relating to Our Common Shares and the Trading Market—As a foreign private issuer, we have followed home country practice even though we are considered a ‘controlled company’ under Nasdaq corporate governance rules, which could adversely affect our public shareholders.”

Item 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

None.

Item 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

There has been no change in independent accountants for our Company during the two most recent fiscal years or any subsequent interim period except as previously reported in our Report of Foreign Private Issuer on Form 6-K (File No. 001-41433), filed with the SEC on December 26, 2023. There have been no disagreements of the type required to be disclosed by Item 16F(b).

Item 16G. CORPORATE GOVERNANCE

We are a “foreign private issuer” as defined under the federal securities laws of the U.S. and the Nasdaq listing standards. Under the federal securities laws of the United States, foreign private issuers are subject to different disclosure requirements than U.S.-domiciled public companies. We intend to take all actions necessary for us to maintain our status as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the Exchange Act and other applicable rules adopted by the SEC, and the Nasdaq listing standards. Under the SEC rules and the Nasdaq listing standards, a foreign private issuer is subject to less stringent corporate governance requirements. Subject to certain exceptions, the SEC and Nasdaq permit a foreign private issuer to follow its home country practice in lieu of their respective rules and listing standards. In general, our articles of incorporation and the Companies Act govern our corporate affairs.

64

In particular, as a foreign private issuer, we follow Japanese law and corporate practice in lieu of the corporate governance provisions set out under Nasdaq Rule 5600, the requirement in Nasdaq Rule 5250(b)(3) to disclose third party director and nominee compensation, and the requirement in Nasdaq Rule 5250(d) to distribute annual and interim reports. Of particular note, the following rules under Nasdaq Rule 5600 differ from Japanese law requirements:

● Nasdaq Rule 5605(b)(1) requires that at least a majority of a listed company’s board of directors be independent directors, and Nasdaq Rule 5605(b)(2) requires that independent directors regularly meet in executive session, where only independent directors are present. Under our current corporate structure, the Companies Act does not require independent directors. However, our board of directors is currently comprised of three directors, one of which is considered “independent,” as determined in accordance with the applicable Nasdaq rules;

● Nasdaq Rule 5605(c)(2)(A) requires a listed company to have an audit committee composed entirely of not less than three directors, each of whom must be independent. Under Japanese law, a company may have a statutory auditor or a board of auditors. We have a three-member board of corporate auditors. See “Item 6. Directors, Senior Management and Employees—C. Board Practices—Board of Corporate Auditors” for additional information;

● Nasdaq Rule 5605(d) requires, among other things, that a listed company’s compensation committee be comprised of at least two members, each of whom is an independent director as defined under such rule. Our board of directors collectively participates in the discussions and determination of compensation for our executive, directors, and corporate auditors, and other compensation related matters;

● Nasdaq Rule 5605(e) requires that a listed company’s nomination and corporate governance committee be comprised solely of independent directors. Our board of directors does not have a standalone nomination and corporate governance committee. Our board of directors collectively participates in the nomination process of potential directors and corporate auditors and oversee our corporate governance practices; and

● Nasdaq Rule 5620(c) sets out a quorum requirement of 33-1/3% applicable to meetings of shareholders. In accordance with Japanese law and generally accepted business practices, our articles of incorporation provide that there is no quorum requirement for a general resolution of our shareholders. However, under the Companies Act and our articles of incorporation, a quorum of not less than one-third of the total number of voting rights is required in connection with the election of directors, statutory auditors, and certain other matters.

Item 16H. MINE SAFETY DISCLOSURE

Not applicable.

Item 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

Item 16J. INSIDER TRADING POLICIES

We will be required to begin compliance with the disclosure and tagging requirements under this item in the annual report on Form 20-F for the fiscal year ending March 31, 2024.

Item 16K. CYBERSECURITY

Pursuant to the applicable SEC transition guidance, the disclosure required by Item 16K will be applicable to the Company from the fiscal year ending March 31, 2024.

65

Part III

Item 17. FINANCIAL STATEMENTS

We have elected to provide financial statements pursuant to Item 18.

Item 18. FINANCIAL STATEMENTS

The consolidated financial statements of Warrantee are included at the end of this annual report.

66

Item 19. EXHIBITS

EXHIBIT INDEX

Exhibit No.	Description
1.1*	Amended and Restated Articles of Incorporation of the Registrant (English Translation)
2.1	Form of Deposit Agreement among the Registrant, the depositary, and the owners and holders of the ADSs issued thereunder (incorporated by reference to Exhibit 4.1 of our Registration Statement on Form F-1 (File No. 333-272367) filed with the U.S. Securities and Exchange Commission on June 2, 2023)
2.2	Specimen American depositary receipt (included in Exhibit 2.1)
2.3*	Description of the rights of each class of securities registered
4.1	Agency Agreement between the Registrant and Paygene Co., Ltd., dated April 1, 2021 (English translation) (incorporated by reference to Exhibit 10.1 of our Registration Statement on Form F-1 (File No. 333-272367) filed with the U.S. Securities and Exchange Commission on June 2, 2023)
4.2	Memorandum of Amendment between the Registrant and Paygene Co., Ltd., dated December 22, 2021 (English translation) (incorporated by reference to Exhibit 10.2 of our Registration Statement on Form F-1 (File No. 333-272367) filed with the U.S. Securities and Exchange Commission on June 2, 2023)
4.3	Agency Agreement between the Registrant and Beauken Co., Ltd. dated May 27, 2022 (English translation) (incorporated by reference to Exhibit 10.3 of our Registration Statement on Form F-1 (File No. 333-272367) filed with the U.S. Securities and Exchange Commission on June 2, 2023)
4.4	Agency Agreement between the Registrant and Connect Plus Co., Ltd. dated May 30, 2022 (English translation) (incorporated by reference to Exhibit 10.4 of our Registration Statement on Form F-1 (File No. 333-272367) filed with the U.S. Securities and Exchange Commission on June 2, 2023)
4.5	Agency Agreement between the Registrant and Y’s, Inc. dated May 30, 2022 (English translation) (incorporated by reference to Exhibit 10.5 of our Registration Statement on Form F-1 (File No. 333-272367) filed with the U.S. Securities and Exchange Commission on June 2, 2023)
4.6*	English Translation of the Loan Agreement dated August 1, 2023 by and between the Registrant and Yusuke Shono
8.1	List of subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of our Registration Statement on Form F-1 (File No. 333-272367) filed with the U.S. Securities and Exchange Commission on June 2, 2023)
11.1*	Code of Ethics and Business Conduct
12.1*	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12.2*	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
13.1**	Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
13.2**	Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97.1*	Compensation Recovery Policy of the Registrant
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed with this annual report on Form 20-F

** Furnished with this annual report on Form 20-F

67

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

	Warrantee Inc.
	By:	/s/ Yusuke Shono
		Yusuke Shono
		Chief Executive Officer and Director
		(Principal Executive Officer)
Date: January 31, 2024

68

WARRANTEE INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

TABLE OF CONTENTS

CONTENTS	PAGE(S)
CONSOLIDATED FINANCIAL STATEMENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID: 6783)	F-2
CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2023 AND 2022	F-3
CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE FISCAL YEARS ENDED MARCH 31, 2023, 2022, AND 2021	F-4
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT) FOR THE FISCAL YEARS ENDED MARCH 31, 2023, 2022, AND 2021	F-6
CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FISCAL YEARS ENDED MARCH 31, 2023, 2022, AND 2021	F-7
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS	F-8

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of

Warrantee Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Warrantee Inc. and its subsidiaries (collectively, the “Company”) as of March 31, 2023 and 2022, and the related consolidated statements of income (loss), consolidated statements of comprehensive income (loss), consolidated statements of shareholders’ equity (deficit), and consolidated statements of cash flows for each of the three years in the period ended March 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial positions of the Company as of March 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph - Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has a negative working capital of ¥156.4 million and ¥112.7 million as of March 31, 2023 and 2022, respectively. The Company has a history of recurring losses, including a loss from operations of ¥89.8 million and ¥27.8 million for the years ended March 31, 2022 and 2021, respectively. This operating loss have resulted in an accumulated deficits of ¥470.6 million and ¥511.9 million as of March 31, 2023 and 2022, respectively. Management's descriptions in regard to these matters are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statement. We believe that our audits provide a reasonable basis for our opinion.

/s/ Assentsure PAC

We have served as the Company’s auditor since 2023.

Singapore

January 31, 2024

PCAOB ID Number 6783

F-2

WARRANTEE INC.

CONSOLIDATED BALANCE SHEETS

As of March 31, 2023 and 2022

(Yen in thousands, except share data)

	March 31,
	2023		2022
Assets
Current assets:
Cash and cash equivalents	¥	1,728	¥	14,012
Trade accounts receivable		—		2,700
Other receivables		363		6,908
Prepaid compensation asset		190		4,533
Prepaid expenses and other current assets		8,096		2,026
Total current assets		10,377		30,179
Non-current assets:
Property and equipment, net		35,930		34,160
Right-of-Use Assets		60,692		—
Deferred offering costs		149,157		116,059
Other assets		10,404		2,412
Total non-current assets		256,183		152,631
Total assets	¥	266,560	¥	182,810
Liabilities and shareholders’ equity
Current liabilities:
Accounts payable	¥	1,485	¥	1,485
Accrued expenses and other current liabilities		100,385		101,035
Consumption taxes payable		9,765		2,347
Current portion of long-term debt, net of debt issuance costs		9,791		4,970
Deferred revenue		9,831		33,000
Current portion of lease liabilities		35,474		—
Total current liabilities		166,731		142,837
Non-current liabilities:
Long-term debt, excluding current portion, net of debt issuance costs		70,593		79,474
Lease liabilities		25,218		—
Total non-current liabilities		95,811		79,474
Total liabilities		262,542		222,311
Shareholders’ equity (deficit):
Common shares, ¥6.83043 par value - 80,000,000 shares authorized, 20,004,000 shares issued and outstanding as of March 31, 2023 and 2022		136,636		136,636
Additional paid-in capital		337,299		337,299
Accumulated deficit		(470,605)		(511,908)
Accumulated other comprehensive loss		688		(1,528)
Total shareholders’ equity (deficit)		4,018		(39,501)
Total liabilities and shareholders’ equity (deficit)	¥	266,560	¥	182,810

The accompanying notes are an integral part of the consolidated financial statements.
​

F-3

WARRANTEE INC.

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

For the Fiscal Years Ended March 31, 2023, 2022, and 2021

(Yen in thousands, except share and per share data)

	Fiscal Years Ended March 31,
	2023		2022		2021
Revenue	¥	243,218	¥	224,727	¥	212,000
Cost of revenue		2,097		2,516		25,146
Gross profit		241,121		222,211		186,854
Operating expenses:
Selling, general and administrative expenses		188,528		312,053		214,608
Income (loss) from operations		52,593		(89,842)		(27,754)
Other income (expenses):
Other income (loss), net		(421)		541		5,971
Interest expenses		(3,598)		(2,984)		(3,424)
Foreign currency loss, net		(7,271)		(4,795)		(591)
Total other income (expenses), net		(11,290)		(7,238)		1,956
Income (loss) before income taxes		41,303		(97,080)		(25,798)
Income tax expenses		—		—		—
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Net income (loss) per share attributable to common shareholders, basic	¥	2.06	¥	(4.85)	¥	(1.29)
Weighted-average shares outstanding used to compute net income (loss) per share, basic		20,004,000		20,004,000		20,004,000
Net income (loss) per share attributable to common shareholders, dilutive	¥	1.95	¥	(4.85)	¥	(1.29)
Weighted-average shares outstanding used to compute net income (loss) per share, dilutive		21,222,348		20,004,000		20,004,000

The accompanying notes are an integral part of the consolidated financial statements.

F-4

WARRANTEE INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

For the Fiscal Years Ended March 31, 2023, 2022, and 2021

(Yen in thousands)

	Fiscal Years Ended March 31,
	2023		2022		2021
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Foreign currency translation adjustments, net of tax		2,216		(1,285)		—
Comprehensive income (loss)	¥	43,519	¥	(98,365)	¥	(25,798)

The accompanying notes are an integral part of the consolidated financial statements.
​

F-5

WARRANTEE INC.

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT)

For the Fiscal Years Ended March 31, 2023, 2022, and 2021

(Yen in thousands, except share data)

								Accumulated
				Additional				Other		Total
	Common Shares			Paid-In		Accumulated		Comprehensive		Shareholders’
	Shares	Amount		Capital		Deficit		Income (Loss)		Equity (Deficit)
Balance, March 31, 2020	20,004,000	¥	136,636	¥	129,270	¥	(389,030)	¥	—	¥	(123,124)
Receipts from related parties	—		—		6,129		—		—		6,129
Share-based compensation	—		—		201,900		—		—		201,900
Foreign currency translation adjustments, net of tax	—		—		—		—		(243)		(243)
Net loss	—		—		—		(25,798)		—		(25,798)
Total comprehensive loss for the fiscal year	—		—		—		(25,798)		(243)		(26,041)
Balance, March 31, 2021	20,004,000		136,636		337,299		(414,828)		(243)		58,864
Foreign currency translation adjustments, net of tax	—		—		—		—		(1,285)		(1,285)
Net loss	—		—		—		(97,080)		—		(97,080)
Total comprehensive loss for the fiscal year	—		—		—		(97,080)		(1,285)		(98,365)
Balance, March 31, 2022	20,004,000	¥	136,636	¥	337,299	¥	(511,908)	¥	(1,528)	¥	(39,501)
Foreign currency translation adjustments, net of tax	—		—		—		—		2,216		2,216
Net income	—		—		—		41,303		—		41,303
Total comprehensive income for the fiscal year	—		—		—		41,303		2,216		43,519
Balance, March 31, 2023	20,004,000	¥	136,636	¥	337,299	¥	(470,605)	¥	688	¥	4,018

The accompanying notes are an integral part of the consolidated financial statements.
​

F-6

WARRANTEE INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Fiscal Years Ended March 31, 2023, 2022, and 2021

(Yen in thousands)

	Fiscal Years Ended March 31,
	2023		2022		2021
Cash flow from operating activities:
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		17,175		862		115
Amortization of debt issuance costs		69		69		68
Share-based compensation expense		4,343		83,976		111,684
Changes in operating assets and liabilities:
Trade accounts receivable		2,700		8,000		(9,614)
Consumption taxes receivable		—		5,310		5,206
Other receivables		6,545		(6,908)		―
Deferred contract costs		—		―		17,617
Prepaid expenses and other current assets		(5,948)		4,386		2,848
Other assets		(7,714)		—		—
Accounts payable		—		(2,700)		―
Due to related parties		—		―		(1,413)
Accrued expenses and other current liabilities		(1,408)		57,338		13,420
Consumption taxes payable		7,418		(6,730)		9,077
Deferred revenue		(22,821)		33,000		(106,919)
Deposits received		—		―		(16,760)
Other		—		42		2,512
Net cash provided by operating activities		41,662		79,565		2,043
Cash flow from investing activities:
Purchases of property and equipment		(8,670)		(20,841)		—
Cash used in investing activities		(8,670)		(20,841)		—
Cash flow from financing activities:
Proceeds from stock options issued		―		—		1,707
Proceeds from long-term debt		—		500		25,000
Repayment of long-term debt		(4,129)		(1,718)		(1,619)
Receipts from related parties		—		—		6,129
Repayment of lease liabilities		(9,147)		—		—
Payment of deferred offering costs		(33,098)		(58,881)		(43,771)
Net cash used in financing activities		(46,374)		(60,099)		(12,554)
Effect of exchange rate changes on cash and cash equivalents		1,098		9		(173)
Net decrease in cash and cash equivalents		(12,284)		(1,366)		(10,684)
Cash and cash equivalents
Beginning of year		14,012		15,378		26,062
End of year	¥	1,728	¥	14,012	¥	15,378
Supplemental disclosures of cash flow information:
Cash paid for interest	¥	2,927	¥	2,919	¥	3,362
Non-cash investing and financing activities:
Purchases of property and equipment included in accrued expenses	¥	319	¥	14,087	¥	—
Accrued offering costs	¥	—	¥	4,400	¥	13,200

The accompanying notes are an integral part of the consolidated financial statements.

F-7

WARRANTEE INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the Fiscal Years Ended March 31, 2023, 2022, and 2021

1. Nature of Operations

Warrantee Inc. (“Warrantee”) and its wholly-owned subsidiary (collectively, the “Company”) provide sponsored marketing services used in the durables vertical (the “Durables Vertical”) and the commercial healthcare vertical (the “Commercial Healthcare Vertical”). Warrantee was incorporated in October 2013, and its wholly-owned subsidiary, Warrantee Pte. Ltd. (“Warrantee Pte.”) was incorporated in December 2019 in Singapore. The Company’s fiscal year end is March 31.

The Durables Vertical business model allows participating users (“Participant Users”) to receive warranty services for repair or replacement of electric appliances, kitchen appliances and other equipment free of charge in exchange for personal information, including purchase data. The Company organizes the data and provides it with the prior consent of Participant Users to corporate sponsor companies (“Corporate Sponsors”). This information allows Corporate Sponsors to market their products efficiently. In return for the information, the Corporate Sponsors pay sponsor fees to the Company which in turn the Company uses to purchase extended warranty coverage for the products of Participant Users. The Company itself does not provide the extended warranties; it purchases such coverage from third party providers.

The Company commenced a new model of Durables Vertical during the fiscal year ended March 31, 2022. The new model allows clinics participating in the Company’s campaigns (“Participant Clinics”) to receive warranty services for repair or replacement of their medical equipment free of charge in exchange for clinic information, including the name of the clinics, phone numbers, and addresses. The Company organizes the data and provides it with the prior consent of Participant Clinics to Corporate Sponsors. This information allows Corporate Sponsors to market their products efficiently. In return for the information, the Corporate Sponsors pay sponsor fees to the Company which in turn the Company uses to purchase extended warranty coverage for the products of Participant Clinics. The Company itself does not provide the extended warranties; it purchases such coverage from third party providers.

During the fiscal year ended March 31, 2021, the Company expanded its business model into Commercial Healthcare Vertical, which allows Participant Users to receive complimentary examinations or treatments for a range of specified ailments and procedures, including polymerase chain reaction testing, genetic testing, and arthritic and orthopedic procedures. During the fiscal year ended March 31, 2021, the Company also conducted sales promotions on behalf of Corporate Sponsors to Participant Users based on the results of their genetic tests. Similar to the Durables Vertical, the Company gathers information from Participant Users with their prior consent and then provides the information, including feedback on the relevant healthcare services, to Corporate Sponsors. Data collected includes basic profile information of the patient in addition to specific, targeted data on personal health markers and responses to the specific treatment, procedure, or healthcare product. In return for the information, the Corporate Sponsors pay sponsor fees to the Company which in turn the Company pays the costs for the healthcare services. The result is that Participant Users are able to enjoy the benefits of healthcare services for free and the Corporate Sponsors are able to use the information to market its product efficiently.

The Company’s customers, or Corporate Sponsors, include manufacturers and distributors of home appliances, healthcare equipment, and health food distributors. All customers are located throughout Japan for the presented periods, and the Company is headquartered in Japan.

As described in Note 2, Summary of Significant Accounting Policies, “Revenue Recognition,” the Company recognized other source of revenue from System Development during the fiscal year ended March 31, 2021 and from Advertising, Licensing, and System Development during the fiscal year ended March 31, 2022. However, the Company does not expect to generate this type of revenue in future periods.

F-8

On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus (“COVID-19”) as a pandemic. The Company did not observe significant impacts on its business or results of operations for the fiscal years ended March 31, 2023, 2022, or 2021 due to the global emergence of COVID-19. The Company also applied for the subsidy program for sustaining businesses by the Japanese government with COVID-19 special treatment. For the fiscal year ended March 31, 2021, the Company received ¥2,000 thousand from the subsidy program. The subsidy is not limited in scope and can help cover a wide variety of purposes. The Japanese government subsidies of non-operating nature with no further conditions to be met are recorded in “Other income” in the Consolidated Statements of Income (Loss) when received. While the extent to which COVID-19 impacts the Company’s future results will depend on future developments, the pandemic and associated economic impacts could result in an impact to the Company’s future financial condition, results of operations and cash flows.

Going concern

The Company had a negative working capital of ¥156.4 million and ¥112.7 million as of March 31, 2023 and 2022, respectively. The Company has a history of recurring losses, including a loss from operations of ¥89.8 million and ¥27.8 million for the fiscal years ended March 31, 2022 and 2021, respectively. This operating loss had resulted in an accumulated deficits of ¥470.6 million and ¥511.9 million as of March 31, 2023 and 2022, respectively.

The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to attract and retain revenue generating customers, acquire new customer contracts, and secure additional financing.

The Company may consider obtaining additional financing in the future through the issuance of the Company’s common shares, through other equity or debt financings, or other means. The Company, however, is dependent upon its ability to obtain new revenue generating customer contracts, secure equity, and/or debt financing and there are no assurances that the Company will be successful. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are presented in Japanese yen, the currency of the country in which the Company is incorporated and primarily operates. The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Reclassification

Certain accounts in the prior period consolidated financial statements have been reclassified to conform to the presentation of the current year consolidated financial statements. Foreign currency loss, net during the fiscal year ended March 31, 2021 of ¥591 thousand was reclassified from other income, net to a separate line item in the Consolidated Statements of Income (Loss). This reclassification had no effect on the previously reported operating results.

Principles of Consolidation

The consolidated financial statements include the accounts of Warrantee and its wholly owned subsidiary, Warrantee Pte. Warrantee Pte. has a fiscal year end of December 31, and the accounts of Warrantee Pte. are included in the Company’s consolidated financial statements based on the fiscal year of Warrantee Pte. All intercompany accounts and transactions, including capital increase during a reporting time lag, have been eliminated upon consolidation.

F-9

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the reporting date, and the reported amounts of revenue and expense during the reporting period. These estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future and include, but are not limited to, useful lives of capitalized software, valuation of stock options, and valuation allowance against net deferred tax assets. Actual results could differ from those estimates.

Segment Information

The Company operates as one operating segment. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer (“CEO”), who reviews financial information for purposes of making operating decisions, assessing financial performance, and allocating resources. The Company’s CODM evaluates financial information on a consolidated basis. As of March 31, 2023, 2022, and 2021, there was no revenue derived or long-lived assets held outside of Japan.

Concentration of Customers

For the fiscal years ended March 31, 2023, 2022, and 2021, two customers, one customer, and two customers, respectively, each accounted for more than 10% of the consolidated revenue. Revenue from those customers totaled ¥243,218 thousand, ¥224,727 thousand, and ¥177,000 thousand of the total consolidated revenue for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. The following represents sales revenue attributable to each of these customers as a percentage of total consolidated revenue for each respective year.

	Percentage of Revenue
	For the fiscal years ended March 31,
	2023		2022		2021
Customer A	88	%	100	%	—
Customer B	—		—		51	%
Customer C	12	%	—		33	%

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents.

Trade Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable primarily consist of amounts billed and currently due from customers, net of an allowance for doubtful accounts, if recorded. When the Company has an unconditional right to payment, subject only to the passage of time, the right is treated as receivable. Fees billed in advance of the related contractual term represent contract liabilities and are presented as deferred revenue. Typical payment terms provide for customer payment within 30 days of the contract date.

Trade accounts receivables are subject to collection risk. The Company performs evaluations of its customers’ financial positions and generally extends credit on account, without collateral. The Company determines the need for an allowance for doubtful accounts based upon various factors, including credit quality of the customer, age of the receivable balance and current economic conditions.

There were no bad debt expense or allowance for doubtful accounts recorded as of and for the fiscal years ended March 31, 2023, 2022, and 2021.

F-10

Property and Equipment, Net

Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method, depending on the pattern of consumption of the economic benefits by asset class, over the estimated useful lives of the assets. The estimated useful lives are four years for computers and three to six years for furniture and fixtures. Repair and maintenance costs are expensed as incurred. The Company records depreciation expense in selling, general and administrative expenses and cost of revenue on the Consolidated Statements of Income (Loss).

Capitalized Software, Net

The Company capitalizes certain costs in property and equipment associated with website and software developed for internal use in accordance with ASC 350-50, Intangibles - Goodwill and Other - Website Development Costs and ASC 350-40, Intangibles - Goodwill and Other - Internal Use Software when both the preliminary project design and the testing stage are completed and management has authorized further funding for the project, which it deems probable of completion and to be used for the function intended. Capitalized costs include amounts directly related to website and software development such as fees paid to third-party vendors. Capitalization of such costs ceases when the project is substantially complete and ready for its intended use. Capitalized costs are amortized, beginning in the period the product is ready for its intended use, on a straight-line basis over the estimated useful life of the product, five years. Costs incurred during the preliminary stages of development and ongoing maintenance costs are expensed as incurred.

Impairment or Disposal of Long-Lived Assets

Long-lived assets used in operations, which include capitalized software developed for internal use and property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if the carrying amount is not recoverable when compared to the Company’s undiscounted cash flows and the impairment loss is measured based on the difference between the carrying amount and fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell.

Leases

Leases are principally comprised of operating leases for office space. The Company determines that a contract contains a lease if they obtain substantially all of the economic benefits of, and the right to direct the use of, an asset identified in the contract. For leases with terms greater than 12 months, the Company records a right-of-use asset and a lease liability representing the present value of future lease payments. The discount rate used to measure the lease asset and liability is determined at the beginning of the lease term using the rate implicit in the lease, if readily determinable, or the Company’s collateralized incremental borrowing rate. For those contracts that include fixed rental payments for both the use of the asset (“lease costs”) as well as for other occupancy or service costs relating to the asset (“non-lease costs”), the Company generally includes both the lease costs and non-lease costs in the measurement of the lease asset and liability.

Lease expenses and income for the Company’s operating leases are recognized on a straight-line basis over the lease term, with the exception of variable lease costs, which are expensed as incurred.

Debt Issuance Costs

Debt issuance costs are amortized as interest expense on a basis which approximates the effective interest method over the term of the related debt. Debt issuance costs are reported at cost, less accumulated amortization and are presented in the Consolidated Balance Sheets as a direct deduction from the carrying value of the associated debt.

F-11

Deferred Offering Costs

Deferred offering costs are capitalized and consist of fees incurred in connection with the anticipated sale of common shares in an IPO and include direct incremental legal, accounting, printing, and other IPO-related costs. Upon completion of an IPO, these deferred costs will be reclassified to shareholders’ equity and recorded against the proceeds from the offering. In the event a proposed IPO is deemed not likely to be completed, the deferred offering costs would be charged to expenses in the period of such determination.

Foreign Currency

The Company uses Japanese yen as its reporting currency. Warrantee’s functional currency is the Japanese yen and the functional currency of Warrantee Pte. is the Singapore dollar. Financial statements of Warrantee Pte. are prepared using the functional currency and translated into Japanese yen for reporting purposes. Assets and liabilities are translated using the fiscal year end foreign exchange rate, and income and expenses are translated using the average exchange rate for the period. Foreign currency translation adjustments related to the financial statements of Warrantee Pte. net of related income tax effects, are credited or charged directly to the foreign currency translation adjustments account, a component of accumulated other comprehensive income (loss). The tax effects related to the foreign currency translation of financial statements of Warrantee Pte. are not recognized unless it is apparent that the temporary differences will reverse in the foreseeable future. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency of the respective entity at the fiscal year end foreign exchange rate, and gains and losses resulting from such remeasurement are included in foreign exchange gains (losses). Foreign currency denominated income and expenses are remeasured using the average exchange rate for the period.

Share-Based Compensation

The Company applies the provisions of ASC Topic 718, Compensation — Stock Compensation. The Company measures the cost of employee and non-employee services received in exchange for awards of equity instruments at the fair value of the award on the grant date and recognizes the cost over the requisite service period which the employee and non-employee are required to provide services in exchange for the award. Compensation costs are recognized on a straight-line basis over the requisite service period of the awards which are expected to be vested. For non-employee vesting periods that have implicit service periods based on the achievement of a performance condition, a change in the estimated achievement of performance conditions will be recognized prospectively over the revised non-employee vesting period. For awards with performance conditions, compensation cost is recognized when the condition is probable of being achieved, or in the case of a liquidity event, when the liquidity event occurs. The Company uses option pricing methods that require the input of subjective assumptions, including the expected term, expected volatility, dividend yield and risk-free interest rate. For awards with market conditions, the Company uses a hybrid method between a discounted cash flow method and Monte Carlo simulation models to value the awards. The Company has elected to recognize forfeitures as they occur.

Revenue Recognition

The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) for all periods presented in the consolidated financial statements. To determine the appropriate amount of revenue to be recognized in accordance with ASC 606, the Company follows a five-step model as follows:

1 – Identification of the contract with a customer;

2 – Identification of the performance obligation in the contract;

3 – Determination of the transaction price;

4 – Allocation of the transaction price to the performance obligation in the contract; and

5 – Recognition of revenue when, or as, a performance obligation is satisfied.

F-12

The Company’s revenue is primarily derived from the Durables Vertical and the Commercial Healthcare Vertical. The Company’s services are marketed and sold directly to the customers. The Company assesses the contract term as the period in which the parties to the contract have enforceable rights and obligations. The contract term may differ from the stated term in contracts with certain termination or renewal rights, depending on whether there are substantive penalties associated with those rights. Customer contracts are generally standardized and noncancellable for the duration of the stated contract term. Consumption taxes collected and remitted to tax authorities are excluded from revenue. The Company may use third-party vendors to provide certain goods or services to its customers. The Company evaluates those relationships to determine whether revenue should be reported gross or net. The Company recognizes revenue on a gross basis where it acts as principal and controls the goods and services used to fulfill the performance obligations to the customer and on a net basis where it acts as an agent. The Company has not acted as an agent during the fiscal years ended March 31, 2023, 2022, and 2021.

Durables Vertical:

Performance Obligations

Revenue from the Durables Vertical is primarily comprised of sponsorship fees from Corporate Sponsors in exchange for Participant Users’ personal information or Participant Clinics’ information (collectively, “Participants’ Data”). During the sponsorship campaigns, the Company aggregates Participants’ Data, organizes that data, and then provides it to Corporate Sponsors. The Company has identified one performance obligation, the delivery of Participants’ Data. All other immaterial deliverables occur prior to this, but revenue is not recognized until the delivery of Participants’ Data which is the performance obligation. Accordingly, the Company recognizes revenue at a point in time when the personal information is provided to, or accepted by, Corporate Sponsors upon satisfying its single distinct performance obligation.

Contractual Consideration

The transaction price is generally fixed at contract inception. However, the Company’s contracts with Corporate Sponsors within Durables Vertical may include a specified quantity, which entitles the customer to refunds, when defined quantity levels are not met at the end of the provision period. These arrangements represent a form of variable consideration, which is estimated using the most likely amount method to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of March 31, 2023 and 2022.

Commercial Healthcare Vertical:

Performance Obligations

Revenue from the Commercial Healthcare Vertical is primarily comprised of sponsorship fees from Corporate Sponsors in exchange for healthcare-related promotional campaigns. During healthcare-related promotional campaigns targeted to Participant Users based on results of their free genetic test kits, the Company has the stand-ready obligation to provide promotional services for the duration of the campaign promotion period. Accordingly, revenue is recognized ratably based on the time-elapsed method over the contractual term with the Corporate Sponsor.

Contractual Consideration

The transaction price may be fixed at contract inception within the Commercial Healthcare Vertical in a form of non-refundable minimum guarantee but may also have a component of variable consideration such as sales incentives which are calculated by multiplying the amount of work accomplished by a fixed unit price of remuneration. Due to the variable consideration being entirely constrained, the sales incentive is excluded from the transaction price until the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of March 31, 2023 and 2022.

F-13

Other Revenue:

System Development: System development revenue is generated by the development and the delivery of the system that meets the customer’s specifications. There is one performance obligation as all promises are interrelated to delivering a completed system. The title to the system is transferred to the customer upon acceptance. The Company typically recognizes revenue upon the customer’s acceptance as the control over the product is transferred to the customer and the Company’s performance obligations are satisfied. When third-party vendors participate in the provisioning of the system, the Company recognizes the related revenue on a gross basis as the Company is the principal in these arrangements.

Transaction Price

The transaction price is the amount of consideration to which the Company expects to be entitled to for transferring goods and services to the customer.

Payments from the customers are often made in advance before satisfaction of the performance obligations. Generally, payments are due within 30 days of delivery of the goods or service. In instances where the timing of revenue recognition differs from the timing of the right to invoice, the Company has determined that a significant financing component generally does not exist. Additionally, the Company has elected the practical expedient that permits an entity not to recognize a significant financing component if the time between the transfer of a good or service and payment is one year or less.

Disaggregation of Revenue

The table reflects revenue by major source for the following periods:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Sources of revenue:
Durables Vertical	¥	213,218	¥	224,727	¥	85,000
Commercial Healthcare Vertical		30,000		—		107,000
System Development		—		—		20,000
Total revenue	¥	243,218	¥	224,727	¥	212,000

Contract Balances

The timing of revenue recognition may not align with the right to invoice the customer. The Company records trade accounts receivable when it has the unconditional right to issue an invoice and receive payment regardless of whether revenue has been recognized. If revenue has not yet been recognized, then deferred revenue is also recorded. Deferred revenue classified as current on the Consolidated Balance Sheets are expected to be recognized as revenue within one year. If revenue is recognized in advance of the right to invoice, a contract asset is recorded.

Changes in deferred revenue were as follows:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Balance, beginning of year	¥	33,000	¥	—	¥	106,919
Revenue earned		(33,000)		—		(106,919)
Deferral of revenue		9,831		33,000		—
Balance, end of year	¥	9,831	¥	33,000	¥	—

Changes in deferred revenue are primarily due to the timing of revenue recognition and cash collections.

F-14

Remaining Performance Obligations

Remaining performance obligations represent the aggregate amount of the transaction price allocated to the remaining obligations that the Company has not performed under its customer contracts. The Company has elected to use the optional exemption in ASC 606-10-50-14, which exempts an entity from such disclosures if a performance obligation is part of a contract with an original expected duration of one year or less.

As of March 31, 2023, deferred revenue represented the Company’s remaining performance obligations related to prepaid consideration for the campaign starting during the year ending March 31, 2024 with a new customer, all of which is expected to be recognized within one year.

Deferred Contract Costs

Sales commissions that are incremental to the acquisition of customer contracts, are capitalized as deferred contract costs on the Consolidated Balance Sheets when the period of benefit is determined to be greater than one year. Amortization of deferred contract acquisition costs is included within selling, general and administrative expenses in the Consolidated Statements of Income (Loss).

The Company also capitalizes certain costs to fulfill a contract related to its proprietary products or services if they are identifiable, generate or enhance resources used to satisfy future performance obligations and are expected to be recovered under ASC Topic 340-40, Other Assets and Deferred Costs-Contracts with Customers. Amortization of deferred contract fulfillment costs is included within cost of revenue in the Consolidated Statements of Income (Loss).

Deferred contract costs are amortized to be consistent with the timing of transfer to the customer of the goods or services to which the costs relate, either at a point in time or over time in proportion to the amount of the related goods and services transferred to the customer. The Company periodically reviews these capitalized contract costs to determine whether changes in events or circumstances have occurred that could impact the period of benefit of these assets. There were no impairment losses recorded for the periods presented.

As of March 31, 2023 and 2022, the Company had no deferred costs to obtain and fulfill a contract. During the fiscal years ended March 31, 2022 and 2021, the Company amortized ¥1,500 thousand and ¥17,692 thousand of costs to obtain and fulfill the contract, respectively, and capitalized ¥1,575 thousand of costs to fulfill the contract during the fiscal year ended March 31, 2021.

Cost of Revenue

For the fiscal years ended March 31, 2023 and 2022, cost of revenue primarily comprised of the insurance costs, depreciation and amortization and personnel-related expenses. For the fiscal year ended March 31, 2021, the cost of revenue also included the direct cost to develop software products, Participant User recruiting costs for the Durables Vertical, and genetic testing costs for Commercial Healthcare Vertical.

Advertising Costs

Advertising costs are expensed as incurred and presented within selling, general and administrative expenses in the Consolidated Statements of Income (Loss). Advertising costs were ¥11,790 thousand, ¥325 thousand, and ¥888 thousand for the fiscal years ended March 31, 2023, 2022, and 2021, respectively.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the differences between the financial statement and tax basis of assets, liabilities and net operating loss by using enacted tax rate in effect for the year in which the differences are expected to reverse. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

F-15

The Company recognizes deferred tax assets to the extent that these assets are believed to be more likely than not to be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are more likely than not expected to be realized. In making such a determination, all available positive and negative evidence is considered, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations.

Warrantee and its subsidiary file tax returns in the tax jurisdictions of Japan and Singapore. Tax benefits for uncertain tax positions are based upon management’s evaluation of the information available at the reporting date. To be recognized in the consolidated financial statements, a tax benefit must be at least more likely than not of being sustained based on technical merits. The benefit for positions meeting the recognition threshold is measured as the largest benefit more likely than not of being realized upon settlement with a taxing authority that has full knowledge of all relevant information.

Net Income (Loss) per Share

Basic net income (loss) per common share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.

For purposes of the diluted net income (loss) per common share calculation, stock options are considered to be potentially dilutive securities. However, as disclosed in Note 8, Share-Based Compensation, the Company’s 2nd and 3rd Series stock options include a triggering liquidation performance condition prior to vesting. As such, these are treated as contingently issuable shares and will be excluded from potential dilutive impact until the triggering liquidation performance condition is satisfied.

Recently Issued Accounting Pronouncements

As an emerging growth company, the Jumpstart Our Business Startups Act allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to delay adoption of certain new or revised accounting standards. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies.

Financial Instruments — Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which is intended to provide more decision-useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. ASU 2016-13 revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to accounts receivable. This standard is effective for annual reporting periods beginning after December 15, 2022 for non-public entities, including interim periods within that reporting period. Early adoption is permitted. The Company is currently in process of evaluating the impact of this standard on the Company’s consolidated financial statements. The Company does not expect the adoption of this standard to have a material effect on the Company’s consolidated financial statements. As an emerging growth company, the Company will adopt this standard effective April 1, 2023.

F-16

3. Property and Equipment, Net

As of the dates specified below, property and equipment, net consisted of the following:

	Yen in thousands
	March 31,
	2023		2022
Capitalized software	¥	43,598	¥	34,928
Computers		999		999
Furniture and fixtures		632		632
Total property and equipment		45,229		36,559
Less: Accumulated depreciation and amortization		(9,299)		(2,399)
Total property and equipment, net	¥	35,930	¥	34,160

Included in capitalized software were ¥6,386 thousand and ¥28,136 thousand of assets under construction as of March 31, 2023 and 2022, respectively. The Company recognized depreciation and amortization expenses on property and equipment of ¥6,900 thousand, ¥862 thousand, and ¥115 thousand for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. The Company records depreciation and amortization expenses in selling, general, and administrative expenses and cost of revenue on the Consolidated Statements of Income (Loss).

4. Leases

The Company has operating leases primarily for office space. Lease costs are generally fixed, with certain contracts containing variable payments for non-lease costs based on usage and escalations in the lessors’ annual costs.

As of March 31, 2023 and 2022, the following amounts were recorded on the Consolidated Balance Sheets relating to the Company’s operating leases.

	Yen in thousands
	March 31,
	2023		2022
Right-of-Use Assets
Operating lease assets	¥	60,692	¥	—
Lease Liabilities
Operating lease liabilities	¥	60,692	¥	—

Supplemental balance sheet information related to leases consisted of the following:

	For the fiscal years ended March 31,
	2023		2022
Remaining lease term and discount rate:
Weighted average remaining lease term (years)	1.8		—
Weighted average discount rate	4.24	%	—

Future minimum lease payments under non-cancelable leases as of March 31, 2023, were as follows (in thousand yen):

Fiscal Year ending March 31,
2024	¥	33,360
2025		27,370
Total lease payments		60,730
Less amounts representing interest		(38)
Present value of lease payments		60,692

F-17

5. Fair Value of Financial Instruments

The Company reports financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis in accordance with ASC Topic 820 Fair Value Measurement (“ASC 820”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

ASC 820 also establishes a fair value hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value into three levels. U.S. GAAP established a hierarchy framework to classify the fair value based on the observability of significant inputs to the measurement.

The levels of the fair value hierarchy are as follows:

Level 1:    Determined using an unadjusted quoted price in an active market for identical assets or liabilities.

Level 2:    Estimated using inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly.

Level 3:    Estimated using unobservable inputs that are significant to the fair value of the assets or liabilities.

The carrying value of cash and cash equivalents, trade accounts receivable, consumption taxes receivable, other receivables, accounts payable, accrued expenses and consumption taxes payable approximate their fair value due to their short-term nature.

There were no assets or liabilities measured at fair value on “recurring” basis during 2023 and 2022. Since there is no material difference between the market interest rate and the contract rate, the carrying value of the Company’s debt approximated its fair value as of March 31, 2023 and 2022.

6. Commitments and Contingencies

Legal Matters

From time to time in the normal course of business, the Company is subject to various legal matters, such as threatened or pending claims or proceedings. There were no such material matters as of and for the fiscal years ended March 31, 2023 and 2022. The following lawsuit is currently pending against the Company:

A lawsuit demanding payment of the unpaid development fees by Freude Inc. is pending in Fukuoka District Court. It is still premature to determine the outcome of the lawsuit. The maximum potential loss if the Company loses the case is ¥13,027 thousand plus 14.6 per annum from February 1, 2019.

Indemnification

In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with third parties. To date, the Company has not paid any material claims or been required to defend any material actions related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

F-18

7. Debt

The Company’s borrowings, including short-term and long-term portions consisted of the following:

			Yen in thousands
			March 31,
	Interest Rate	Maturity	2023		2022
Amended term loan with Japan Finance Corporation	0.36% to 1.26%	August 31, 2026	¥	13,975	¥	15,500
Term loan with Resona Bank, Limited	0.00% to 1.20%	November 30, 2030		24,220		25,000
Term loan with SBI Estate Finance Co., Ltd.	6.00%	September 5, 2037		43,187		45,011
Total long-term debt				81,382		85,511
Less: unamortized debt issuance costs				(998)		(1,067)
Subtotal				80,384		84,444
Current portion of long-term debt, net of debt issuance costs				(9,791)		(4,970)
Long-term debt, excluding current portion, net of debt issuance costs			¥	70,593	¥	79,474

On September 3, 2014, the Company entered into the term loan agreement with Japan Finance Corporation for ¥15,000 thousand, which matured on September 30, 2021. The term loan incurs variable interest at 0.90% through 8.55% per annum. The term loan agreement does not require periodic principal repayments and is payable in full upon maturity.

On September 30, 2021, the Company refinanced the existing term loan with Japan Finance Corporation to extend the maturity date to August 31, 2026, and changed the interest rate. This refinancing resulted in ¥500 thousand of net proceeds. The variable interest rate per annum on the new term loan is 0.36% from September 30, 2021 to September 30, 2024, and 1.26% from October 1, 2024 to the maturity date. The new term loan agreement requires monthly principal repayments beginning from September 30, 2022 to the maturity date. Yusuke Shono, the CEO of the Company, has guaranteed the term loan agreement with Japan Finance Corporation.

On December 18, 2020, the Company entered into the term loan agreement with Resona Bank, Limited, for ¥25,000 thousand, which matures on November 30, 2030. The interest rate per annum on the term loan is variable at 0% through December 17, 2023 and 1.20% from December 18, 2023 to maturity. The term loan agreement requires monthly principal repayments beginning from December 31, 2022 to the maturity date. Yusuke Shono, the CEO of the Company, has guaranteed the term loan agreement with Resona Bank, Limited.

On August 31, 2017, the Company entered into the term loan agreement with SBI Estate Finance Co., Ltd. for ¥52,000 thousand, which matures on September 5, 2037. Cash proceeds received for this term loan were ¥50,623 thousand, net of issuance costs. The contract interest rate on the term loan was 6.00% per annum and the effective interest rate was 6.28% per annum as of March 31, 2023 and 2022. The effective interest rate was higher than the contract rate due to amortization of debt issuance costs related to the term loan. The term loan agreement requires equal monthly repayments with principal and interest for ¥373 thousand.

F-19

The debt issuance costs of ¥1,377 thousand are being amortized over the 20-year life of the term loan resulting in ¥69 thousand, ¥69 thousand, and ¥68 thousand of issuance costs being amortized through interest expense for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. Unamortized debt issuance costs are ¥998 thousand and ¥1,067 thousand as of March 31, 2023 and 2022, respectively and are presented in the Consolidated Balance Sheets as a direct deduction from the carrying value of the debt. Yusuke Shono, the CEO of the Company, has guaranteed the term loan agreement with SBI Estate Finance Co., Ltd. and pledged his personal assets as collateral.

None of the term loan agreements contain any financial covenants.

Contractual maturities of long-term debt as of March 31, 2023 are as follows:

	(Yen in thousands)
2024	¥	9,860
2025		9,076
2026		9,203
2027		7,062
2028		5,575
Thereafter		40,606
Total	¥	81,382

8. Share-Based Compensation

2nd and 3rd Series Stock Options

On June 26, 2016 and March 30, 2017, as part of the 2nd Series and 3rd Series of stock options (collectively, the “2nd and 3rd Series”), the Company granted options to purchase 540,000 and 81,000 common shares, respectively. Each option can be exercised for one common share. The contractual term of the 2nd and 3rd Series stock options is ten years, and the grantee must be employed by the Company at the time of exercise to exercise their rights. The 2nd and 3rd Series stock option’s fair value as of grant date was ¥11 and ¥35 per share, respectively. The exercise price of the 2nd and 3rd Series stock options were ¥19 and ¥56 per share, respectively.

The general terms of the 2nd and 3rd Series require both service and performance conditions to be satisfied prior to vesting. The performance condition will be satisfied upon a liquidity event defined as an IPO on any of the stock exchanges in Japan or overseas. As the Company cannot conclude that a liquidity event is probable, no compensation costs were recorded in these consolidated financial statements related to the 2nd and 3rd Series.

As of March 31, 2023, total unrecognized compensation cost related to the unvested share-based awards was ¥825 thousand.

4th Series Stock Options

On January 29, 2021, the Board of Directors and shareholders of the Company approved the issuance of the 4^th Series stock options (“4^th Series”) and stock options to purchase total 2,019,000 common shares were granted to the Company’s director, employee, and external subcontractors on February 3, 2021 and the Company’s CEO and external subcontractor on March 31, 2021. Each option can be exercised for one common share. The contractual term of the awards is ten years beginning after February 3, 2021.

The stock option’s fair value as of grant date is ¥100 per share and the exercise price of the stock option is ¥56 per share. The stock options include a market condition whereby the options become non-exercisable if there are any subsequent sales or issuance of common shares with a price less than ¥55.66. There are no other service or performance conditions.

Cash received from stock options granted for the fiscal year ended March 31, 2021 was ¥1,707 thousand, and is included in additional paid-in capital in the Consolidated Balance Sheets as of March 31, 2023 and 2022. Upon issuance, the grantees paid an issue price per share of less than ¥1, resulting from the share split.

F-20

As the options are fully exercisable at grant date subject only to the market condition, the Company recognized the full compensation cost for employees at the grant date. As the recognition of compensation cost for non-employees should be in the same manner as if the Company had paid cash for the goods or services, the Company recognized a prepaid compensation asset and recognizes the compensation cost on a straight-line basis over the implicit service period for certain non-employees. These non-employees provide services directly related to helping the Company achieve an IPO. There is a mutual understanding between these non-employees and the Company that they will provide services from grant date through the Company’s IPO. To recognize compensation cost for these non-employees, the Company initially used an expected IPO date of January 31, 2022, which was based on its best estimate at the time of grant but subsequently revised the expected IPO date of July 2023 during the fiscal year ended March 31, 2023. A change in the expected IPO date will be recognized prospectively over the revised non-employee vesting period.

Total share-based compensation expense for 4th Series stock options included in selling, general, and administrative expenses in the Consolidated Statements of Income (Loss) was ¥4,343 thousand, ¥83,976 thousand, and ¥111,684 thousand for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. As of March 31, 2023, there was ¥190 thousand of unrecognized expense included in prepaid compensation asset related to 4th Series stock options in the Consolidated Balance Sheets.

The fair value of the 4th Series is estimated using a hybrid method between a discounted cash flow method and Monte Carlo simulation model, estimating the probability-weighted value across multiple scenarios. The Company considered a near-term IPO scenario for a discounted cash flow method and a long-term IPO scenario for Monte Carlo simulation model.

Expected Term — The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The expected term of option was estimated utilizing the simplified method because the Company did not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The simplified method primarily is calculated as the midpoint between the requisite service period and the contractual term of option.

Expected Volatility — The expected stock price volatility assumption was determined by examining the historical volatilities of comparable publicly traded companies within the Company’s industry.

Risk-Free Interest Rate — The risk-free rate assumption was based on the U.S. treasury rate that was consistent with the expected term of the Company’s stock options.

Expected Dividend — The expected dividend assumption was based on the Company’s history and expectation of dividend payouts. The Company does not currently pay dividends on the common shares; therefore, a dividend yield of 0% was used in the Monte Carlo simulation model.

Fair Value of Common Shares — The fair value of the common shares underlying the stock options has historically been the responsibility of and determined by the Company’s Board of Directors. Because there has been no public market for the Company’s common shares, the Board of Directors has used independent third-party valuations of the Company’s common shares, operating and financial performance, and general and industry-specific economic outlook, amongst other factors.

The following assumptions were used in the Monte Carlo calculation for the Series 4 stock options:

Expected life of options		10 years
Expected volatility		60.0	%
Risk-free interest rate		1.2% - 1.7	%
Expected dividend yield		—
Weighted-average grant-date fair value of stock option	¥	72

F-21

A summary of the activity of the Company’s 2nd, 3rd, and 4th Series as of and for the fiscal years ended March 31, 2023, 2022, and 2021 is presented below:

The aggregate intrinsic value of the outstanding and exercisable options was calculated based on the estimated fair value of common shares of ¥144 per share.

				Years
		Yen		Weighted-
		Weighted-		average	Thousands of Yen
		average		remaining	Aggregate
	Number of	exercise		contractual	intrinsic
	shares	price		term	value
Outstanding as of April 1, 2020	54,000	¥	25	6.4	¥	—
Granted	2,019,000		56	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2021	2,073,000		55	9.7		—
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2022	2,073,000		55	8.7		183,497
Exercisable as of March 31, 2022	2,019,000	¥	56	8.8	¥	177,073
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2023	2,073,000		55	7.7		183,497
Exercisable as of March 31, 2023	2,019,000	¥	56	7.8	¥	177,073

9. Net Income (Loss) per Share

The following table sets forth the computation of basic and diluted net loss per share:

	Yen in thousands, except share and per share data
	For the fiscal years ended March 31,
	2023		2022		2021
Basic:
Numerator:
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share		20,004,000		20,004,000		20,004,000
Basic net income (loss) per share	¥	2.06	¥	(4.85)	¥	(1.29)
Assuming Dilution:
Numerator:
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share		20,004,000		20,004,000		20,004,000
Dilutive securities issuable - Stock option plans		1,218,348		—		—
Total weighted-average diluted shares outstanding		21,222,348		20,004,000		20,004,000
Diluted net income (loss) per share	¥	1.95	¥	(4.85)	¥	(1.29)

F-22

Basic net income (loss) per common share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.

As disclosed in Note 8, Share-Based Compensation, the Company’s 2^nd and 3^rd Series stock options include a triggering liquidation performance condition prior to vesting. As such, these are treated as contingently issuable shares and will be excluded from potential dilutive impact until the triggering liquidation performance condition is satisfied. The 4^th Series stock options outstanding have no dilutive impacts for the fiscal years ended March 31, 2022 and 2021 due to the antidilutive effect. The following potentially dilutive shares have been excluded from the calculation of diluted net income (loss) per share for each period.

	March 31,
	2023	2022	2021
2nd and 3rd Series stock options outstanding	54,000	54,000	54,000
4th Series stock options outstanding	—	2,019,000	2,019,000
Total potentially dilutive shares	54,000	2,073,000	2,073,000

10. Income Taxes

The components of income (loss) before income taxes, by geography, consisted of the following:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Japan	¥	78,203	¥	(80,543)	¥	(11,355)
Singapore		(36,900)		(16,537)		(14,443)
Income (Loss) before income taxes	¥	41,303	¥	(97,080)	¥	(25,798)

Warrantee is subject to national and local income taxes in Japan which, in the aggregate, indicate a statutory rate of approximately 34.59% for the fiscal years ended March 31, 2023, 2022, and 2021. The statutory tax rate in effect for the year in which the temporary differences are expected to reverse is used to calculate the tax effects of temporary differences that are expected to reverse in the future years.

A reconciliation of income tax expenses to the amount of income tax benefit at the statutory rate in Japan for the fiscal years ended March 31, 2023, 2022, and 2021 is as follows:

		Yen in thousands
		For the fiscal years ended March 31,
	2023		2022		2021
Income tax expenses (benefit) at the statutory rate	¥	14,286	¥	(33,580)	¥	(8,923)
Increase (reduction) in taxes resulting from:
Non-deductible share-based compensation expense		1,502		29,047		38,631
Deferred offering costs		(11,449)		(17,323)		(19,707)
Change in valuation allowance		(19,371)		15,982		(15,139)
Different tax rates in different jurisdictions		6,491		2,844		2,541
Disallowed losses		6,273		2,748		2,455
Other		2,268		282		142
Income tax expense	¥	—	¥	—	¥	—

F-23

Significant components of deferred tax assets and liabilities are as follows:

	Yen in thousands
	For the fiscal years ended
	March 31,
	2023	2022
Deferred tax assets:
Net operating loss carryforwards	102,559	135,400
Operating lease liabilities	20,980	—
Accrued expenses and reserves	12,209	—
Other	615	2,223
Total deferred tax assets	136,363	137,623
Deferred tax liabilities:
Right-of-use assets	(20,980)	—
Debt issuance costs	(346)	(369)
Other receivables	—	(2,274)
Capitalized software	(64)	(1,011)
Other	(737)	(362)
Total deferred tax liabilities	(22,127)	(4,016)
Less: valuation allowance	(114,236)	(133,607)
Net deferred tax assets	—	—

Due to the Company’s history of net losses and the difficulty in predicting future results, the Company concluded it was not more likely than not that the net operating loss carryforwards would be utilized. Accordingly, it has established a valuation allowance against net deferred tax assets. Significant management judgment is required in determining the Company’s deferred tax assets and liabilities and valuation allowances for purposes of assessing its ability to realize any future benefit from its net deferred tax assets. The Company intends to maintain this valuation allowance until sufficient positive evidence exists to support the reversal of the valuation allowance. Income tax expense recorded in the future will be reduced to the extent that sufficient positive evidence materializes to support a reversal of, or decrease in, the Company’s valuation allowance. The net changes in the total valuation allowance for net deferred tax assets for the fiscal years ended March 31, 2023, 2022, and 2021 consisted of the following:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Valuation allowance at beginning of year	¥	133,607	¥	117,625	¥	117,527
Additions (deductions)		(19,371)		15,982		(15,139)
Change in statutory tax rate		—		—		15,237
Valuation allowance at end of year	¥	144,236	¥	133,607	¥	117,625

The Company had net operating loss carryforwards of ¥296,499 thousand in Japan as of March 31, 2023, which are available as an offset against future taxable income. These carryforwards are scheduled to expire as follows:

Fiscal years ending March 31,	Yen in thousands
Between 2024 and 2027	¥	122,286
Between 2028 and 2031		125,915
2032 and thereafter		48,298
Total	¥	296,499

As of March 31, 2023, the Company’s Singapore subsidiary had not generated any revenue and was deemed to be a dormant company under Singaporean tax law. Net operating losses generated in dormant tax year are not allowed to be carryforward to offset future taxable income, as such no tax benefit related to the Singapore net operating loss has been included in the deferred tax assets.

The Company has made no provision for the income taxes on undistributed earnings of a foreign subsidiary since it is the Company’s intention to permanently reinvest such earnings in its foreign subsidiary.

F-24

The Company has determined that it is more likely than not that a tax benefit will be sustained, therefore no uncertain tax benefit has been recognized.

For the fiscal years ended March 31, 2023, 2022, and 2021, the Company had no uncertain tax positions anticipated to significantly increase or decrease within 12 months.

Interest and penalties related to income tax matters are recognized as a component of selling, general and administrative expenses in the Consolidated Statements of Income (Loss), if applicable. The Company did not have any interest or penalties associated with any uncertain tax benefits that have been accrued or recognized as of and for the fiscal years ended March 31, 2023, 2022, and 2021.

The Company files national and local income tax returns within Japan and Singapore. As of March 31, 2023, the Company was not, nor had it been, under income tax examination but may be subject to examination in the future. The tax authorities could perform tax examinations on years as early as the tax year ended March 31, 2016.

11. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

	Yen in thousands
	March 31,
	2023		2022
Accrued compensation	¥	4,846	¥	2,737
Accrued offering costs		—		4,400
Accrued audit fees		44,392		50,188
Accrued professional fees		35,519		19,273
Withholding taxes payable		4,455		2,435
Accrued purchases of property and equipment		639		14,087
Other accrued expenses and current liabilities		10,534		7,915
Total	¥	100,385	¥	101,035

12. Shareholders’ Equity

Common Shares

On October 12, 2021, the Company’s Board of Directors approved, a 1,500-for-one share split of its issued and outstanding common shares. In connection with the 1,500-for-one share split, the total number of authorized common shares increased from 10,000,000 to 40,000,000.

On November 14, 2022, the Company’s Board of Directors further approved a two-for-one share split of its issued and outstanding common shares, and the share split became effective on November 29, 2022. In connection with the two-for-one share split, the total number of authorized common shares increased from 40,000,000 to 80,000,000.

All common share, stock option, and per share information in the Company’s consolidated financial statements and accompanying notes has been restated to give retroactive presentation related to the share splits for all periods presented.

F-25

As of March 31, 2023, the Company has authorized 80,000,000 common shares. Each holder of common shares shall be entitled to one vote for each share held as of the record date and shall be entitled to receive dividends, when, as and if declared by the shareholders’ meeting or the Board of Directors. The total common shares outstanding as of March 31, 2023 were 20,004,000 shares.

Warrantee is subject to the Companies Act in Japan. The significant provisions in the Companies Act that affect financial and accounting matters are summarized below:

Common shares

Under the Companies Act, issuances of common shares are required to be credited to the common share account for at least 50% of the proceeds and to the additional paid-in capital account for the remaining amounts.

Dividends

Under the Companies Act, companies can pay dividends at any time during the year in addition to the year-end dividend upon resolution at the shareholders meeting. The Companies Act permits companies to distribute dividends-in-kind (non-cash assets) to shareholders subject to certain limitations and additional requirements. Semiannual interim dividends may also be paid once a year upon resolution by the Board of Directors if the articles of incorporation of the company so stipulate. The Companies Act provides certain limitations on the amounts available for dividends or the purchase of treasury shares.

The amount available for dividends under the Companies Act is calculated based on the amount recorded in the Company’s non-consolidated financial statements prepared in accordance with accounting principles generally accepted in Japan. As a result, there was no amount available for dividends due to the accumulated deficit as of March 31, 2023.

Increases / decreases and transfer of common shares, reserve, and surplus

The Companies Act requires that an amount equal to 10% of dividends must be appropriated as legal reserve (a component of retained earnings) or as additional paid-in capital (a component of capital surplus) depending on the equity account charged upon the payment of such dividends until the total of the aggregate amount of legal reserve and additional paid-in capital equals 25% of common shares. Under the Companies Act, the total amount of additional paid-in capital and legal reserve may be reversed without limitation. The Companies Act also provides that common shares, legal reserve, additional paid-in capital, and other capital surplus and retained earnings can be transferred among the accounts under certain conditions upon resolution of the shareholders. During the fiscal year ended March 31, 2021, the Company reduced its common shares capital and additional paid in capital by ¥125,636 thousand and ¥135,399 thousand, respectively and transferred ¥261,035 thousand in its non-consolidated financial statements to reduce the accumulated deficit upon resolution of the shareholders.

13. Related-Party Transactions

Transactions with the CEO of the Company and ZENY Inc.

For the fiscal year ended March 31, 2021, the Company had certain funding transactions with Yusuke Shono, the CEO of the Company, and ZENY Inc., a personal asset management company wholly owned by the CEO of the Company for general operating needs of ¥28,640 thousand, and the entire amount totaled ¥30,053 thousand had been repaid by March 31, 2021. Also, a receivable of ¥17 thousand from ZENY Inc. was collected during the fiscal year ended March 31, 2021. Therefore, there was no remaining balance related to ZENY Inc. in the Consolidated Balance Sheets as of March 31, 2022 and 2021. The payable and receivable with these related parties were non-interest bearing.

As of and for the fiscal year ended March 31, 2021, the Company and ZENY Inc. had been under common control of the CEO of the Company since the CEO of the Company and ZENY Inc. had 78.1% and 10.4% of the Company’s common shares, respectively. However, ZENY Inc. completed its dissolution of the corporation on September 1, 2021, and the CEO of the Company assumed the 10.4% of the Company’s common shares, which ZENY Inc. had held prior to the dissolution, as of March 31, 2022.

F-26

Transactions with ESCO & Marketing Inc. and Peijen Inc.

During the fiscal year ended March 31, 2021, the Company collected the non-interest-bearing short-term funding of ¥6,112 thousand, which was provided during the fiscal year ended March 31, 2020, for ESCO & Marketing Inc. and Peijen Inc., two wholly owned companies by the CEO of the Company. The short-term funding was provided for general operating needs prior to the fiscal year ended March 31, 2021. The capital relationship between the CEO of the Company and these companies was terminated during the fiscal year ended March 31, 2021.

The collections of the receivable from related parties are included as a component of the shareholders’ equity on the Consolidated Balance Sheets.

Guarantees by the CEO of the Company

As described in Note 7, Debt, the CEO of the Company has guaranteed the Company’s term loan agreement with SBI Estate Finance Co., Ltd. and pledged his personal assets as collateral. The CEO of the Company has also guaranteed the Company’s term loan agreements with Resona Bank, Limited and Japan Finance Corporation.

The Company entered into a lease agreement on April 1, 2015 for its headquarter location in Osaka City, Osaka, Japan. The current lease term expires on February 27, 2024 and its lease payment is ¥148 thousand per month. The CEO of the Company is a guarantor of this lease.

14. Subsequent Events

On July 27, 2023, the Company closed its initial public offering, in which the Company sold 2,400,000 American Depositary Shares (“ADSs”) at a public offering price of US$4.00 per ADS. Each ADS represents one common share of the Company. The Company received net proceeds of US$7,191 thousand after deducting underwiring discounts and commissions and other offering costs.

On August 1, 2023, the Company entered into a term loan agreement with the CEO of the Company for $2,700 thousand with a maturity date of March 31, 2024. The interest rate of the term loan is 6.00% per annum.

F-27

EX-1.1

Exhibit 1.1

Articles of Incorporation of Warrantee Inc,

Chapter Ⅰ. General Provisions

Article 1 (Company Name)

The company name of this company is “Kabushiki Kaisha Warrantee”, which is expressed in English as “Warrantee Inc.” (hereinafter referred to as “the Company”).

Article 2 (Purpose)

The purpose of the Company is to conduct the following businesses:

(1) Solution business using IT;

(2) Consulting business;

(3) Non-life insurance agency business;

(4) Home appliance sales business; and

(5) Any business incidental to the preceding items.

Article 3 (Location of head office)

The Company shall have its head office in the city of Osaka, Osaka.

Article 4 (Organizational bodies)

The Company shall have the following organizational bodies in addition to the general meeting of shareholders and directors:

(1) Board of directors;

(2) Corporate auditors; and

(3) Board of corporate auditors.

Article 5 (Method for public notice)

Public notices by the Company shall be published in a form of electronic public notice, provided, however, that in the event that the Company is unable to publish public notices in an electronic form due to accidents or any other unavoidable events, the public notices shall be published in the Nihon Keizai (Nikkei) Shimbun.

1

Chapter Ⅱ. Shares

Article 6 (Total number of shares authorized to issue)

The total number of shares authorized to issue of the Company shall be 80 million shares.

Article 7 (Acquisition of shares for treasury)

The Company may acquire treasury shares by a resolution of the board of directors in accordance with Paragraph 2 of Article 165 of the Companies Act.

Article 8 (Shareholder registry administrator)

1. The Company shall have a shareholder registry administrator.

2. The shareholder registry administrator and the location of its office shall be determined by a resolution of the board of directors.

3. The preparation and keeping of the Company’s shareholder registry and stock option registry as well as other affairs related to the shareholder registry and stock option registry shall be assigned to the shareholder registry administrator, and the Company shall not handle them.

Article 9 (Regulations for handling shares)

The handling and fees related to the Company’s shares shall be in accordance with the regulations for handling shares established by the board of directors in addition to laws and ordinances as well as these Articles of Incorporation.

Chapter Ⅲ. General Meetings of Shareholders

Article 10 (Convocation)

The Company shall convene an annual general meeting of shareholders within three (3) months of the day following the end of each fiscal year, and an extraordinary meeting of shareholders, as and when required.

Article 11 (Record date)

The record date for voting rights at an annual general meeting of shareholders shall be March 31 of each year.

Article 12 (Convenor and chairperson)

1. A CEO, unless otherwise specifically stipulated in laws, shall convene a meeting of the shareholders and shall act as the chairman therein.

2. If the CEO is unable to so convene or act due to accidents, other directors shall act in place of the CEO, in accordance with the order decided upon in advance by a resolution of the board of directors.

2

Article 13 (Deemed provision by disclosure of reference documents for meeting of shareholders through internet)

With respect to the convocation of a meeting of the shareholders, the Company may deem as fully provided to the shareholders information on the matters to be stated or presented in the reference documents for the meeting of the shareholders, business report, financial statements, and consolidated financial statements, by disclosing such information by methods which use internet in accordance with the provisions of the Ordinance of the Ministry of Justice.

Article 14 (Resolution method)

1. Unless otherwise specifically provided by laws and regulations or these Articles of Incorporation, resolutions at a meeting of the shareholders shall be passed by a majority of the votes of shareholders present at the meeting, who are entitled to exercise the votes.

2. Resolutions set forth in Article 309, Paragraph 2 of the Companies Act shall be passed at a meeting of the shareholders by two-thirds or more of the votes of shareholders present at the meeting, with a quorum of one-third or more of the votes of the shareholders who are entitled to exercise their votes.

Article 15 (Exercise of voting rights by proxy)

A shareholder or his/her legal representative may exercise voting rights by authorizing another shareholder who has voting rights in the Company as proxy, provided, however, a document evidencing the authority shall be presented to the Company for each meeting of the shareholders.

Chapter IV. Directors and Board of Directors

Article 16 (Number of directors)

The number of directors of the Company shall be seven (7) or fewer.

Article 17 (Election of directors)

1. The election of directors shall be made by a resolution passed by a majority of the votes of shareholders present at a meeting of the shareholders, with a quorum of one-third or more of the votes of the shareholders who are entitled to exercise their voting rights at the meeting.

2. No cumulative voting shall be used for a resolution for the election of directors.

3

Article 18 (Term of office of directors)

1. The term of office of a director shall be until the conclusion of the annual meeting of the shareholders for the last fiscal year ending in two (2) years of the election.

2. The term of office of a director who is elected to fill a vacancy or elected as an additional director shall be the same as the remaining term of his or her predecessor or the remining term of the other incumbent directors.

Article 19 (Representative director and executive directors)

1. The board of directors shall elect a representative director(s) by a resolution of the board of directors.

2. When the Company has one representative director, the representative director shall be CEO. When the Company has two or more representative directors, one CEO shall be selected from among the representative directors by a resolution of the board of directors.

3. In addition to the preceding paragraph, the board of directors may elect a small number of chairperson(s), vice-president(s), senior managing director(s), and managing director(s).

Article 20 (Convenor and chairperson meetings of the board of directors)

1. A CEO shall convene a meeting of the board of directors and shall act as the chairperson of the meetings, unless otherwise specifically stipulated in laws and regulations.

2. If the CEO is unable to so convene or act due to accidents, other directors shall act in place of the CEO, in accordance with the order decided upon in advance by a resolution of the board of directors.

Article 21 (Convocation notice of meetings of board of directors)

1. A notice to convene a meeting of the board of directors shall be given to each director and corporate auditor at least three (3) days before the date set for the meeting, provided, however, in case of emergency, such period may be shortened.

2. A meeting of the board of directors may be held without the convocation procedures if all directors and corporate auditors give consent.

Article 22 (Resolution method of board of directors)

1. The resolutions at a meeting of the board of directors shall be passed by a majority of the votes of directors present at the meeting, with a quorum of the majority or more of the votes of the shareholders who are entitled to exercise their voting rights at the meeting.

2. When a director proposes a matter for the purpose of a resolution of board of directors, if all directors (limited to those entitled to participate in resolutions on relevant matters) agree on the resolutions of the board of directors in writing or electromagnetic records, the Company shall deem the board of directors to have approved the resolution, provided, however, that this shall not apply when corporate auditors express an objection.

4

Article 23 (Rules concerning board of directors)

Any matter related to the board of directors shall be governed by the internal rules concerning the board of directors established by the board of directors as well as laws, regulations and these Articles of Incorporation.

Article 24 (Remuneration etc. of directors)

Any remuneration, bonus and other financial benefit (hereinafter referred to as the “Remuneration, etc.”) to be received by the directors as consideration for the performance of their duties from the Company shall be determined by a resolution at a meeting of the shareholders.

Article 25 (Directors liability exemption)

1. Pursuant to the provisions of Article 426, Paragraph 1 of the Companies Act, the Company may exempt directors (including former directors) from their liabilities for loss or damage arising from the conduct specified under Article 423 of the Companies Act to the extent permitted by laws and regulations by a resolution of the board of directors.

2. Pursuant to the provisions of Article 427 of the Companies Act, the Company may enter into an agreement with non-executive directors to limit their liabilities for loss or damage arising from their conducts under Article 423 of the Companies Act, provided, however, that the maximum amount of liability under the agreement shall be the minimum liability amount stipulated by laws and regulations.

Chapter V: Corporate Auditors and Board of Corporate Auditors

Article 26 (Number of corporate auditors)

The number of corporate auditors of the Company shall be five (5) or fewer.

Article 27 (Election of corporate auditors)

The election of corporate auditors shall be made by a resolution passed by a majority of the votes of shareholders present at a meeting of the shareholders, with a quorum of one-third or more of the votes of the shareholders who are entitled to exercise their voting rights at the meeting.

Article 28 (Term of office of corporate auditors)

1. The term of office of a corporate auditor shall be until the conclusion of the annual meeting of the shareholders for the last fiscal year ending within four (4) years of the election.

5

2. The term of office of a corporate auditor who is elected to fill a vacancy shall be the same as the remaining term of his or her predecessor.

Article 29 (Full-Time Corporate Auditor)

The board of corporate auditors shall elect full-time corporate auditor(s) by its resolution.

Article 30 (Convocation notice of meetings of board of corporate auditors)

1. A notice to convene a meeting of the board of corporate auditors shall be given to each corporate auditor at least three (3) days before the date set for the meeting, provided, however, in case of emergency, such period may be shortened.

2. A meeting of the board of corporate auditors may be held without the convocation procedures if all directors and corporate auditors give consent.

Article 31 (Resolution method of board of corporate auditors)

Unless otherwise specifically provided by laws and regulations, the resolutions at a meeting of the board of corporate auditors shall be passed by a majority of the votes of corporate auditors.

Article 32 (Rules Concerning the Board of Corporate Auditors)

Any matter related to the board of corporate auditors shall be governed by internal rules concerning the board of corporate auditors established by the board of corporate auditors as well as laws, regulations and these Articles of Incorporation.

Article 33 (Remuneration etc. of corporate auditors)

The Remuneration, etc. of corporate auditors shall be determined by a resolution at a meeting of the shareholders.

Article 34 (Corporate auditors liability exemption)

1. Pursuant to the provisions of Article 426, Paragraph 1 of the Companies Act, the Company may exempt corporate auditors (including former corporate auditors) from their liabilities for loss or damage arising from the conduct specified under Article 423 of the Companies Act to the extent permitted by laws and regulations by a resolution of the board of directors.

2. Pursuant to the provisions of Article 427 of the Companies Act, the Company may enter into an agreement with corporate auditors to limit their liabilities for loss or damage arising from their conducts under Article 423 of the Companies Act, provided, however, that the maximum amount of liability under the agreement shall be the minimum liability amount stipulated by laws and regulations.

6

Chapter VI. Accounting

Article 35 (Fiscal year)

The fiscal year of the Company shall be one year, from April 1 to March 31 of the following year.

Article 36 (Dividends distribution and record date)

The Company may distribute retained earnings as end of the period dividends to shareholders or registered pledgees of shares by resolution of an annual general meeting of shareholders with March 31 every year as the record date.

Article 37 (Interim dividends and record date)

The Company may distribute retained earnings as interim dividends to shareholders or registered pledgee of shares by a resolution of the board of directors with September 30 every year as the record date.

Article 38 (Statue of limitations on dividends)

If the payment of retained earnings made by the Company is not received after three years from the provision of the payment, the Company shall be exempt from the obligation to make such payment.

I certify that the copy of these Articles of Incorporation is the same with the original.

11/29/2022

2-4-1-1103 Doshomachi, Chuo-ku, Osaka City, Osaka

Warrantee Inc.

CEO Yusuke Shono

- END -

7

EX-2.3

Exhibit 2.3

Description of Rights of Each Class of Securities

Registered under Section 12 of the Securities Exchange Act of 1934, as Amended (the “Exchange Act”)

American depositary shares (“ADSs”) of Warrantee Inc. (“we,” “our,” “our Company,” or “us”) are listed and traded on the Nasdaq Capital Market under the symbol “WRNT,” and in connection with this listing (but not for trading), the ADSs have been registered under Section 12(b) of the Exchange Act. Each ADS represents one of our common shares (“Common Shares”). This exhibit contains a description of the rights of the holders of Common Shares and ADSs.

Description of Common Shares

The following is a summary of the material terms of our share capital and our articles of incorporation, including a summary of the relevant provisions of applicable share handling regulations, of the Companies Act and the Act on Book-Entry Transfer of Company Bonds, Shares, etc. of Japan (Shasai Kabushiki tou no Furikae ni kansuru Houritsu) (Act No. 75 of 2001, as amended) (including regulations promulgated thereunder, the “Book-Entry Act”) relating to joint-stock corporations (kabushiki kaisha), and of certain related laws and legislation, each as currently in effect. Because it is a summary, this discussion should be read together with our articles of incorporation and the applicable share handling regulations.

Type and Class of Securities (Item 9.A.5 of Form 20-F)

We are a joint-stock corporation incorporated in Japan under the Companies Act. The rights of our shareholders are represented by our common shares as described below, and our shareholders’ liability is limited to the amount of their respective holdings in such shares. As of the date hereof, our authorized share capital consists of 80,000,000 common shares, of which 20,004,000 shares are outstanding, and our total registered capital is JPY11,000,000. All currently outstanding common shares are fully-paid and non-assessable.

Pre-Emptive Rights (Item 9.A.3 of Form 20-F)

Holders of Common Shares have no pre-emptive rights under our Articles of Incorporation.

Limitations or Qualifications (Item 9.A.6 of Form 20-F)

The Companies Act provides specific rights for shareholders owning a substantial number of voting rights:

· A shareholder holding 90% or more of the total number of voting rights of all shareholders has the right to demand that all other shareholders sell their shares to such shareholder who holds 90% or more of the voting rights;

· Shareholders holding 10% or more of the total number of voting rights of all shareholders, or 10% or more of the total number of our outstanding shares, have the right to apply to a court of competent jurisdiction for our dissolution.

· Shareholders who have held 3% or more of the total number of voting rights of all shareholders for six months or more have the right to demand the convening of a shareholders’ meeting.

· Shareholders who have held 3% or more of the total number of voting rights of all shareholders, or 3% or more of the total number of our outstanding shares, for six months or more have certain rights under the Companies Act, which include the right to:

· apply to a competent court for removal of a director or a corporate auditor; and

· apply to a competent court for removal of a liquidator.

· Shareholders holding 3% or more of the total number of voting rights of all shareholders have the right to object to the exculpation of a director or a corporate auditor from certain liabilities.

· Shareholders holding 3% or more of the total number of voting rights of all shareholders, or 3% or more of the total number of our outstanding shares, have certain rights under the Companies Act, which include the right to:

· examine our accounting books and documents and make copies of them; and

· apply to a competent court for the appointment of an inspector to inspect our operation and/or financial condition.

· Shareholders who have held 1% or more of the total number of voting rights of all shareholders for six months or more have the right to apply to a competent court for the appointment of an inspector to review the correctness of the convocation and voting procedures of a shareholders’ meeting.

· Shareholders who have held 1% or more of the total number of voting rights of all shareholders, or 300 or more voting rights, for six months or more have the right to demand that certain matters be added to the agenda items at a shareholders’ meeting.

· Shareholders holding 1% or more of the total number of voting rights of all shareholders, or 1% or more of the total number of our outstanding shares, have the right to institute a derivative action to enforce the liabilities of directors or corporate auditors of our material subsidiaries that satisfy statutory requirements.

· Shareholders who have held any number of shares for six months or more have the right to demand that we take certain actions under the Companies Act, which include the rights to demand:

· the institution of an action to enforce the liabilities of our directors or corporate auditors;

· the institution of an action to disgorge from a recipient the benefit of a proprietary nature given in relation to the exercise of the right of a shareholder; and

· on our behalf, that a director ceases an illegal or ultra vires action.

There are no provisions under the Companies Act or our articles of incorporation which forces shareholders to make additional contributions when requested by us.

Limitations on Liability

Our articles of incorporation permit us to exempt, by resolution of our board of directors, corporate auditors from liabilities arising in connection with their failure to execute their duties in good faith (but without gross negligence), to the fullest extent permitted by the Companies Act. In addition, our articles of incorporation permit us to exempt, by resolution of our board of directors, non-executive directors from liabilities arising in connection with any failure to execute their duties in good faith or due to simple negligence (excluding gross negligence and willful misconduct), to the fullest extent permitted by the Companies Act. Should our board of directors, exempt a corporate auditor or non-executive director from any such liabilities, our rights and those of our shareholders to file shareholders’ derivative suits on behalf of our Company to recover monetary damages from such director or corporate auditor for breach of their duties under the Companies Act will be eliminated or reduced. However, exculpation does not apply to any director or corporate auditor if they have breached their duties under the Companies Act intentionally (koi) or by gross negligence (ju-kashitsu). Furthermore, we may

enter into agreements for the limitation of liabilities with our non-executive directors and corporate auditors. If we do so, we expect that these agreements will eliminate or reduce our rights and those of our shareholders as described above.

Rights of Other Types of Securities (Item 9.A.7 of Form 20-F)

Not applicable.

Rights of Shareholders of our Common Shares (Item 10.B.3 and 10.B.4 of Form 20-F)

Voting Rights and Shareholder Meetings

Our articles of incorporation provide that each annual meeting of our shareholders must be held within three months after the end of each fiscal year. Our fiscal year ends on March 31, and therefore, we must hold our annual shareholders’ meeting by the end of June of each year. In addition, shareholders meetings to consider and vote on extraordinary matters may be held as necessary, provided that we satisfy all of the procedural requirements under both our articles of incorporation and the Companies Act.

Our common shares allocate one vote per share at shareholders’ meetings. Our articles of incorporation provide for a simple majority approval on most matters submitted for shareholder vote, unless otherwise required by laws or regulations. As required by law, and as referenced in our articles of incorporation, a two-thirds majority approval is required for any votes on matters specified in Article 309, Paragraph (2) of the Companies Act, which cover, in relevant part, stock purchase requests, treasury stock purchases, purchases of an entire class of shares, demands for share sales by heir, stock consolidations, and amounts paid for the offered shares. In such cases, the quorum requirement is one-third of the outstanding voting rights. Any amendment to our articles of incorporation must be approved by our shareholders at a shareholders’ meeting.

Dividend Rights

We may issue dividends upon a resolution of our common shareholders. We have not issued dividends to our shareholders since the incorporation of our Company.

Liquidation Rights

In accordance with the Companies Act, liquidations must be approved by common shareholders holding at least a two-thirds majority of the shares present at a meeting where the majority of the issued and outstanding shares with voting rights is present.

Articles of incorporation

Objective of our Company under our Articles of incorporation

We have broad authority under Article 2 of our articles of incorporation to conduct our lines of business.

Provisions Regarding our Directors

With respect to the election of directors of our Company, each director must be elected by a majority of our common shareholders entitled to vote at a common shareholders meeting where shareholders holding one-third or more of the voting rights entitled to vote are present. Additionally, any resolution regarding the election of a director cannot be adopted by cumulative voting.

Rights of Shareholders of our Common Shares

Under the Companies Act and our articles of incorporation, holders of our common shares have, among others, the following rights:

· the right to receive dividends when the payment of dividends has been approved at a shareholders’ meeting, with this right lapsing three years after the provision of the payment in accordance with our articles of incorporation;

· the right to vote at a shareholders’ meeting (cumulative voting for the election of directors is not allowed under our articles of incorporation);

· the right to receive surplus in the event of a liquidation; and

· the right to require us to purchase shares subject to certain requirements under the Companies Act when a shareholder opposes certain resolutions, including (i) the transfer of all or material part of our business, (ii) an amendment to our articles of incorporation to establish a restriction on share transfer, (iii) a share exchange or share transfer to establish a holding company, (iv) a company split, or (v) a merger, all of which must, as a general rule, be approved by a special resolution adopted at a shareholders’ meeting.

Under the Companies Act, a company is permitted to make a distribution of surplus to the extent that the aggregate book value of the assets to be distributed to shareholders does not exceed the distributable amount provided for under the Companies Act and the applicable ordinance of the Ministry of Justice as of the effective date of such distribution of surplus. The amount of surplus at any given time shall be the amount of the company’s assets and the book value of the company’s treasury stock after subtracting and adding the amounts of the items provided for under the Companies Act and the applicable ordinance of the Ministry of Justice.

A shareholder is generally entitled to one vote per share at a shareholders’ meeting. In general, under the Companies Act and our articles of incorporation, a shareholders’ meeting may adopt an ordinary resolution by a majority of the voting rights presented at the meeting. The Companies Act and our articles of incorporation require a quorum of not less than one-third of the total number of voting rights in connection with the election of directors and statutory auditors. Under the Companies Act, to avoid exercising improper control in a form of mutual shareholding, an institutional shareholder, 25% or more voting rights of which are directly or indirectly held by us, does not have voting rights at our shareholders’ meeting. We have no voting rights with respect to our own common shares that we hold. Shareholders or their attorney-in-fact may exercise their voting rights through proxies, provided that a shareholder or his/her attorney-in-fact may appoint only one other shareholder who has voting rights as its proxy.

With respect to a special resolution, while the Companies Act generally requires a quorum of the majority of the total number of voting rights and approval of two-thirds of the voting rights presented at the meeting in connection with any material corporate actions, it allows a company to reduce the quorum for such special resolutions pursuant to its articles of incorporation to one-third (or greater than one-third) of the total number of voting rights. We adopted a quorum of not less than one-third of the total number of voting rights in our articles of incorporation for special resolutions for material corporate actions, such as:

· a reduction of the stated capital (except when a company reduces the stated capital within a certain amount as provided for under the Companies Act);

· an amendment to our articles of incorporation;

· establishment of a 100% parent-subsidiary relationship through a share exchange or share transfer requiring shareholders’ approval;

· a dissolution, merger, or consolidation requiring shareholders’ approval;

· a company split requiring shareholders’ approval;

· a transfer of all or an important part of our business;

· a takeover of the entire business of any other corporation requiring shareholders’ approval;

· issuance of new shares at a substantially favorable price, or issuance of stock acquisition rights or bonds with stock acquisition rights with substantially favorable conditions, to persons other than our shareholders; and

· other material corporate actions provided in the Companies Act.

Under the Companies Act, in order to change the rights of shareholders which are stipulated and defined in our articles of incorporation, we must amend our articles of incorporation. Amendments must, as a general rule, be approved by a special resolution of our shareholders.

Annual meetings and special meetings of shareholders are convened, unless otherwise provided by laws and regulations, by our Chief Executive Officer based on a resolution of our board of directors. Under our articles of incorporation, shareholders of record as of March 31 of each year have the right to attend our annual shareholders’ meeting. We may, by prescribing a record date, determine the shareholders who are stated or recorded in the shareholder registry on the record date as the shareholders entitled to attend and take action at a special shareholders’ meeting, and in this case, we are required to make a public notice of the record date at least two weeks prior to the record date. A convocation notice will be sent to these shareholders at least two weeks prior to the date of the shareholders’ meeting.

Our Acquisition of our Common Shares

Under applicable laws of Japan, we may acquire our common shares:

(i) from a specific shareholder (other than any of our subsidiaries), pursuant to a special resolution of a shareholders’ meeting; or

(ii) from any of our subsidiaries, pursuant to a resolution of our board of directors.

In the case of any acquisition made by way of (i) above, any other shareholder may request within a certain period of time provided under the applicable ordinance of the Ministry of Justice before a shareholders’ meeting that we also purchase the shares held by the requesting shareholder, unless the purchase price or any other consideration to be delivered in exchange for the acquisition of common shares does not exceed the market price of our common shares calculated by the method prescribed in the applicable ordinance of the Ministry of Justice.

In general, an acquisition by us of our common shares must satisfy certain requirements, including that the total amount of the acquisition price may not exceed the distributable amount.

We may hold the common shares which we acquired pursuant to (i) and (ii) above, or we may cancel such shares by a resolution of our board of directors. We may also dispose of such shares pursuant to a resolution of our board of directors, subject to other requirements applicable to the issuance of shares under the Companies Act.

Limitations on the Rights to Own Common Shares (Item 10.B.6 of Form 20-F)

There are no restrictions with respect to non-residents of Japan or foreign shareholders holding our Common Shares or on the exercise of voting rights, except for filing requirements with respect to an acquisition of shares by a Non-Resident of Japan under the Foreign Exchange and Foreign Trade Act of Japan and related regulations. However, pursuant to a provision of our share handling regulations, a shareholder who does not have an address or residence in

Japan is required to file with our transfer agent its temporary address to receive notices in Japan or that of a standing proxy having any address or residence in Japan.

Provisions Affecting Any Change of Control (Item 10.B.7 of Form 20-F)

There are no provisions in our Articles of Incorporation that would have the effect of delaying, deferring, or preventing a change in control that would operate only with respect to a merger, acquisition, or corporate restructuring involving us.

Ownership Threshold (Item 10.B.8 of Form 20-F)

There are no provisions in our Articles of Incorporation or other subordinated rules regarding an ownership threshold, above which shareholder ownership must be disclosed.

Differences Between the Law of Different Jurisdictions (Item 10.B.9 of Form 20-F)

With respect to Items 10.B.2 to 10.B.8, the Company has identified in the responses above where provisions of the Companies Act applicable to the Company is significantly different from the comparable Delaware law.

Changes in Capital (Item 10.B.10 of Form 20-F)

There are no provisions in our Articles of Incorporation governing changes in our Company’s capital more stringent than is required by law.

Debt Securities (Item 12.A of Form 20-F)

Not applicable.

Warrants and Rights (Item 12.B of Form 20-F)

Not applicable.

Other Securities (Item 12.C of Form 20-F)

Not applicable.

Description of American Depositary Shares (Items 12.D.1 and 12.D.2 of Form 20-F)

The Bank of New York Mellon, as depositary, registers and delivers American Depositary Shares, also referred to as ADSs. Each ADS represents one common share (or a right to receive one common shares) deposited with MUFG Bank Ltd., as custodian for the depositary in Japan. Each ADS will also represent any other securities, cash or other property that may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary’s office at which the ADSs are administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.

You may hold ADSs either (A) directly (i) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (ii) by having uncertificated ADSs registered in your name, or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, also called DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.

Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.

As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Japanese law governs shareholder rights. The depositary will be the holder of our common shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.

The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR.

Dividends and Other Distributions

How will you receive dividends and other distributions on our common shares?

The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on common shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of common shares your ADSs represent.

Cash. The depositary will convert any cash dividend or other cash distribution we pay on the common shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.

Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. The depositary will distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution.

Shares. The depositary may distribute additional ADSs representing any common shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell common shares which would require it to deliver a fraction of an ADS (or ADSs representing those common shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new common shares. The depositary may sell a portion of the distributed common shares (or ADSs representing those common shares) sufficient to pay its fees and expenses in connection with that distribution.

Rights to purchase additional shares. If we offer holders of our common shares any rights to subscribe for additional shares or any other rights, the depositary may (i) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders or (iii) sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. In that case, you will receive no value for them. The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.

Other distributions. The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.

The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our common shares or any value for them if it is illegal or impractical for us to make them available to you.

Deposit, Withdrawal, and Cancellation

How are ADSs issued?

The depositary will deliver ADSs if you or your broker deposits our common shares or evidence of rights to receive common shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.

What are the pre-clearance requirements for Foreign Investors to acquire or hold the underlying common shares directly rather than through the depositary?

Under the amendments in 2019 to the Foreign Exchange and Foreign Trade Act of Japan (Act No.228 of 1949, as amended) (“FEFTA”), a proposed transferee of our common shares who is a Foreign Investor (as defined under FEFTA) must submit an application for pre-clearance to the applicable Japanese governmental authority prior to the transfer of our common shares, regardless of the amount of shares to be acquired, which approval may take up to 30 days and could be subject to further extension. Prior to accepting common shares for deposit in return for the issuance of ADSs, the depositary, which is considered a Foreign Investor for purposes of FEFTA, must obtain pre-clearance from the Japanese governmental authority. Accordingly, investors wishing to deposit common shares with the depositary for the issuance of ADSs should notify the depositary at least 30 days prior to such deposit to allow time for the depositary to apply for any required pre-clearance, if not already obtained. The depositary will not accept any common shares for deposit until any required pre-clearance has been obtained. In addition, any Foreign Investor expecting to receive delivery of our common shares upon surrender of ADSs must also obtain pre-clearance from the applicable Japanese governmental authority prior to accepting delivery, which approval may take up to 30 days and could be subject to further extension. Accordingly, ADS holders who are Foreign Investors wishing to surrender ADSs for the purpose of withdrawing the underlying deposited common shares should apply for pre-clearance at least 30 days in advance of such surrender. The depositary will not accept surrender of ADSs for the purpose of withdrawal of common shares until it receives assurances satisfactory to the depositary that any required pre-clearance for the delivery of the common shares to a Foreign Investor has been obtained.

How can ADS holders withdraw the deposited securities?

You may surrender your ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver our common shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary

will deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.

How do ADS holders interchange between certificated ADSs and uncertificated ADSs?

You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.

Voting Rights

How do you vote?

ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders’ meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Japan and the provisions of our articles of incorporation or similar documents, to vote or to have its agents vote the common shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.

Except by instructing the depositary as described above, you won’t be able to exercise voting rights unless you surrender your ADSs and withdraw the common shares. However, you may not know about the meeting enough in advance to withdraw the common shares. In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed.

We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your common shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise voting rights and there may be nothing you can do if your common shares are not voted as you requested.

In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 45 days in advance of the meeting date.

Fees and Expenses
Persons depositing or withdrawing common shares or ADS holders must pay:	For:
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)	Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
$.05 (or less) per ADS	Any cash distribution to ADS holders

A fee equivalent to the fee that would be payable if securities distributed to you had been common shares and the common shares had been deposited for issuance of ADSs	Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders
$.05 (or less) per ADS per calendar year	Depositary services
Registration or transfer fees	Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares
Expenses of the depositary	Cable (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement) Converting foreign currency to U.S. dollars
Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or common shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes	As necessary
Any charges incurred by the depositary or its agents for servicing the deposited securities	As necessary

The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.

From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.

The depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligation to act without negligence or bad faith. The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that

the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from the us in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.

Payment of Taxes

You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.

Tender and Exchange Offers; Redemption, Replacement, or Cancellation of Deposited Securities

The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do so by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish.

If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.

If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs.

If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADRs in exchange for new ADRs identifying the new deposited securities.

If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender of those ADSs or cancel those ADSs upon notice to the ADS holders.

Amendment and Termination

How may the deposit agreement be amended?

We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are

considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.

How may the deposit agreement be terminated?

The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if

· 60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;

· we delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange in the United States or make arrangements for trading of ADSs on the U.S. over-the-counter market;

· we delist our common shares from an exchange outside the United States on which they were listed and do not list the common shares on another exchange outside the United States;

· the depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities Act of 1933;

· we appear to be insolvent or enter insolvency proceedings;

· all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;

· there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or

· there has been a replacement of deposited securities.

If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.

After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph.

Limitations on Obligations and Liability

Limits on our obligations and the obligations of the Depositary; Limits on liability to holders of ADSs

The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:

· are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;

· are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement;

· are not liable if we or it exercises discretion permitted under the deposit agreement;

· are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;

· have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;

· may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person;

· are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and

· the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit.

In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.

Requirements for Depositary Actions

Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of common shares, the depositary may require:

· payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities;

· satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and

· compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.

The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.

Your Right to Receive the Common Shares Underlying your ADSs

ADS holders have the right to cancel their ADSs and withdraw the underlying common shares at any time except:

· when temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer of common shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our common shares;

· when you owe money to pay fees, taxes and similar charges; or

· when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of common shares or other deposited securities.

This right of withdrawal may not be limited by any other provision of the deposit agreement.

Shareholder Communications; Inspection of Register of Holders of ADSs

The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.

Jury Trial Waiver

The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our common shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. You will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary’s compliance with U.S. federal securities laws or the rules and regulations promulgated thereunder.

EX-4.6

Exhibit 4.6

Loan Agreement

Warrantee Inc. (hereinafter referred to as “A”) and Yusuke Shono (hereinafter referred to as “B”) hereby enter into the following loan agreement (hereinafter referred to as the “Agreement”).

(Execution of Loans)

Article 1. A shall lend, and B shall borrow USD2,700,000 (hereinafter referred to as the “Principal”) on August 1, 2023 (hereinafter referred to as the “Execution Date”) under the following articles.

(Preconditions for the Execution of Loans)

Article 2. The preconditions for loans shall be each of the conditions set forth in the following items.

(1) That B has not violated any of the provisions of this Agreement and that no such violation is likely to occur on or after the Execution Date.

(Repayment of the Principal)

Article 3. B shall repay to A the sum of the Principal as set forth in Article 1 and the interest at the rate of 6% per annum by March 31, 2024 in the manner set forth in the following Article.

(Manner of Repayment of the Principal)

Article 4. B shall make repayment to the bank account designated by A. The transfer fee for repayment shall be borne by B.

(Notification)

Article 5. B shall immediately notify A of the occurrence of any of the following events:

(1) The change of B’s address.

(2) The deterioration in B’s credit status or any other similar events.

(Prohibition of Assignment of Claims)

Article 6. Neither A nor B shall assign, pledge, or have a third party undertake the Principal.

(Jurisdiction)

Article 7. In the event that any dispute arises with respect to this Agreement, Tokyo District Court shall have jurisdiction as the court of first instance.

In witness whereof, two copies of this Agreement have been prepared, the first and second being the original, each bearing the seal of the other.

August 1, 2023
	A: /s/ Warrantee Inc.
	1103, 2-4-1 Doshomachi,
	Chuo-ku, Osaka City, Osaka
	Representative Director: Yusuke Shono
	B: /s/ Yusuke Shono
	[*]

EX-11.1

Exhibit 11.1

CODE OF ETHICS AND BUSINESS CONDUCT

1. Introduction.

1.1 The board of directors of Warrantee Inc., joint-stock corporation organized under the laws of Japan (together with its subsidiaries, the “Company”), is committed to conducting the businesses of the Company in accordance with applicable laws, rules, and regulations and the highest standards of business conduct. This Code of Ethic and Business Conduct (this “Code”) covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide all directors, corporate auditors, officers, and employees of the Company. The Company has adopted this Code in order to:

(a)promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest;

(b)promote full, fair, accurate, timely, and understandable disclosure in its communications with and reports to its shareholders, including reports filed with the U.S. Securities and Exchange Commission (the “SEC”) and, if applicable, the securities regulators in Japan, and in other public communications made by the Company;

(c)promote compliance with applicable governmental laws, rules, and regulations, including compliance with rules and regulations of the SEC and The NASDAQ Stock Market LLC (“NASDAQ”);

(d)promote the protection of Company assets, including corporate opportunities and confidential information;

(e)promote fair dealing practices;

(f)deter wrongdoing; and

(g)ensure accountability for adherence to this Code.

1.2 All directors, corporate auditors, officers, and employees are required to be familiar with this Code, comply with its provisions and report any suspected violations as described below in Section 12.

2. Honest and Ethical Conduct.

2.1 The Company’s policy is to promote high standards of integrity by conducting its affairs honestly and ethically. This Code applies to all directors, corporate auditors, officers, and employees of the Company, whether they work for the Company on a full-time, part-time, consultative, or temporary basis.

2.2 Each director, corporate auditor, officer, and employee must act with integrity and observe the highest ethical standards of business conduct in his or her dealings with the

Company’s customers, suppliers, partners, service providers, competitors, employees, and anyone else with whom he or she has contact in the course of performing his or her job.

3. Conflicts of Interest.

3.1 A conflict of interest occurs when an individual’s private interest (or the interest of a member of his or her family) interferes, or even appears to interfere, with the interests of the Company as a whole. A conflict of interest can arise when an employee, officer, corporate auditor, or director (or a member of his or her family) takes actions or has interests that may make it difficult to perform his or her work for the Company objectively and effectively. Conflicts of interest also arise when an employee, officer, corporate auditor, or director (or a member of his or her family) receives improper personal benefits as a result of his or her position in the Company. In general, the following are considered conflicts of interest:

(a)Competing Business. No director, corporate auditor, officer, or employee may be employed by a business that competes with the Company or deprives the Company of any business.

(b)Corporate Opportunity. All directors, corporate auditors, officers, and employees owe a duty to the Company to advance its interests when the opportunity arises. No director, corporate auditor, officer, or employee may take for themselves personally (or for the benefit of friends or family members) opportunities that are discovered through the use of Company assets, property, information, or position. No directors, corporate auditors, officers, and employees may use Company assets, property, information, or position for personal gain (including gain of friends or family members).

(c)Financial Interests.

i. No director, corporate auditor, officer, or employee may have any financial interest (ownership or otherwise), either directly or indirectly through a spouse or other family member, in any other business or entity if such interest adversely affects such person’s performance of duties or responsibilities to the Company, or requires such person to devote time to it during his or her working hours at the Company;

ii. No director, corporate auditor, officer, or employee may hold any ownership interest in a privately held company that is in competition with the Company. Notwithstanding the foregoing, directors, corporate auditors, officers, and employees may hold less than 5% ownership interest in a publicly traded company that is in competition with the Company; provided that if such person’s ownership interest in such publicly traded company increases to 5% or more, he or she must immediately report such ownership to the board of corporate auditors of the Company (the “Board of Corporate Auditors”);

iii. No director, corporate auditor, officer, or employee may obtain loans or guarantees of personal obligations from, or enter into any other personal financial transaction with, any company that is a material customer, supplier, or competitor of the Company. This guideline does not prohibit arms-length transactions with recognized banks or other financial institutions. Loans by the Company to, or guarantees by the Company of obligations of, employees or their family members are of special concern and could constitute improper personal benefits to the recipients of such loans or guarantees, depending on the facts and circumstances; and

iv. Unless pre-approved by the Board of Corporate Auditors, no director, corporate auditor, officer, or employee may hold any ownership interest in a company that has a business relationship with the Company if such person’s duties at the Company include managing or supervising the Company’s business relations with that company.

(d) Service on Boards and Committees. No director, corporate auditor, officer, or employee may serve on a board of directors or trustees or on a committee of any entity (whether profit or not-for-profit) whose interests could reasonably be expected to conflict with those of the Company. Directors, corporate auditors, officers, and employees must obtain prior approval from the Board of Corporate Auditors before accepting any such board or committee position. The Company may revisit its approval of any such position at any time to determine whether such person’s service in such position is still appropriate.

3.2 Whether or not a conflict of interest exists or will exist can be unclear. Conflicts of interest should be avoided unless specifically authorized as described in Sections 3.3 and 3.4.

3.3 Persons other than directors, corporate auditors, and executive officers who have questions about a potential conflict of interest or who become aware of an actual or potential conflict should discuss the matter with, and seek a determination and prior authorization or approval from the Board of Corporate Auditors. A supervisor or an officer may not authorize or approve conflict of interest matters or make determinations as to whether a problematic conflict of interest exists without first providing the Board of Corporate Auditors with a written description of the activity and seeking the Board of Corporate Auditors’ written approval. If the supervisor or officer is himself involved in the potential or actual conflict, the matter should instead be discussed directly with the Board of Corporate Auditors.

3.4 Directors, corporate auditors, and executive officers must seek determinations and prior authorizations or approvals of potential conflicts of interest exclusively from the Board of Corporate Auditors.

4. Compliance.

4.1 Employees, officers, corporate auditors, and directors should comply, both in letter and spirit, with all applicable laws, rules, and regulations in the cities, states, and countries in which the Company operates.

4.2 Although not all employees, officers, corporate auditors, and directors are expected to know the details of all applicable laws, rules, and regulations, it is important to know enough to determine when to seek advice from appropriate personnel. Questions about compliance should be addressed to the Board of Corporate Auditors.

5. Disclosure.

5.1 The Company strives to ensure that the contents of and the disclosures in any reports and documents that the Company files with the SEC or other regulatory authorities, and other public communications, shall be full, fair, accurate, timely, and understandable in accordance with applicable disclosure standards, including standards of materiality, where appropriate. Material information with respect to the Company must be promptly disclosed.

5.2 The Company’s periodic reports and other documents filed with the SEC, including all financial statements and other financial information, must comply with applicable federal securities laws and SEC rules.

5.3 Each director, corporate auditors, officer, and employee who contributes in any way to the preparation or verification of the Company’s financial statements and other financial information must ensure that the Company’s books, records, and accounts are accurately maintained. Each director, corporate auditor, officer, and employee must cooperate fully with the Company’s accounting and internal audit departments, as well as the Company’s independent public accountants and counsel.

5.4 Each director, corporate auditor, officer, and employee who is involved in the Company’s disclosure process must:

(a)be familiar with and comply with the Company’s disclosure controls and procedures and its internal control over financial reporting; and

(b)take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business condition of the Company provide full, fair, accurate, timely, and understandable disclosure.

6. Insider Trading. The U.S. federal and applicable Japanese securities laws are built on the premise that a purchaser and a seller of securities should have equal access to important information regarding the company whose securities they are trading. Consequently, securities laws generally forbid an investor from purchasing or selling securities based upon inside information not available to the other party.

The consequences of insider trading violations can be severe. Directors, corporate auditors, officers, and employees who trade on inside information, or who communicate (or tip) this information to others so that they may trade on it, may face a civil penalty of up to three

times the profit gained (or loss avoided), a substantial criminal fine and a jail term of up to 20 years. Additionally, if the Company or its senior officers do not take appropriate steps to prevent a director, corporate auditor, officer, or employee from insider trading, the Company may also face severe legal consequences, including, among other things, substantial criminal penalties.

6.1 Policy Statement.

(a)Directors, corporate auditors, officers, and employees who have material, non-public (i.e., inside) information about the Company must not buy or sell Company securities until a reasonable time after the inside information has been publicly disclosed. Directors, corporate auditors, officers, and employees are only allowed to trade in Company securities during certain designated periods, known as “Trading Windows,” and also are required to obtain prior clearance from the Board of Corporate Auditors before engaging in any trades in Company securities. You also must not disclose inside information to others outside the Company until a reasonable time after the information has been publicly disclosed.

(b)In addition, it is never appropriate for you to advise others to buy or sell Company securities, and you are prohibited from doing so while in possession of any material inside information.

(c)The Company further prohibits any director, corporate auditor, officer, or employee to sell “short” Company securities, or engage in other transactions where the person will earn a profit based on a decline in the Company’s share price.

(d)The Company also prohibits all directors, corporate auditors, officers, and employees from engaging in any speculative trading involving Company securities, including purchasing or selling “put” options, “call” options, or other publicly-traded options or derivatives on Company securities.

(e)These rules also apply to the use of material, non-public information about other companies (including, for example, the Company’s clients, competitors, and potential business partners).

(f)In addition to you, these rules apply to your spouse, children, and any other family members living with you in your household.

6.2 Further Explanation.

(a)Inside information is material information about a company, including the Company, that has not been publicly disclosed.

(b)Information is material if there is a likelihood that a reasonable investor would consider it important in making an investment decision to purchase, sell, or hold securities. It includes any information that could reasonably affect the price of a security and may be either positive or negative information. Examples of information that may be material include, among others, financial results or projections; proposed mergers, acquisitions, or other changes in assets or business; events regarding the

Company’s securities, such as redemption, changes in dividends, or share splits; changes in customary earnings trends, and information relating to the Company’s products, services, intellectual property, or research and development efforts; developments regarding our partners, agents, distributors, or customers; changes in senior management, key personnel, or the board of directors; and litigation.

(c)Information is non-public until the time it has been effectively disclosed to the public. Effective disclosure generally occurs when information is included in a press release, is revealed during a conference call to which the general public has been invited to participate, or, when required, is included in the Company’s public filings with the SEC. Under certain circumstances, effective disclosure may occur by other means.

(d)The investing public must have sufficient time to analyze and absorb the information that has been disclosed before those possessing previously non-public information can trade. For matters disclosed in a Company’s press release or conference call, a good rule of thumb is that purchases and sales can be made beginning two full trading days after the disclosure. In any event, all directors, corporate auditors, officers, and employees are prohibited from carrying out any trades in Company securities (save for certain exempt transactions such as exercise of stock options without sale of the underlying shares) other than within the quarterly Trading Window established by the Company, and only after seeking and obtaining pre-clearance for the trade from the Board of Corporate Auditors.

(e)A director, corporate auditor, officer, or employee who has inside information about the Company or another company is prohibited from: (a) trading in the Company’s or the other company’s securities (including derivative securities such as put and call options); (b) having others trade in the Company’s or the other company’s securities for his or her benefit; and (c) disclosing the inside information to (or tipping) anyone else who might then trade. These prohibitions apply during Trading Windows as well, and continue for as long as the information remains material and non-public, including after termination for any reason of the director, corporate auditor, officer, or employee’s employment or other relationship with the Company.

(f)A director, corporate auditor, officer, or employee who has inside information about the Company may, nonetheless, usually exercise the Company’s stock options for cash (but may not sell the option shares he or she receives upon the exercise). These cash option exercises purchases are allowed because the other party to the transactions is the Company itself, and because the option exercise purchase price does not vary with the market, but, rather, is fixed in advance under the terms of the option plan. You may also engage in “net exercises” and have the Company withhold shares to satisfy your tax obligations. You should contact the Board of Corporate Auditors with any questions.

7. Protection and Proper Use of Company Assets.

7.1 All directors, corporate auditors, officers, and employees should protect the Company’s assets and ensure their efficient use. Theft, carelessness, and waste have a direct impact on the Company’s profitability and are prohibited.

7.2 All Company assets should be used only for legitimate business purposes. Any suspected incident of fraud or theft should be reported for investigation immediately.

7.3 The obligation to protect Company assets includes the Company’s proprietary information. Proprietary information includes intellectual property such as trade secrets, patents, trademarks, and copyrights, as well as business and marketing plans, engineering and manufacturing ideas, designs, databases, records, and any nonpublic financial data or reports. Unauthorized use or distribution of this information is prohibited and could also be illegal and result in civil or criminal penalties. All inventions, creative works, computer software, and technical or trade secrets developed by a director, corporate auditor, officer, or employee in the course of performing such person’s duties or primarily through the use of the Company’s assets or resources while working at the Company are the property of the Company.

8. Company Records. All company records must be complete, accurate and reliable in all material respects. There is never an acceptable reason to make false or misleading entries. Undisclosed or unrecorded funds, payments, or receipts are strictly prohibited. Directors, corporate auditors, officers, and employees are required to understand and comply with the Company’s recordkeeping policy. Directors, corporate auditors, officers, and employees should contact the Board of Corporate Auditors if he/she has any questions regarding the recordkeeping policy.

9. Confidentiality. Directors, corporate auditors, officers, and employees should maintain the confidentiality of information entrusted to them by the Company or by its customers, suppliers, or partners, except when disclosure is expressly authorized or is required or permitted by law. Confidential information includes all nonpublic information (regardless of its source) that might be of use to the Company’s competitors or harmful to the Company or its customers, suppliers or partners if disclosed.

10. Fair Dealing. Each director, corporate auditor, officer, and employee must deal fairly with the Company’s customers, suppliers, partners, service providers, competitors, employees, and anyone else with whom he or she has contact in the course of performing his or her job. No director, corporate auditor, officer, or employee may take unfair advantage of anyone through manipulation, concealment, abuse or privileged information, misrepresentation of facts, or any other unfair dealing practice. Directors, corporate auditors, officers, and employees should contact the Board of Corporate Auditors if he/she has any questions regarding the fair dealing policy.

11. Compliance with Laws and Regulations. Each director, corporate auditor, officer, and employee has an obligation to comply with the laws of the cities, states, and countries in which the Company operates. This includes, without limitation, laws covering commercial bribery and kickbacks, patent, copyrights, trademarks and trade secrets, information privacy, insider trading,

offering or receiving gratuities, employment harassment, environmental protection, occupational health and safety, false or misleading financial information, misuse of corporate assets and foreign currency exchange activities. Directors, corporate auditors, officers, and employees are expected to understand and comply with all laws, rules, and regulations that apply to their positions at the Company. If any doubt exists about whether a course of action is lawful, the employee should seek advice immediately from the Board of Corporate Auditors.

12. Discrimination and Harassment. The Company is firmly committed to providing equal opportunity in all aspects of employment and will not tolerate any discrimination or harassment based on race, ethnicity, religion, gender, age, national origin or any other protected class.

13. Health and Safety. The Company strives to provide each employee with a safe and healthy work environment. Each director, corporate auditor, officer, or employee has responsibility for maintaining a safe and healthy workplace for all employees by following safety and health rules and practices and reporting accidents, injuries and unsafe equipment, practices, or conditions. Violence and threatening behavior are not permitted. Directors, corporate auditors, officers, and employees should report to work in condition to perform their duties, free from the influence of illegal drugs or alcohol. The use of illegal drugs in the workplace will not be tolerated.

14. Reporting and Enforcement.

14.1 Reporting and Investigation of Violations.

(a)Actions prohibited by this Code involving directors, corporate auditors, or executive officers must be reported to the Board of Corporate Auditors or the external legal firm of the Company.

(b)Actions prohibited by this Code involving anyone other than a director, corporate auditor, or executive officer must be reported to the Board of Corporate Auditors.

(c)After receiving a report of an alleged prohibited action, the Board of Corporate Auditors or the external legal firm must promptly take all appropriate actions necessary to investigate.

(d)All directors, corporate auditors, officers, and employees are expected to cooperate in any internal investigation of misconduct.

14.2 Enforcement.

(a)The Company must ensure prompt and consistent action against violations of this Code.

(b)If, after investigating a report of an alleged prohibited action by a director, corporate auditor, or executive officer, the Board of Corporate Auditors determines that a violation of this Code has occurred, the Board of Corporate Auditors will report such determination to the board of directors.

(c)If, after investigating a report of an alleged prohibited action by any other person, the Board of Corporate Auditors determines that a violation of this Code has occurred, the Board of Corporate Auditors will report such determination to the board of directors.

(d)Upon receipt of a determination that there has been a violation of this Code, the board of directors will take such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal, and, in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.

14.3 Waivers.

(a)The board of directors may, in its discretion, waive any violation of this Code.

(b)Any waiver for a director, corporate auditor, or an executive officer shall be disclosed as required by the SEC and NASDAQ.

14.4 Prohibition on Retaliation.

The Company does not tolerate acts of retaliation against any director, corporate auditor, officer, or employee who makes a good faith report of known or suspected acts of misconduct or other violations of this Code.

EX-12.1

Exhibit 12.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Yusuke Shono, certify that:

1. I have reviewed this annual report on Form 20-F of Warrantee Inc. (the “Company”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the Company as of, and for, the periods presented in this report;

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: January 31, 2024

By:	/s/ Yusuke Shono
	Name:	Yusuke Shono
	Title:	Chief Executive Officer (Principal Executive Officer)

EX-12.2

Exhibit 12.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Yumi Matsudaira, certify that:

1. I have reviewed this annual report on Form 20-F of Warrantee Inc. (the “Company”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the Company as of, and for, the periods presented in this report;

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: January 31, 2024

By:	/s/ Yumi Matsudaira
	Name:	Yumi Matsudaira
	Title:	Chief Financial Officer (Principal Accounting and Financial Officer)

EX-13.1

Exhibit 13.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Warrantee Inc. (the “Company”) on Form 20-F for the year ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yusuke Shono, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: January 31, 2024

By:	/s/ Yusuke Shono
	Name:	Yusuke Shono
	Title:	Chief Executive Officer (Principal Executive Officer)

EX-13.2

Exhibit 13.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Warrantee Inc. (the “Company”) on Form 20-F for the year ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yumi Matsudaira, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: January 31, 2024

By:	/s/ Yumi Matsudaira
	Name:	Yumi Matsudaira
	Title:	Chief Financial Officer (Principal Accounting and Financial Officer)

EX-97.1

Exhibit 97.1

WARRANTEE INC.

COMPENSATION RECOVERY POLICY

Effective November 27, 2023

In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Exchange Act Rule 10D-1, and the listing standards of the national securities exchange (the “Exchange”) on which the securities of Warrantee Inc. (the “Company”) are listed, the Company’s Board of Directors (the “Board”) has adopted this Compensation Recovery Policy (the “Policy”).

Capitalized terms used in the Policy are defined in Section I below. The application of the Policy to Executive Officers is not discretionary, except to the limited extent provided in Section G below, and applies without regard to whether an Executive Officer was at fault.

A. Persons Covered by the Policy

The Policy is binding and enforceable against all Executive Officers. Each Executive Officer will be required to sign and return to the Company an acknowledgement that such Executive Officer will be bound by the terms and comply with the Policy. The failure to obtain such acknowledgement will have no impact on the applicability or enforceability of the Policy.

B. Administration of the Policy

The Compensation Committee of the Board (the “Committee”) has full-delegated authority to administer the Policy. The Committee is authorized to interpret and construe the Policy and to make all determinations necessary, appropriate, or advisable for the administration of the Policy. In addition, if determined in the discretion of the Board, the Policy may be administered by the independent members of the Board or another committee of the Board made up of independent members of the Board, in which case all references to the Committee will be deemed to refer to such independent members of the Board or such other Board committee. All determinations of the Committee will be final and binding and will be given the maximum deference permitted by law.

C. Accounting Restatements Requiring Application of the Policy

If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (an “Accounting Restatement”), then the Committee must determine the excess compensation, if any, that must be recovered (the “Excess Compensation”). The Company’s obligation to recover Excess Compensation is not dependent on if or when the restated financial statements are filed.

D. Compensation Covered by the Policy

The Policy applies to all Incentive-Based Compensation Received by an Executive Officer:

(a) after beginning service as an Executive Officer;

(b) who served as an Executive Officer at any time during the performance period for that Incentive-Based Compensation;

(c) while the Company has a class of securities listed on the Exchange;

(d) during the three completed fiscal years immediately preceding the Accounting Restatement Determination Date. In addition to these last three completed fiscal years, the Policy must apply to any transition period (that results from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years. However, a transition period between the last day of the Company’s previous fiscal year end and the first day of the Company’s new fiscal year that comprises a period of nine to 12 months would be deemed a completed fiscal year; and

(e) on or after October 2, 2023.

E. Excess Compensation Subject to Recovery of the Policy

Excess Compensation is the amount of Incentive-Based Compensation Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had such Incentive-Based Compensation been determined based on the restated amounts (this is referred to in the listings standards as “erroneously awarded incentive-based compensation”) and must be computed without regard to any taxes paid.

To determine the amount of Excess Compensation for Incentive-Based Compensation based on stock price or total shareholder return, where it is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received and the Company must maintain documentation of the determination of that reasonable estimate and provide the documentation to the Exchange.

F. Repayment of Excess Compensation

The Company must recover Excess Compensation reasonably promptly and Executive Officers are required to repay Excess Compensation to the Company. Subject to applicable law, the Company may recover Excess Compensation by requiring the Executive Officer to repay such amount to the Company by direct payment to the Company or such other means or combination of means as the Committee determines to be appropriate (these determinations do not need to be identical as to each Executive Officer). These means may include:

(a) requiring reimbursement of cash Incentive-Based Compensation previously paid;

(b) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;

(c) offsetting the amount to be recovered from any unpaid or future compensation to be paid by the Company or any affiliate of the Company to the Executive Officer;

(d) cancelling outstanding vested or unvested equity awards; and/or

(e) taking any other remedial and recovery action permitted by law, as determined by the Committee.

The repayment of Excess Compensation must be made by an Executive Officer notwithstanding any Executive Officer’s belief (whether or not legitimate) that the Excess Compensation had been previously earned under applicable law and therefore is not subject to recovery.

In addition to its rights to recovery under the Policy, the Company or any affiliate of the Company may take any legal actions it determines appropriate to enforce an Executive Officer’s obligations to the Company or its affiliate or to discipline an Executive Officer, including (without limitation) termination of employment, institution of civil proceedings, reporting of misconduct to appropriate governmental authorities, reduction of future compensation opportunities, or change in role. The decision to take any actions described in the preceding sentence will not be subject to the approval of the Committee and can be made by the Board, any committee of the Board, or any duly authorized officer of the Company or of any applicable affiliate of the Company.

G. Limited Exceptions to the Policy

The Company must recover Excess Compensation in accordance with the Policy except to the limited extent that any of the conditions set forth below are met, and the Committee determines that recovery of the Excess Compensation would be impracticable:

(a) The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before reaching this conclusion, the Company must make a reasonable attempt to recover the Excess Compensation, document the reasonable attempt(s) taken to so recover, and provide that documentation to the Exchange;

(b) Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before reaching this conclusion, the Company must obtain an opinion of home country counsel, acceptable to the Exchange, that recovery would result in such a violation, and must provide such opinion to the Exchange; or

(c) Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the legal requirements as such;

H. Other Important Information in the Policy

Notwithstanding the terms of any of the Company’s organizational documents (including, but not limited to, the Company’s bylaws), any corporate policy or any contract (including, but not limited to, any indemnification agreement), neither the Company nor any affiliate of the Company will indemnify or provide advancement for any Executive Officer against any loss of Excess Compensation, or any claims relating to the Company’s enforcement of its rights under the Policy. Neither the Company nor any affiliate of the Company will pay for or reimburse insurance premiums for an insurance policy that covers potential recovery obligations. In the event that pursuant to the Policy the Company is required to recover Excess Compensation from an Executive Officer who is no longer an employee, the Company will be entitled to seek recovery in order to comply with applicable law, regardless of the terms of any release of claims or separation agreement such individual may have signed. Neither the Company nor any affiliate of the Company will enter into any agreement that exempts any Incentive-Based Compensation that is granted, paid, or awarded to an Executive Officer from the application of the Policy or that waives the Company’s right to recovery of any Excess Compensation, and the Policy shall supersede any such agreement (whether entered into before, on, or after the adoption of the Policy).

The Committee or Board may review and modify the Policy from time to time.

If any provision of the Policy or the application of any such provision to any Executive Officer is adjudicated to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other provisions of the Policy or the application of such provision to another Executive Officer, and the invalid, illegal or unenforceable provisions will be deemed amended to the minimum extent necessary to render any such provision or application enforceable.

The Policy will terminate and no longer be enforceable when the Company ceases to be a listed issuer within the meaning of Section 10D of the Exchange Act.

I. Definitions

“Accounting Restatement Determination Date” means the earlier to occur of: (a) the date the Board, a committee of the Board, or one or more of the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.

“Executive Officer” means each individual who is or was ever designated as an “officer” by the Board in accordance with Exchange Act Rule 16a-1(f).

“Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures. Stock price and total shareholder return are also Financial Reporting Measures. A Financial Reporting Measure need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission.

“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure (for the avoidance of doubt, no compensation that is potentially subject to recovery under the Policy will be earned until the Company’s right to recover under the Policy has lapsed) and excludes the following: salaries, bonuses paid solely at the discretion of the Committee or Board that are not paid from a bonus pool that is determined by satisfying a Financial Reporting Measure, bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period, non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures, and equity awards for which the grant is not contingent upon achieving any Financial Reporting Measure performance goal and vesting is contingent solely upon completion of a specified employment period (e.g., time-based vesting equity awards) and/or attaining one or more non-Financial Reporting Measures.

“Received” means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-Based Compensation is “Received” under the Policy in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt, the Policy does not apply to Incentive-Based Compensation for which the Financial Reporting Measure is attained prior to October 2, 2023.

ACKNOWLEDGEMENT

I acknowledge that I have received and read the Compensation Recovery Policy (the “Policy”) of Warrantee Inc. (the “Company”).

I understand and acknowledge that the Policy applies to me, and all of my beneficiaries, heirs, executors, administrators, or other legal representatives and that the Company’s right to recovery in order to comply with applicable law will apply, regardless of the terms of any release of claims or separation agreement I have signed or will sign in the future.

I agree to be bound by and to comply with the Policy and understand that determinations of the Committee (as such term is used in the Policy) will be final and binding and will be given the maximum deference permitted by law.

I understand and agree that my current indemnification rights, whether in an individual agreement or the Company’s organizational documents, exclude the right to be indemnified for amounts required to be recovered under the Policy.

I understand that my failure to comply in all respects with the Policy is a basis for termination of my employment with the Company and any affiliate of the Company, as well as any other appropriate discipline.

I understand that neither the Policy, nor the application of the Policy to me, gives rise to a resignation for good reason (or similar concept) by me under any applicable employment agreement or arrangement.

I acknowledge that if I have questions concerning the meaning or application of the Policy, it is my responsibility to seek guidance from the Company’s legal department or my own personal advisers.

I acknowledge that neither this Acknowledgement nor the Policy is meant to constitute an employment contract.

Please review, sign, and return this form to the Company.

[*], 2023

(print name and title)

(signature)

XML

Document and Entity Information	12 Months Ended
	Mar. 31, 2023 shares
Document and Entity Information
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Mar. 31, 2023
Current Fiscal Year End Date	--03-31
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41433
Entity Registrant Name	WARRANTEE INC.
Entity Incorporation, State or Country Code	M0
Entity Address, Address Line One	1103, Kitahama Craft
Entity Address, Address Line Two	2-4-1 Doshomachi, Chuo-ku
Entity Address, City or Town	Osaka City
Entity Address, Postal Zip Code	541-0045
Entity Address, Country	JP
Entity Common Stock, Shares Outstanding	22,404,000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	U.S. GAAP
Entity Shell Company	false
Auditor Name	Assentsure PAC
Auditor Location	Singapore
Auditor Firm ID	6783
Entity Central Index Key	0001900564
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false
American Depositary Shares
Document and Entity Information
Title of 12(b) Security	American depositary shares, each representing onecommon share
Trading Symbol	WRNT
Security Exchange Name	NASDAQ
Common shares
Document and Entity Information
Title of 12(b) Security	Common shares
No Trading Symbol Flag	true
Security Exchange Name	NASDAQ
Business Contact
Document and Entity Information
Entity Address, Address Line One	1103, Kitahama Craft
Entity Address, Address Line Two	2-4-1 Doshomachi, Chuo-ku
Entity Address, City or Town	Osaka City
Entity Address, Postal Zip Code	541-0045
Entity Address, Country	JP
Contact Personnel Name	Yusuke Shono
City Area Code	81
Local Phone Number	6227-8775
Contact Personnel Email Address	y.shouno@warrantee.co.jp

XML

CONSOLIDATED BALANCE SHEETS - JPY (¥) ¥ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Current assets:
Cash and cash equivalents	¥ 1,728	¥ 14,012
Trade accounts receivable		2,700
Other receivables	363	6,908
Prepaid compensation asset	190	4,533
Prepaid expenses and other current assets	8,096	2,026
Total current assets	10,377	30,179
Non-current assets:
Property and equipment, net	35,930	34,160
Right-of-Use Assets	60,692
Deferred offering costs	149,157	116,059
Other assets	10,404	2,412
Total non-current assets	256,183	152,631
Total assets	266,560	182,810
Current liabilities:
Accounts payable	1,485	1,485
Accrued expenses and other current liabilities	100,385	101,035
Consumption taxes payable	9,765	2,347
Current portion of long-term debt, net of debt issuance costs	9,791	4,970
Deferred revenue	9,831	33,000
Current portion of lease liabilities	35,474
Total current liabilities	166,731	142,837
Non-current liabilities:
Long-term debt, excluding current portion, net of debt issuance costs	70,593	79,474
Lease liabilities	25,218
Total non-current liabilities	95,811	79,474
Total liabilities	262,542	222,311
Shareholders' equity (deficit):
Common shares, ¥6.83043 par value - 80,000,000 shares authorized, 20,004,000 shares issued and outstanding as of March 31, 2023 and 2022	136,636	136,636
Additional paid-in capital	337,299	337,299
Accumulated deficit	(470,605)	(511,908)
Accumulated other comprehensive loss	688	(1,528)
Total shareholders' equity (deficit)	4,018	(39,501)
Total liabilities and shareholders' equity (deficit)	¥ 266,560	¥ 182,810

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - ¥ / shares	Mar. 31, 2023	Mar. 31, 2022
CONSOLIDATED BALANCE SHEETS
Common stock par value (in Yens per share)	¥ 6.83043	¥ 6.83043
Common shares authorized (in shares)	80,000,000	80,000,000
Common shares issued (in shares)	20,004,000	20,004,000
Common shares outstanding (in shares)	20,004,000	20,004,000

XML

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
CONSOLIDATED STATEMENTS OF INCOME (LOSS)
Revenue	¥ 243,218	¥ 224,727	¥ 212,000
Cost of revenue	2,097	2,516	25,146
Gross profit	241,121	222,211	186,854
Operating expenses:
Selling, general and administrative expenses	188,528	312,053	214,608
Income (loss) from operations	52,593	(89,842)	(27,754)
Other income (expenses):
Other income (loss), net	(421)	541	5,971
Interest expenses	(3,598)	(2,984)	(3,424)
Foreign currency loss, net	(7,271)	(4,795)	(591)
Total other income (expenses), net	(11,290)	(7,238)	1,956
Income (loss) before income taxes	41,303	(97,080)	(25,798)
Net income (loss)	¥ 41,303	¥ (97,080)	¥ (25,798)
Net income (loss) per share attributable to common shareholders, basic	¥ 2.06	¥ (4.85)	¥ (1.29)
Weighted-average shares outstanding used to compute net income (loss) per share, basic	20,004,000	20,004,000	20,004,000
Net income (loss) per share attributable to common shareholders, dilutive	¥ 1.95	¥ (4.85)	¥ (1.29)
Weighted-average shares outstanding used to compute net income (loss) per share, dilutive	21,222,348	20,004,000	20,004,000

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net Income (Loss)	¥ 41,303	¥ (97,080)	¥ (25,798)
Foreign currency translation adjustments, net of tax	2,216	(1,285)	(243)
Comprehensive income (loss)	¥ 43,519	¥ (98,365)	¥ (25,798)

XML

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - JPY (¥) ¥ in Thousands	Common Shares	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
Balance, beginning (in shares) at Mar. 31, 2020	20,004,000
Balance, beginning at Mar. 31, 2020	¥ 136,636	¥ 129,270	¥ (389,030)		¥ (123,124)
Receipts from related parties		6,129			6,129
Share-based compensation		201,900			201,900
Foreign currency translation adjustments, net of tax				¥ (243)	(243)
Net Income (Loss)			(25,798)		(25,798)
Total comprehensive income (loss) for the fiscal year			(25,798)	(243)	(26,041)
Balance, ending (in shares) at Mar. 31, 2021	20,004,000
Balance, ending at Mar. 31, 2021	¥ 136,636	337,299	(414,828)	(243)	58,864
Foreign currency translation adjustments, net of tax				(1,285)	(1,285)
Net Income (Loss)			(97,080)		(97,080)
Total comprehensive income (loss) for the fiscal year			(97,080)	(1,285)	¥ (98,365)
Balance, ending (in shares) at Mar. 31, 2022	20,004,000				20,004,000
Balance, ending at Mar. 31, 2022	¥ 136,636	337,299	(511,908)	(1,528)	¥ (39,501)
Foreign currency translation adjustments, net of tax				2,216	2,216
Net Income (Loss)			41,303		41,303
Total comprehensive income (loss) for the fiscal year			41,303	2,216	¥ 43,519
Balance, ending (in shares) at Mar. 31, 2023	20,004,000				20,004,000
Balance, ending at Mar. 31, 2023	¥ 136,636	¥ 337,299	¥ (470,605)	¥ 688	¥ 4,018

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Cash flow from operating activities:
Net income (loss)	¥ 41,303	¥ (97,080)	¥ (25,798)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	17,175	862	115
Amortization of debt issuance costs	69	69	68
Share-based compensation expense	4,343	83,976	111,684
Changes in operating assets and liabilities:
Trade accounts receivable	2,700	8,000	(9,614)
Consumption taxes receivable		5,310	5,206
Other receivables	6,545	(6,908)
Deferred contract costs			17,617
Prepaid expenses and other current assets	(5,948)	4,386	2,848
Other assets	(7,714)
Accounts payable		(2,700)
Due to related parties			(1,413)
Accrued expenses and other current liabilities	(1,408)	57,338	13,420
Consumption taxes payable	7,418	(6,730)	9,077
Deferred revenue	(22,821)	33,000	(106,919)
Deposits received			(16,760)
Other		42	2,512
Net cash provided by operating activities	41,662	79,565	2,043
Cash flow from investing activities:
Purchases of property and equipment	(8,670)	(20,841)
Cash used in investing activities	(8,670)	(20,841)
Cash flow from financing activities:
Proceeds from stock options issued			1,707
Proceeds from long-term debt		500	25,000
Repayment of long-term debt	(4,129)	(1,718)	(1,619)
Receipts from related parties			6,129
Repayment of lease liabilities	(9,147)
Payment of deferred offering costs	(33,098)	(58,881)	(43,771)
Net cash used in financing activities	(46,374)	(60,099)	(12,554)
Effect of exchange rate changes on cash and cash equivalents	1,098	9	(173)
Net decrease in cash and cash equivalents	(12,284)	(1,366)	(10,684)
Cash and cash equivalents
Beginning of year	14,012	15,378	26,062
End of year	1,728	14,012	15,378
Supplemental disclosures of cash flow information:
Cash paid for interest	2,927	2,919	3,362
Non-cash investing and financing activities:
Purchases of property and equipment included in accrued expenses	¥ 319	14,087
Accrued offering costs		¥ 4,400	¥ 13,200

XML

Nature of Operations

12 Months Ended

Mar. 31, 2023

Nature of Operations

Nature of Operations

1. Nature of Operations

Warrantee Inc. (“Warrantee”) and its wholly-owned subsidiary (collectively, the “Company”) provide sponsored marketing services used in the durables vertical (the “Durables Vertical”) and the commercial healthcare vertical (the “Commercial Healthcare Vertical”). Warrantee was incorporated in October 2013, and its wholly-owned subsidiary, Warrantee Pte. Ltd. (“Warrantee Pte.”) was incorporated in December 2019 in Singapore. The Company’s fiscal year end is March 31.

The Durables Vertical business model allows participating users (“Participant Users”) to receive warranty services for repair or replacement of electric appliances, kitchen appliances and other equipment free of charge in exchange for personal information, including purchase data. The Company organizes the data and provides it with the prior consent of Participant Users to corporate sponsor companies (“Corporate Sponsors”). This information allows Corporate Sponsors to market their products efficiently. In return for the information, the Corporate Sponsors pay sponsor fees to the Company which in turn the Company uses to purchase extended warranty coverage for the products of Participant Users. The Company itself does not provide the extended warranties; it purchases such coverage from third party providers.

The Company commenced a new model of Durables Vertical during the fiscal year ended March 31, 2022. The new model allows clinics participating in the Company’s campaigns (“Participant Clinics”) to receive warranty services for repair or replacement of their medical equipment free of charge in exchange for clinic information, including the name of the clinics, phone numbers, and addresses. The Company organizes the data and provides it with the prior consent of Participant Clinics to Corporate Sponsors. This information allows Corporate Sponsors to market their products efficiently. In return for the information, the Corporate Sponsors pay sponsor fees to the Company which in turn the Company uses to purchase extended warranty coverage for the products of Participant Clinics. The Company itself does not provide the extended warranties; it purchases such coverage from third party providers.

During the fiscal year ended March 31, 2021, the Company expanded its business model into Commercial Healthcare Vertical, which allows Participant Users to receive complimentary examinations or treatments for a range of specified ailments and procedures, including polymerase chain reaction testing, genetic testing, and arthritic and orthopedic procedures. During the fiscal year ended March 31, 2021, the Company also conducted sales promotions on behalf of Corporate Sponsors to Participant Users based on the results of their genetic tests. Similar to the Durables Vertical, the Company gathers information from Participant Users with their prior consent and then provides the information, including feedback on the relevant healthcare services, to Corporate Sponsors. Data collected includes basic profile information of the patient in addition to specific, targeted data on personal health markers and responses to the specific treatment, procedure, or healthcare product. In return for the information, the Corporate Sponsors pay sponsor fees to the Company which in turn the Company pays the costs for the healthcare services. The result is that Participant Users are able to enjoy the benefits of healthcare services for free and the Corporate Sponsors are able to use the information to market its product efficiently.

The Company’s customers, or Corporate Sponsors, include manufacturers and distributors of home appliances, healthcare equipment, and health food distributors. All customers are located throughout Japan for the presented periods, and the Company is headquartered in Japan.

As described in Note 2, Summary of Significant Accounting Policies, “Revenue Recognition,” the Company recognized other source of revenue from System Development during the fiscal year ended March 31, 2021 and from Advertising, Licensing, and System Development during the fiscal year ended March 31, 2022. However, the Company does not expect to generate this type of revenue in future periods.

On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus (“COVID-19”) as a pandemic. The Company did not observe significant impacts on its business or results of operations for the fiscal years ended March 31, 2023, 2022, or 2021 due to the global emergence of COVID-19. The Company also applied for the subsidy program for sustaining businesses by the Japanese government with COVID-19 special treatment. For the fiscal year ended March 31, 2021, the Company received ¥2,000 thousand from the subsidy program. The subsidy is not limited in scope and can help cover a wide variety of purposes. The Japanese government subsidies of non-operating nature with no further conditions to be met are recorded in “Other income” in the Consolidated Statements of Income (Loss) when received. While the extent to which COVID-19 impacts the Company’s future results will depend on future developments, the pandemic and associated economic impacts could result in an impact to the Company’s future financial condition, results of operations and cash flows.

Going concern

The Company had a negative working capital of ¥156.4 million and ¥112.7 million as of March 31, 2023 and 2022, respectively. The Company has a history of recurring losses, including a loss from operations of ¥89.8 million and ¥27.8 million for the fiscal years ended March 31, 2022 and 2021, respectively. This operating loss had resulted in an accumulated deficits of ¥470.6 million and ¥511.9 million as of March 31, 2023 and 2022, respectively.

The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to attract and retain revenue generating customers, acquire new customer contracts, and secure additional financing.

The Company may consider obtaining additional financing in the future through the issuance of the Company’s common shares, through other equity or debt financings, or other means. The Company, however, is dependent upon its ability to obtain new revenue generating customer contracts, secure equity, and/or debt financing and there are no assurances that the Company will be successful. The consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts, or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

XML

Summary of Significant Accounting Policies

12 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are presented in Japanese yen, the currency of the country in which the Company is incorporated and primarily operates. The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Reclassification

Certain accounts in the prior period consolidated financial statements have been reclassified to conform to the presentation of the current year consolidated financial statements. Foreign currency loss, net during the fiscal year ended March 31, 2021 of ¥591 thousand was reclassified from other income, net to a separate line item in the Consolidated Statements of Income (Loss). This reclassification had no effect on the previously reported operating results.

Principles of Consolidation

The consolidated financial statements include the accounts of Warrantee and its wholly owned subsidiary, Warrantee Pte. Warrantee Pte. has a fiscal year end of December 31, and the accounts of Warrantee Pte. are included in the Company’s consolidated financial statements based on the fiscal year of Warrantee Pte. All intercompany accounts and transactions, including capital increase during a reporting time lag, have been eliminated upon consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the reporting date, and the reported amounts of revenue and expense during the reporting period. These estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future and include, but are not limited to, useful lives of capitalized software, valuation of stock options, and valuation allowance against net deferred tax assets. Actual results could differ from those estimates.

Segment Information

The Company operates as one operating segment. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer (“CEO”), who reviews financial information for purposes of making operating decisions, assessing financial performance, and allocating resources. The Company’s CODM evaluates financial information on a consolidated basis. As of March 31, 2023, 2022, and 2021, there was no revenue derived or long-lived assets held outside of Japan.

Concentration of Customers

For the fiscal years ended March 31, 2023, 2022, and 2021, two customers, one customer, and two customers, respectively, each accounted for more than 10% of the consolidated revenue. Revenue from those customers totaled ¥243,218 thousand, ¥224,727 thousand, and ¥177,000 thousand of the total consolidated revenue for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. The following represents sales revenue attributable to each of these customers as a percentage of total consolidated revenue for each respective year.

	Percentage of Revenue
	For the fiscal years ended March 31,
	2023		2022		2021
Customer A	88	%	100	%	—
Customer B	—		—		51	%
Customer C	12	%	—		33	%

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents.

Trade Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable primarily consist of amounts billed and currently due from customers, net of an allowance for doubtful accounts, if recorded. When the Company has an unconditional right to payment, subject only to the passage of time, the right is treated as receivable. Fees billed in advance of the related contractual term represent contract liabilities and are presented as deferred revenue. Typical payment terms provide for customer payment within 30 days of the contract date.

Trade accounts receivables are subject to collection risk. The Company performs evaluations of its customers’ financial positions and generally extends credit on account, without collateral. The Company determines the need for an allowance for doubtful accounts based upon various factors, including credit quality of the customer, age of the receivable balance and current economic conditions.

There were no bad debt expense or allowance for doubtful accounts recorded as of and for the fiscal years ended March 31, 2023, 2022, and 2021.

Property and Equipment, Net

Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method, depending on the pattern of consumption of the economic benefits by asset class, over the estimated useful lives of the assets. The estimated useful lives are four years for computers and three to six years for furniture and fixtures. Repair and maintenance costs are expensed as incurred. The Company records depreciation expense in selling, general and administrative expenses and cost of revenue on the Consolidated Statements of Income (Loss).

Capitalized Software, Net

The Company capitalizes certain costs in property and equipment associated with website and software developed for internal use in accordance with ASC 350-50, Intangibles - Goodwill and Other - Website Development Costs and ASC 350-40, Intangibles - Goodwill and Other - Internal Use Software when both the preliminary project design and the testing stage are completed and management has authorized further funding for the project, which it deems probable of completion and to be used for the function intended. Capitalized costs include amounts directly related to website and software development such as fees paid to third-party vendors. Capitalization of such costs ceases when the project is substantially complete and ready for its intended use. Capitalized costs are amortized, beginning in the period the product is ready for its intended use, on a straight-line basis over the estimated useful life of the product, five years. Costs incurred during the preliminary stages of development and ongoing maintenance costs are expensed as incurred.

Impairment or Disposal of Long-Lived Assets

Long-lived assets used in operations, which include capitalized software developed for internal use and property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if the carrying amount is not recoverable when compared to the Company’s undiscounted cash flows and the impairment loss is measured based on the difference between the carrying amount and fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell.

Leases

Leases are principally comprised of operating leases for office space. The Company determines that a contract contains a lease if they obtain substantially all of the economic benefits of, and the right to direct the use of, an asset identified in the contract. For leases with terms greater than 12 months, the Company records a right-of-use asset and a lease liability representing the present value of future lease payments. The discount rate used to measure the lease asset and liability is determined at the beginning of the lease term using the rate implicit in the lease, if readily determinable, or the Company’s collateralized incremental borrowing rate. For those contracts that include fixed rental payments for both the use of the asset (“lease costs”) as well as for other occupancy or service costs relating to the asset (“non-lease costs”), the Company generally includes both the lease costs and non-lease costs in the measurement of the lease asset and liability.

Lease expenses and income for the Company’s operating leases are recognized on a straight-line basis over the lease term, with the exception of variable lease costs, which are expensed as incurred.

Debt Issuance Costs

Debt issuance costs are amortized as interest expense on a basis which approximates the effective interest method over the term of the related debt. Debt issuance costs are reported at cost, less accumulated amortization and are presented in the Consolidated Balance Sheets as a direct deduction from the carrying value of the associated debt.

Deferred Offering Costs

Deferred offering costs are capitalized and consist of fees incurred in connection with the anticipated sale of common shares in an IPO and include direct incremental legal, accounting, printing, and other IPO-related costs. Upon completion of an IPO, these deferred costs will be reclassified to shareholders’ equity and recorded against the proceeds from the offering. In the event a proposed IPO is deemed not likely to be completed, the deferred offering costs would be charged to expenses in the period of such determination.

Foreign Currency

The Company uses Japanese yen as its reporting currency. Warrantee’s functional currency is the Japanese yen and the functional currency of Warrantee Pte. is the Singapore dollar. Financial statements of Warrantee Pte. are prepared using the functional currency and translated into Japanese yen for reporting purposes. Assets and liabilities are translated using the fiscal year end foreign exchange rate, and income and expenses are translated using the average exchange rate for the period. Foreign currency translation adjustments related to the financial statements of Warrantee Pte. net of related income tax effects, are credited or charged directly to the foreign currency translation adjustments account, a component of accumulated other comprehensive income (loss). The tax effects related to the foreign currency translation of financial statements of Warrantee Pte. are not recognized unless it is apparent that the temporary differences will reverse in the foreseeable future. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency of the respective entity at the fiscal year end foreign exchange rate, and gains and losses resulting from such remeasurement are included in foreign exchange gains (losses). Foreign currency denominated income and expenses are remeasured using the average exchange rate for the period.

Share-Based Compensation

The Company applies the provisions of ASC Topic 718, Compensation — Stock Compensation. The Company measures the cost of employee and non-employee services received in exchange for awards of equity instruments at the fair value of the award on the grant date and recognizes the cost over the requisite service period which the employee and non-employee are required to provide services in exchange for the award. Compensation costs are recognized on a straight-line basis over the requisite service period of the awards which are expected to be vested. For non-employee vesting periods that have implicit service periods based on the achievement of a performance condition, a change in the estimated achievement of performance conditions will be recognized prospectively over the revised non-employee vesting period. For awards with performance conditions, compensation cost is recognized when the condition is probable of being achieved, or in the case of a liquidity event, when the liquidity event occurs. The Company uses option pricing methods that require the input of subjective assumptions, including the expected term, expected volatility, dividend yield and risk-free interest rate. For awards with market conditions, the Company uses a hybrid method between a discounted cash flow method and Monte Carlo simulation models to value the awards. The Company has elected to recognize forfeitures as they occur.

Revenue Recognition

The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) for all periods presented in the consolidated financial statements. To determine the appropriate amount of revenue to be recognized in accordance with ASC 606, the Company follows a five-step model as follows:

1 – Identification of the contract with a customer;

2 – Identification of the performance obligation in the contract;

3 – Determination of the transaction price;

4 – Allocation of the transaction price to the performance obligation in the contract; and

5 – Recognition of revenue when, or as, a performance obligation is satisfied.

The Company’s revenue is primarily derived from the Durables Vertical and the Commercial Healthcare Vertical. The Company’s services are marketed and sold directly to the customers. The Company assesses the contract term as the period in which the parties to the contract have enforceable rights and obligations. The contract term may differ from the stated term in contracts with certain termination or renewal rights, depending on whether there are substantive penalties associated with those rights. Customer contracts are generally standardized and noncancellable for the duration of the stated contract term. Consumption taxes collected and remitted to tax authorities are excluded from revenue. The Company may use third-party vendors to provide certain goods or services to its customers. The Company evaluates those relationships to determine whether revenue should be reported gross or net. The Company recognizes revenue on a gross basis where it acts as principal and controls the goods and services used to fulfill the performance obligations to the customer and on a net basis where it acts as an agent. The Company has not acted as an agent during the fiscal years ended March 31, 2023, 2022, and 2021.

Durables Vertical:

Performance Obligations

Revenue from the Durables Vertical is primarily comprised of sponsorship fees from Corporate Sponsors in exchange for Participant Users’ personal information or Participant Clinics’ information (collectively, “Participants’ Data”). During the sponsorship campaigns, the Company aggregates Participants’ Data, organizes that data, and then provides it to Corporate Sponsors. The Company has identified one performance obligation, the delivery of Participants’ Data. All other immaterial deliverables occur prior to this, but revenue is not recognized until the delivery of Participants’ Data which is the performance obligation. Accordingly, the Company recognizes revenue at a point in time when the personal information is provided to, or accepted by, Corporate Sponsors upon satisfying its single distinct performance obligation.

Contractual Consideration

The transaction price is generally fixed at contract inception. However, the Company’s contracts with Corporate Sponsors within Durables Vertical may include a specified quantity, which entitles the customer to refunds, when defined quantity levels are not met at the end of the provision period. These arrangements represent a form of variable consideration, which is estimated using the most likely amount method to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of March 31, 2023 and 2022.

Commercial Healthcare Vertical:

Performance Obligations

Revenue from the Commercial Healthcare Vertical is primarily comprised of sponsorship fees from Corporate Sponsors in exchange for healthcare-related promotional campaigns. During healthcare-related promotional campaigns targeted to Participant Users based on results of their free genetic test kits, the Company has the stand-ready obligation to provide promotional services for the duration of the campaign promotion period. Accordingly, revenue is recognized ratably based on the time-elapsed method over the contractual term with the Corporate Sponsor.

Contractual Consideration

The transaction price may be fixed at contract inception within the Commercial Healthcare Vertical in a form of non-refundable minimum guarantee but may also have a component of variable consideration such as sales incentives which are calculated by multiplying the amount of work accomplished by a fixed unit price of remuneration. Due to the variable consideration being entirely constrained, the sales incentive is excluded from the transaction price until the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of March 31, 2023 and 2022.

Other Revenue:

System Development: System development revenue is generated by the development and the delivery of the system that meets the customer’s specifications. There is one performance obligation as all promises are interrelated to delivering a completed system. The title to the system is transferred to the customer upon acceptance. The Company typically recognizes revenue upon the customer’s acceptance as the control over the product is transferred to the customer and the Company’s performance obligations are satisfied. When third-party vendors participate in the provisioning of the system, the Company recognizes the related revenue on a gross basis as the Company is the principal in these arrangements.

Transaction Price

The transaction price is the amount of consideration to which the Company expects to be entitled to for transferring goods and services to the customer.

Payments from the customers are often made in advance before satisfaction of the performance obligations. Generally, payments are due within 30 days of delivery of the goods or service. In instances where the timing of revenue recognition differs from the timing of the right to invoice, the Company has determined that a significant financing component generally does not exist. Additionally, the Company has elected the practical expedient that permits an entity not to recognize a significant financing component if the time between the transfer of a good or service and payment is one year or less.

Disaggregation of Revenue

The table reflects revenue by major source for the following periods:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Sources of revenue:
Durables Vertical	¥	213,218	¥	224,727	¥	85,000
Commercial Healthcare Vertical		30,000		—		107,000
System Development		—		—		20,000
Total revenue	¥	243,218	¥	224,727	¥	212,000

Contract Balances

The timing of revenue recognition may not align with the right to invoice the customer. The Company records trade accounts receivable when it has the unconditional right to issue an invoice and receive payment regardless of whether revenue has been recognized. If revenue has not yet been recognized, then deferred revenue is also recorded. Deferred revenue classified as current on the Consolidated Balance Sheets are expected to be recognized as revenue within one year. If revenue is recognized in advance of the right to invoice, a contract asset is recorded.

Changes in deferred revenue were as follows:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Balance, beginning of year	¥	33,000	¥	—	¥	106,919
Revenue earned		(33,000)		—		(106,919)
Deferral of revenue		9,831		33,000		—
Balance, end of year	¥	9,831	¥	33,000	¥	—

Changes in deferred revenue are primarily due to the timing of revenue recognition and cash collections.

Remaining Performance Obligations

Remaining performance obligations represent the aggregate amount of the transaction price allocated to the remaining obligations that the Company has not performed under its customer contracts. The Company has elected to use the optional exemption in ASC 606-10-50-14, which exempts an entity from such disclosures if a performance obligation is part of a contract with an original expected duration of one year or less.

As of March 31, 2023, deferred revenue represented the Company’s remaining performance obligations related to prepaid consideration for the campaign starting during the year ending March 31, 2024 with a new customer, all of which is expected to be recognized within one year.

Deferred Contract Costs

Sales commissions that are incremental to the acquisition of customer contracts, are capitalized as deferred contract costs on the Consolidated Balance Sheets when the period of benefit is determined to be greater than one year. Amortization of deferred contract acquisition costs is included within selling, general and administrative expenses in the Consolidated Statements of Income (Loss).

The Company also capitalizes certain costs to fulfill a contract related to its proprietary products or services if they are identifiable, generate or enhance resources used to satisfy future performance obligations and are expected to be recovered under ASC Topic 340-40, Other Assets and Deferred Costs-Contracts with Customers. Amortization of deferred contract fulfillment costs is included within cost of revenue in the Consolidated Statements of Income (Loss).

Deferred contract costs are amortized to be consistent with the timing of transfer to the customer of the goods or services to which the costs relate, either at a point in time or over time in proportion to the amount of the related goods and services transferred to the customer. The Company periodically reviews these capitalized contract costs to determine whether changes in events or circumstances have occurred that could impact the period of benefit of these assets. There were no impairment losses recorded for the periods presented.

As of March 31, 2023 and 2022, the Company had no deferred costs to obtain and fulfill a contract. During the fiscal years ended March 31, 2022 and 2021, the Company amortized ¥1,500 thousand and ¥17,692 thousand of costs to obtain and fulfill the contract, respectively, and capitalized ¥1,575 thousand of costs to fulfill the contract during the fiscal year ended March 31, 2021.

Cost of Revenue

For the fiscal years ended March 31, 2023 and 2022, cost of revenue primarily comprised of the insurance costs, depreciation and amortization and personnel-related expenses. For the fiscal year ended March 31, 2021, the cost of revenue also included the direct cost to develop software products, Participant User recruiting costs for the Durables Vertical, and genetic testing costs for Commercial Healthcare Vertical.

Advertising Costs

Advertising costs are expensed as incurred and presented within selling, general and administrative expenses in the Consolidated Statements of Income (Loss). Advertising costs were ¥11,790 thousand, ¥325 thousand, and ¥888 thousand for the fiscal years ended March 31, 2023, 2022, and 2021, respectively.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the differences between the financial statement and tax basis of assets, liabilities and net operating loss by using enacted tax rate in effect for the year in which the differences are expected to reverse. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that these assets are believed to be more likely than not to be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are more likely than not expected to be realized. In making such a determination, all available positive and negative evidence is considered, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations.

Warrantee and its subsidiary file tax returns in the tax jurisdictions of Japan and Singapore. Tax benefits for uncertain tax positions are based upon management’s evaluation of the information available at the reporting date. To be recognized in the consolidated financial statements, a tax benefit must be at least more likely than not of being sustained based on technical merits. The benefit for positions meeting the recognition threshold is measured as the largest benefit more likely than not of being realized upon settlement with a taxing authority that has full knowledge of all relevant information.

Net Income (Loss) per Share

Basic net income (loss) per common share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.

For purposes of the diluted net income (loss) per common share calculation, stock options are considered to be potentially dilutive securities. However, as disclosed in Note 8, Share-Based Compensation, the Company’s 2nd and 3rd Series stock options include a triggering liquidation performance condition prior to vesting. As such, these are treated as contingently issuable shares and will be excluded from potential dilutive impact until the triggering liquidation performance condition is satisfied.

Recently Issued Accounting Pronouncements

As an emerging growth company, the Jumpstart Our Business Startups Act allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to delay adoption of certain new or revised accounting standards. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies.

Financial Instruments — Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which is intended to provide more decision-useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. ASU 2016-13 revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to accounts receivable. This standard is effective for annual reporting periods beginning after December 15, 2022 for non-public entities, including interim periods within that reporting period. Early adoption is permitted. The Company is currently in process of evaluating the impact of this standard on the Company’s consolidated financial statements. The Company does not expect the adoption of this standard to have a material effect on the Company’s consolidated financial statements. As an emerging growth company, the Company will adopt this standard effective April 1, 2023.

XML

Property and Equipment, Net

12 Months Ended

Mar. 31, 2023

Property and Equipment, Net

Property and Equipment, Net

3. Property and Equipment, Net

As of the dates specified below, property and equipment, net consisted of the following:

	Yen in thousands
	March 31,
	2023		2022
Capitalized software	¥	43,598	¥	34,928
Computers		999		999
Furniture and fixtures		632		632
Total property and equipment		45,229		36,559
Less: Accumulated depreciation and amortization		(9,299)		(2,399)
Total property and equipment, net	¥	35,930	¥	34,160

Included in capitalized software were ¥6,386 thousand and ¥28,136 thousand of assets under construction as of March 31, 2023 and 2022, respectively. The Company recognized depreciation and amortization expenses on property and equipment of ¥6,900 thousand, ¥862 thousand, and ¥115 thousand for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. The Company records depreciation and amortization expenses in selling, general, and administrative expenses and cost of revenue on the Consolidated Statements of Income (Loss).

XML

Leases

12 Months Ended

Mar. 31, 2023

Leases

Leases

4. Leases

The Company has operating leases primarily for office space. Lease costs are generally fixed, with certain contracts containing variable payments for non-lease costs based on usage and escalations in the lessors’ annual costs.

As of March 31, 2023 and 2022, the following amounts were recorded on the Consolidated Balance Sheets relating to the Company’s operating leases.

	Yen in thousands
	March 31,
	2023		2022
Right-of-Use Assets
Operating lease assets	¥	60,692	¥	—
Lease Liabilities
Operating lease liabilities	¥	60,692	¥	—

Supplemental balance sheet information related to leases consisted of the following:

	For the fiscal years ended March 31,
	2023		2022
Remaining lease term and discount rate:
Weighted average remaining lease term (years)	1.8		—
Weighted average discount rate	4.24	%	—

Future minimum lease payments under non-cancelable leases as of March 31, 2023, were as follows (in thousand yen):

Fiscal Year ending March 31,
2024	¥	33,360
2025		27,370
Total lease payments		60,730
Less amounts representing interest		(38)
Present value of lease payments		60,692

XML

Fair Value of Financial Instruments

12 Months Ended

Mar. 31, 2023

Fair Value of Financial Instruments

Fair Value of Financial Instruments

5. Fair Value of Financial Instruments

The Company reports financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis in accordance with ASC Topic 820 Fair Value Measurement (“ASC 820”). ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

ASC 820 also establishes a fair value hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value into three levels. U.S. GAAP established a hierarchy framework to classify the fair value based on the observability of significant inputs to the measurement.

The levels of the fair value hierarchy are as follows:

Level 1:    Determined using an unadjusted quoted price in an active market for identical assets or liabilities.

Level 2:    Estimated using inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly.

Level 3:    Estimated using unobservable inputs that are significant to the fair value of the assets or liabilities.

The carrying value of cash and cash equivalents, trade accounts receivable, consumption taxes receivable, other receivables, accounts payable, accrued expenses and consumption taxes payable approximate their fair value due to their short-term nature.

There were no assets or liabilities measured at fair value on “recurring” basis during 2023 and 2022. Since there is no material difference between the market interest rate and the contract rate, the carrying value of the Company’s debt approximated its fair value as of March 31, 2023 and 2022.

XML

Commitments and Contingencies

12 Months Ended

Mar. 31, 2023

Commitments and Contingencies

Commitments and Contingencies

6. Commitments and Contingencies

Legal Matters

From time to time in the normal course of business, the Company is subject to various legal matters, such as threatened or pending claims or proceedings. There were no such material matters as of and for the fiscal years ended March 31, 2023 and 2022. The following lawsuit is currently pending against the Company:

A lawsuit demanding payment of the unpaid development fees by Freude Inc. is pending in Fukuoka District Court. It is still premature to determine the outcome of the lawsuit. The maximum potential loss if the Company loses the case is ¥13,027 thousand plus 14.6 per annum from February 1, 2019.

Indemnification

In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with third parties. To date, the Company has not paid any material claims or been required to defend any material actions related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.

XML

Debt

12 Months Ended

Mar. 31, 2023

Debt

Debt

7. Debt

The Company’s borrowings, including short-term and long-term portions consisted of the following:

			Yen in thousands
			March 31,
	Interest Rate	Maturity	2023		2022
Amended term loan with Japan Finance Corporation	0.36% to 1.26%	August 31, 2026	¥	13,975	¥	15,500
Term loan with Resona Bank, Limited	0.00% to 1.20%	November 30, 2030		24,220		25,000
Term loan with SBI Estate Finance Co., Ltd.	6.00%	September 5, 2037		43,187		45,011
Total long-term debt				81,382		85,511
Less: unamortized debt issuance costs				(998)		(1,067)
Subtotal				80,384		84,444
Current portion of long-term debt, net of debt issuance costs				(9,791)		(4,970)
Long-term debt, excluding current portion, net of debt issuance costs			¥	70,593	¥	79,474

On September 3, 2014, the Company entered into the term loan agreement with Japan Finance Corporation for ¥15,000 thousand, which matured on September 30, 2021. The term loan incurs variable interest at 0.90% through 8.55% per annum. The term loan agreement does not require periodic principal repayments and is payable in full upon maturity.

On September 30, 2021, the Company refinanced the existing term loan with Japan Finance Corporation to extend the maturity date to August 31, 2026, and changed the interest rate. This refinancing resulted in ¥500 thousand of net proceeds. The variable interest rate per annum on the new term loan is 0.36% from September 30, 2021 to September 30, 2024, and 1.26% from October 1, 2024 to the maturity date. The new term loan agreement requires monthly principal repayments beginning from September 30, 2022 to the maturity date. Yusuke Shono, the CEO of the Company, has guaranteed the term loan agreement with Japan Finance Corporation.

On December 18, 2020, the Company entered into the term loan agreement with Resona Bank, Limited, for ¥25,000 thousand, which matures on November 30, 2030. The interest rate per annum on the term loan is variable at 0% through December 17, 2023 and 1.20% from December 18, 2023 to maturity. The term loan agreement requires monthly principal repayments beginning from December 31, 2022 to the maturity date. Yusuke Shono, the CEO of the Company, has guaranteed the term loan agreement with Resona Bank, Limited.

On August 31, 2017, the Company entered into the term loan agreement with SBI Estate Finance Co., Ltd. for ¥52,000 thousand, which matures on September 5, 2037. Cash proceeds received for this term loan were ¥50,623 thousand, net of issuance costs. The contract interest rate on the term loan was 6.00% per annum and the effective interest rate was 6.28% per annum as of March 31, 2023 and 2022. The effective interest rate was higher than the contract rate due to amortization of debt issuance costs related to the term loan. The term loan agreement requires equal monthly repayments with principal and interest for ¥373 thousand.

The debt issuance costs of ¥1,377 thousand are being amortized over the 20-year life of the term loan resulting in ¥69 thousand, ¥69 thousand, and ¥68 thousand of issuance costs being amortized through interest expense for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. Unamortized debt issuance costs are ¥998 thousand and ¥1,067 thousand as of March 31, 2023 and 2022, respectively and are presented in the Consolidated Balance Sheets as a direct deduction from the carrying value of the debt. Yusuke Shono, the CEO of the Company, has guaranteed the term loan agreement with SBI Estate Finance Co., Ltd. and pledged his personal assets as collateral.

None of the term loan agreements contain any financial covenants.

Contractual maturities of long-term debt as of March 31, 2023 are as follows:

	(Yen in thousands)
2024	¥	9,860
2025		9,076
2026		9,203
2027		7,062
2028		5,575
Thereafter		40,606
Total	¥	81,382

XML

Share-Based Compensation

12 Months Ended

Mar. 31, 2023

Share-Based Compensation

Share-Based Compensation

8. Share-Based Compensation

2nd and 3rd Series Stock Options

On June 26, 2016 and March 30, 2017, as part of the 2nd Series and 3rd Series of stock options (collectively, the “2nd and 3rd Series”), the Company granted options to purchase 540,000 and 81,000 common shares, respectively. Each option can be exercised for one common share. The contractual term of the 2nd and 3rd Series stock options is ten years, and the grantee must be employed by the Company at the time of exercise to exercise their rights. The 2nd and 3rd Series stock option’s fair value as of grant date was ¥11 and ¥35 per share, respectively. The exercise price of the 2nd and 3rd Series stock options were ¥19 and ¥56 per share, respectively.

The general terms of the 2nd and 3rd Series require both service and performance conditions to be satisfied prior to vesting. The performance condition will be satisfied upon a liquidity event defined as an IPO on any of the stock exchanges in Japan or overseas. As the Company cannot conclude that a liquidity event is probable, no compensation costs were recorded in these consolidated financial statements related to the 2nd and 3rd Series.

As of March 31, 2023, total unrecognized compensation cost related to the unvested share-based awards was ¥825 thousand.

4th Series Stock Options

On January 29, 2021, the Board of Directors and shareholders of the Company approved the issuance of the 4^th Series stock options (“4^th Series”) and stock options to purchase total 2,019,000 common shares were granted to the Company’s director, employee, and external subcontractors on February 3, 2021 and the Company’s CEO and external subcontractor on March 31, 2021. Each option can be exercised for one common share. The contractual term of the awards is ten years beginning after February 3, 2021.

The stock option’s fair value as of grant date is ¥100 per share and the exercise price of the stock option is ¥56 per share. The stock options include a market condition whereby the options become non-exercisable if there are any subsequent sales or issuance of common shares with a price less than ¥55.66. There are no other service or performance conditions.

Cash received from stock options granted for the fiscal year ended March 31, 2021 was ¥1,707 thousand, and is included in additional paid-in capital in the Consolidated Balance Sheets as of March 31, 2023 and 2022. Upon issuance, the grantees paid an issue price per share of less than ¥1, resulting from the share split.

As the options are fully exercisable at grant date subject only to the market condition, the Company recognized the full compensation cost for employees at the grant date. As the recognition of compensation cost for non-employees should be in the same manner as if the Company had paid cash for the goods or services, the Company recognized a prepaid compensation asset and recognizes the compensation cost on a straight-line basis over the implicit service period for certain non-employees. These non-employees provide services directly related to helping the Company achieve an IPO. There is a mutual understanding between these non-employees and the Company that they will provide services from grant date through the Company’s IPO. To recognize compensation cost for these non-employees, the Company initially used an expected IPO date of January 31, 2022, which was based on its best estimate at the time of grant but subsequently revised the expected IPO date of July 2023 during the fiscal year ended March 31, 2023. A change in the expected IPO date will be recognized prospectively over the revised non-employee vesting period.

Total share-based compensation expense for 4th Series stock options included in selling, general, and administrative expenses in the Consolidated Statements of Income (Loss) was ¥4,343 thousand, ¥83,976 thousand, and ¥111,684 thousand for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. As of March 31, 2023, there was ¥190 thousand of unrecognized expense included in prepaid compensation asset related to 4th Series stock options in the Consolidated Balance Sheets.

The fair value of the 4th Series is estimated using a hybrid method between a discounted cash flow method and Monte Carlo simulation model, estimating the probability-weighted value across multiple scenarios. The Company considered a near-term IPO scenario for a discounted cash flow method and a long-term IPO scenario for Monte Carlo simulation model.

Expected Term — The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The expected term of option was estimated utilizing the simplified method because the Company did not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. The simplified method primarily is calculated as the midpoint between the requisite service period and the contractual term of option.

Expected Volatility — The expected stock price volatility assumption was determined by examining the historical volatilities of comparable publicly traded companies within the Company’s industry.

Risk-Free Interest Rate — The risk-free rate assumption was based on the U.S. treasury rate that was consistent with the expected term of the Company’s stock options.

Expected Dividend — The expected dividend assumption was based on the Company’s history and expectation of dividend payouts. The Company does not currently pay dividends on the common shares; therefore, a dividend yield of 0% was used in the Monte Carlo simulation model.

Fair Value of Common Shares — The fair value of the common shares underlying the stock options has historically been the responsibility of and determined by the Company’s Board of Directors. Because there has been no public market for the Company’s common shares, the Board of Directors has used independent third-party valuations of the Company’s common shares, operating and financial performance, and general and industry-specific economic outlook, amongst other factors.

The following assumptions were used in the Monte Carlo calculation for the Series 4 stock options:

Expected life of options		10 years
Expected volatility		60.0	%
Risk-free interest rate		1.2% - 1.7	%
Expected dividend yield		—
Weighted-average grant-date fair value of stock option	¥	72

A summary of the activity of the Company’s 2nd, 3rd, and 4th Series as of and for the fiscal years ended March 31, 2023, 2022, and 2021 is presented below:

The aggregate intrinsic value of the outstanding and exercisable options was calculated based on the estimated fair value of common shares of ¥144 per share.

				Years
		Yen		Weighted-
		Weighted-		average	Thousands of Yen
		average		remaining	Aggregate
	Number of	exercise		contractual	intrinsic
	shares	price		term	value
Outstanding as of April 1, 2020	54,000	¥	25	6.4	¥	—
Granted	2,019,000		56	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2021	2,073,000		55	9.7		—
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2022	2,073,000		55	8.7		183,497
Exercisable as of March 31, 2022	2,019,000	¥	56	8.8	¥	177,073
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2023	2,073,000		55	7.7		183,497
Exercisable as of March 31, 2023	2,019,000	¥	56	7.8	¥	177,073

XML

Net Income (Loss) per Share

12 Months Ended

Mar. 31, 2023

Net Income (Loss) per Share

Net Loss per Share

9. Net Income (Loss) per Share

The following table sets forth the computation of basic and diluted net loss per share:

	Yen in thousands, except share and per share data
	For the fiscal years ended March 31,
	2023		2022		2021
Basic:
Numerator:
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share		20,004,000		20,004,000		20,004,000
Basic net income (loss) per share	¥	2.06	¥	(4.85)	¥	(1.29)
Assuming Dilution:
Numerator:
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share		20,004,000		20,004,000		20,004,000
Dilutive securities issuable - Stock option plans		1,218,348		—		—
Total weighted-average diluted shares outstanding		21,222,348		20,004,000		20,004,000
Diluted net income (loss) per share	¥	1.95	¥	(4.85)	¥	(1.29)

Basic net income (loss) per common share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.

As disclosed in Note 8, Share-Based Compensation, the Company’s 2^nd and 3^rd Series stock options include a triggering liquidation performance condition prior to vesting. As such, these are treated as contingently issuable shares and will be excluded from potential dilutive impact until the triggering liquidation performance condition is satisfied. The 4^th Series stock options outstanding have no dilutive impacts for the fiscal years ended March 31, 2022 and 2021 due to the antidilutive effect. The following potentially dilutive shares have been excluded from the calculation of diluted net income (loss) per share for each period.

	March 31,
	2023	2022	2021
2nd and 3rd Series stock options outstanding	54,000	54,000	54,000
4th Series stock options outstanding	—	2,019,000	2,019,000
Total potentially dilutive shares	54,000	2,073,000	2,073,000

XML

Income Taxes

12 Months Ended

Mar. 31, 2023

Income Taxes

Income Taxes

10. Income Taxes

The components of income (loss) before income taxes, by geography, consisted of the following:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Japan	¥	78,203	¥	(80,543)	¥	(11,355)
Singapore		(36,900)		(16,537)		(14,443)
Income (Loss) before income taxes	¥	41,303	¥	(97,080)	¥	(25,798)

Warrantee is subject to national and local income taxes in Japan which, in the aggregate, indicate a statutory rate of approximately 34.59% for the fiscal years ended March 31, 2023, 2022, and 2021. The statutory tax rate in effect for the year in which the temporary differences are expected to reverse is used to calculate the tax effects of temporary differences that are expected to reverse in the future years.

A reconciliation of income tax expenses to the amount of income tax benefit at the statutory rate in Japan for the fiscal years ended March 31, 2023, 2022, and 2021 is as follows:

		Yen in thousands
		For the fiscal years ended March 31,
	2023		2022		2021
Income tax expenses (benefit) at the statutory rate	¥	14,286	¥	(33,580)	¥	(8,923)
Increase (reduction) in taxes resulting from:
Non-deductible share-based compensation expense		1,502		29,047		38,631
Deferred offering costs		(11,449)		(17,323)		(19,707)
Change in valuation allowance		(19,371)		15,982		(15,139)
Different tax rates in different jurisdictions		6,491		2,844		2,541
Disallowed losses		6,273		2,748		2,455
Other		2,268		282		142
Income tax expense	¥	—	¥	—	¥	—

Significant components of deferred tax assets and liabilities are as follows:

	Yen in thousands
	For the fiscal years ended
	March 31,
	2023	2022
Deferred tax assets:
Net operating loss carryforwards	102,559	135,400
Operating lease liabilities	20,980	—
Accrued expenses and reserves	12,209	—
Other	615	2,223
Total deferred tax assets	136,363	137,623
Deferred tax liabilities:
Right-of-use assets	(20,980)	—
Debt issuance costs	(346)	(369)
Other receivables	—	(2,274)
Capitalized software	(64)	(1,011)
Other	(737)	(362)
Total deferred tax liabilities	(22,127)	(4,016)
Less: valuation allowance	(114,236)	(133,607)
Net deferred tax assets	—	—

Due to the Company’s history of net losses and the difficulty in predicting future results, the Company concluded it was not more likely than not that the net operating loss carryforwards would be utilized. Accordingly, it has established a valuation allowance against net deferred tax assets. Significant management judgment is required in determining the Company’s deferred tax assets and liabilities and valuation allowances for purposes of assessing its ability to realize any future benefit from its net deferred tax assets. The Company intends to maintain this valuation allowance until sufficient positive evidence exists to support the reversal of the valuation allowance. Income tax expense recorded in the future will be reduced to the extent that sufficient positive evidence materializes to support a reversal of, or decrease in, the Company’s valuation allowance. The net changes in the total valuation allowance for net deferred tax assets for the fiscal years ended March 31, 2023, 2022, and 2021 consisted of the following:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Valuation allowance at beginning of year	¥	133,607	¥	117,625	¥	117,527
Additions (deductions)		(19,371)		15,982		(15,139)
Change in statutory tax rate		—		—		15,237
Valuation allowance at end of year	¥	144,236	¥	133,607	¥	117,625

The Company had net operating loss carryforwards of ¥296,499 thousand in Japan as of March 31, 2023, which are available as an offset against future taxable income. These carryforwards are scheduled to expire as follows:

Fiscal years ending March 31,	Yen in thousands
Between 2024 and 2027	¥	122,286
Between 2028 and 2031		125,915
2032 and thereafter		48,298
Total	¥	296,499

As of March 31, 2023, the Company’s Singapore subsidiary had not generated any revenue and was deemed to be a dormant company under Singaporean tax law. Net operating losses generated in dormant tax year are not allowed to be carryforward to offset future taxable income, as such no tax benefit related to the Singapore net operating loss has been included in the deferred tax assets.

The Company has made no provision for the income taxes on undistributed earnings of a foreign subsidiary since it is the Company’s intention to permanently reinvest such earnings in its foreign subsidiary.

The Company has determined that it is more likely than not that a tax benefit will be sustained, therefore no uncertain tax benefit has been recognized.

For the fiscal years ended March 31, 2023, 2022, and 2021, the Company had no uncertain tax positions anticipated to significantly increase or decrease within 12 months.

Interest and penalties related to income tax matters are recognized as a component of selling, general and administrative expenses in the Consolidated Statements of Income (Loss), if applicable. The Company did not have any interest or penalties associated with any uncertain tax benefits that have been accrued or recognized as of and for the fiscal years ended March 31, 2023, 2022, and 2021.

The Company files national and local income tax returns within Japan and Singapore. As of March 31, 2023, the Company was not, nor had it been, under income tax examination but may be subject to examination in the future. The tax authorities could perform tax examinations on years as early as the tax year ended March 31, 2016.

XML

Accrued Expenses and Other Current Liabilities

12 Months Ended

Mar. 31, 2023

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

11. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following:

	Yen in thousands
	March 31,
	2023		2022
Accrued compensation	¥	4,846	¥	2,737
Accrued offering costs		—		4,400
Accrued audit fees		44,392		50,188
Accrued professional fees		35,519		19,273
Withholding taxes payable		4,455		2,435
Accrued purchases of property and equipment		639		14,087
Other accrued expenses and current liabilities		10,534		7,915
Total	¥	100,385	¥	101,035

XML

Shareholders' Equity

12 Months Ended

Mar. 31, 2023

Shareholders' Equity

Shareholders' Equity

12. Shareholders’ Equity

Common Shares

On October 12, 2021, the Company’s Board of Directors approved, a 1,500-for-one share split of its issued and outstanding common shares. In connection with the 1,500-for-one share split, the total number of authorized common shares increased from 10,000,000 to 40,000,000.

On November 14, 2022, the Company’s Board of Directors further approved a two-for-one share split of its issued and outstanding common shares, and the share split became effective on November 29, 2022. In connection with the two-for-one share split, the total number of authorized common shares increased from 40,000,000 to 80,000,000.

All common share, stock option, and per share information in the Company’s consolidated financial statements and accompanying notes has been restated to give retroactive presentation related to the share splits for all periods presented.

As of March 31, 2023, the Company has authorized 80,000,000 common shares. Each holder of common shares shall be entitled to one vote for each share held as of the record date and shall be entitled to receive dividends, when, as and if declared by the shareholders’ meeting or the Board of Directors. The total common shares outstanding as of March 31, 2023 were 20,004,000 shares.

Warrantee is subject to the Companies Act in Japan. The significant provisions in the Companies Act that affect financial and accounting matters are summarized below:

Common shares

Under the Companies Act, issuances of common shares are required to be credited to the common share account for at least 50% of the proceeds and to the additional paid-in capital account for the remaining amounts.

Dividends

Under the Companies Act, companies can pay dividends at any time during the year in addition to the year-end dividend upon resolution at the shareholders meeting. The Companies Act permits companies to distribute dividends-in-kind (non-cash assets) to shareholders subject to certain limitations and additional requirements. Semiannual interim dividends may also be paid once a year upon resolution by the Board of Directors if the articles of incorporation of the company so stipulate. The Companies Act provides certain limitations on the amounts available for dividends or the purchase of treasury shares.

The amount available for dividends under the Companies Act is calculated based on the amount recorded in the Company’s non-consolidated financial statements prepared in accordance with accounting principles generally accepted in Japan. As a result, there was no amount available for dividends due to the accumulated deficit as of March 31, 2023.

Increases / decreases and transfer of common shares, reserve, and surplus

The Companies Act requires that an amount equal to 10% of dividends must be appropriated as legal reserve (a component of retained earnings) or as additional paid-in capital (a component of capital surplus) depending on the equity account charged upon the payment of such dividends until the total of the aggregate amount of legal reserve and additional paid-in capital equals 25% of common shares. Under the Companies Act, the total amount of additional paid-in capital and legal reserve may be reversed without limitation. The Companies Act also provides that common shares, legal reserve, additional paid-in capital, and other capital surplus and retained earnings can be transferred among the accounts under certain conditions upon resolution of the shareholders. During the fiscal year ended March 31, 2021, the Company reduced its common shares capital and additional paid in capital by ¥125,636 thousand and ¥135,399 thousand, respectively and transferred ¥261,035 thousand in its non-consolidated financial statements to reduce the accumulated deficit upon resolution of the shareholders.

XML

Related-Party Transactions

12 Months Ended

Mar. 31, 2023

Related-Party Transactions

Related-Party Transactions

13. Related-Party Transactions

Transactions with the CEO of the Company and ZENY Inc.

For the fiscal year ended March 31, 2021, the Company had certain funding transactions with Yusuke Shono, the CEO of the Company, and ZENY Inc., a personal asset management company wholly owned by the CEO of the Company for general operating needs of ¥28,640 thousand, and the entire amount totaled ¥30,053 thousand had been repaid by March 31, 2021. Also, a receivable of ¥17 thousand from ZENY Inc. was collected during the fiscal year ended March 31, 2021. Therefore, there was no remaining balance related to ZENY Inc. in the Consolidated Balance Sheets as of March 31, 2022 and 2021. The payable and receivable with these related parties were non-interest bearing.

As of and for the fiscal year ended March 31, 2021, the Company and ZENY Inc. had been under common control of the CEO of the Company since the CEO of the Company and ZENY Inc. had 78.1% and 10.4% of the Company’s common shares, respectively. However, ZENY Inc. completed its dissolution of the corporation on September 1, 2021, and the CEO of the Company assumed the 10.4% of the Company’s common shares, which ZENY Inc. had held prior to the dissolution, as of March 31, 2022.

Transactions with ESCO & Marketing Inc. and Peijen Inc.

During the fiscal year ended March 31, 2021, the Company collected the non-interest-bearing short-term funding of ¥6,112 thousand, which was provided during the fiscal year ended March 31, 2020, for ESCO & Marketing Inc. and Peijen Inc., two wholly owned companies by the CEO of the Company. The short-term funding was provided for general operating needs prior to the fiscal year ended March 31, 2021. The capital relationship between the CEO of the Company and these companies was terminated during the fiscal year ended March 31, 2021.

The collections of the receivable from related parties are included as a component of the shareholders’ equity on the Consolidated Balance Sheets.

Guarantees by the CEO of the Company

As described in Note 7, Debt, the CEO of the Company has guaranteed the Company’s term loan agreement with SBI Estate Finance Co., Ltd. and pledged his personal assets as collateral. The CEO of the Company has also guaranteed the Company’s term loan agreements with Resona Bank, Limited and Japan Finance Corporation.

The Company entered into a lease agreement on April 1, 2015 for its headquarter location in Osaka City, Osaka, Japan. The current lease term expires on February 27, 2024 and its lease payment is ¥148 thousand per month. The CEO of the Company is a guarantor of this lease.

XML

Subsequent Events

12 Months Ended

Mar. 31, 2023

Subsequent Events

Subsequent Events

14. Subsequent Events

On July 27, 2023, the Company closed its initial public offering, in which the Company sold 2,400,000 American Depositary Shares (“ADSs”) at a public offering price of US$4.00 per ADS. Each ADS represents one common share of the Company. The Company received net proceeds of US$7,191 thousand after deducting underwiring discounts and commissions and other offering costs.

On August 1, 2023, the Company entered into a term loan agreement with the CEO of the Company for $2,700 thousand with a maturity date of March 31, 2024. The interest rate of the term loan is 6.00% per annum.

XML

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Basis of Presentation

Basis of Presentation

The accompanying consolidated financial statements are presented in Japanese yen, the currency of the country in which the Company is incorporated and primarily operates. The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Reclassification

Reclassification

Certain accounts in the prior period consolidated financial statements have been reclassified to conform to the presentation of the current year consolidated financial statements. Foreign currency loss, net during the fiscal year ended March 31, 2021 of ¥591 thousand was reclassified from other income, net to a separate line item in the Consolidated Statements of Income (Loss). This reclassification had no effect on the previously reported operating results.

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of Warrantee and its wholly owned subsidiary, Warrantee Pte. Warrantee Pte. has a fiscal year end of December 31, and the accounts of Warrantee Pte. are included in the Company’s consolidated financial statements based on the fiscal year of Warrantee Pte. All intercompany accounts and transactions, including capital increase during a reporting time lag, have been eliminated upon consolidation.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the reporting date, and the reported amounts of revenue and expense during the reporting period. These estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future and include, but are not limited to, useful lives of capitalized software, valuation of stock options, and valuation allowance against net deferred tax assets. Actual results could differ from those estimates.

Segment Information

Segment Information

The Company operates as one operating segment. The Company’s chief operating decision maker (“CODM”) is its Chief Executive Officer (“CEO”), who reviews financial information for purposes of making operating decisions, assessing financial performance, and allocating resources. The Company’s CODM evaluates financial information on a consolidated basis. As of March 31, 2023, 2022, and 2021, there was no revenue derived or long-lived assets held outside of Japan.

Concentration of Customers

Concentration of Customers

For the fiscal years ended March 31, 2023, 2022, and 2021, two customers, one customer, and two customers, respectively, each accounted for more than 10% of the consolidated revenue. Revenue from those customers totaled ¥243,218 thousand, ¥224,727 thousand, and ¥177,000 thousand of the total consolidated revenue for the fiscal years ended March 31, 2023, 2022, and 2021, respectively. The following represents sales revenue attributable to each of these customers as a percentage of total consolidated revenue for each respective year.

	Percentage of Revenue
	For the fiscal years ended March 31,
	2023		2022		2021
Customer A	88	%	100	%	—
Customer B	—		—		51	%
Customer C	12	%	—		33	%

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an initial maturity date of three months or less to be cash equivalents.

Trade Accounts Receivable and Allowance for Doubtful Accounts

Trade Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable primarily consist of amounts billed and currently due from customers, net of an allowance for doubtful accounts, if recorded. When the Company has an unconditional right to payment, subject only to the passage of time, the right is treated as receivable. Fees billed in advance of the related contractual term represent contract liabilities and are presented as deferred revenue. Typical payment terms provide for customer payment within 30 days of the contract date.

Trade accounts receivables are subject to collection risk. The Company performs evaluations of its customers’ financial positions and generally extends credit on account, without collateral. The Company determines the need for an allowance for doubtful accounts based upon various factors, including credit quality of the customer, age of the receivable balance and current economic conditions.

There were no bad debt expense or allowance for doubtful accounts recorded as of and for the fiscal years ended March 31, 2023, 2022, and 2021.

Property and Equipment, Net

Property and Equipment, Net

Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method, depending on the pattern of consumption of the economic benefits by asset class, over the estimated useful lives of the assets. The estimated useful lives are four years for computers and three to six years for furniture and fixtures. Repair and maintenance costs are expensed as incurred. The Company records depreciation expense in selling, general and administrative expenses and cost of revenue on the Consolidated Statements of Income (Loss).

Capitalized Software, Net

Capitalized Software, Net

The Company capitalizes certain costs in property and equipment associated with website and software developed for internal use in accordance with ASC 350-50, Intangibles - Goodwill and Other - Website Development Costs and ASC 350-40, Intangibles - Goodwill and Other - Internal Use Software when both the preliminary project design and the testing stage are completed and management has authorized further funding for the project, which it deems probable of completion and to be used for the function intended. Capitalized costs include amounts directly related to website and software development such as fees paid to third-party vendors. Capitalization of such costs ceases when the project is substantially complete and ready for its intended use. Capitalized costs are amortized, beginning in the period the product is ready for its intended use, on a straight-line basis over the estimated useful life of the product, five years. Costs incurred during the preliminary stages of development and ongoing maintenance costs are expensed as incurred.

Impairment or Disposal of Long-Lived Assets

Impairment or Disposal of Long-Lived Assets

Long-lived assets used in operations, which include capitalized software developed for internal use and property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that carrying amounts may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if the carrying amount is not recoverable when compared to the Company’s undiscounted cash flows and the impairment loss is measured based on the difference between the carrying amount and fair value. Long-lived assets held for sale are reported at the lower of cost or fair value less costs to sell.

Leases

Leases

Leases are principally comprised of operating leases for office space. The Company determines that a contract contains a lease if they obtain substantially all of the economic benefits of, and the right to direct the use of, an asset identified in the contract. For leases with terms greater than 12 months, the Company records a right-of-use asset and a lease liability representing the present value of future lease payments. The discount rate used to measure the lease asset and liability is determined at the beginning of the lease term using the rate implicit in the lease, if readily determinable, or the Company’s collateralized incremental borrowing rate. For those contracts that include fixed rental payments for both the use of the asset (“lease costs”) as well as for other occupancy or service costs relating to the asset (“non-lease costs”), the Company generally includes both the lease costs and non-lease costs in the measurement of the lease asset and liability.

Lease expenses and income for the Company’s operating leases are recognized on a straight-line basis over the lease term, with the exception of variable lease costs, which are expensed as incurred.

Debt Issuance Costs

Debt Issuance Costs

Debt issuance costs are amortized as interest expense on a basis which approximates the effective interest method over the term of the related debt. Debt issuance costs are reported at cost, less accumulated amortization and are presented in the Consolidated Balance Sheets as a direct deduction from the carrying value of the associated debt.

Deferred Offering Costs

Deferred Offering Costs

Deferred offering costs are capitalized and consist of fees incurred in connection with the anticipated sale of common shares in an IPO and include direct incremental legal, accounting, printing, and other IPO-related costs. Upon completion of an IPO, these deferred costs will be reclassified to shareholders’ equity and recorded against the proceeds from the offering. In the event a proposed IPO is deemed not likely to be completed, the deferred offering costs would be charged to expenses in the period of such determination.

Foreign Currency

Foreign Currency

The Company uses Japanese yen as its reporting currency. Warrantee’s functional currency is the Japanese yen and the functional currency of Warrantee Pte. is the Singapore dollar. Financial statements of Warrantee Pte. are prepared using the functional currency and translated into Japanese yen for reporting purposes. Assets and liabilities are translated using the fiscal year end foreign exchange rate, and income and expenses are translated using the average exchange rate for the period. Foreign currency translation adjustments related to the financial statements of Warrantee Pte. net of related income tax effects, are credited or charged directly to the foreign currency translation adjustments account, a component of accumulated other comprehensive income (loss). The tax effects related to the foreign currency translation of financial statements of Warrantee Pte. are not recognized unless it is apparent that the temporary differences will reverse in the foreseeable future. Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency of the respective entity at the fiscal year end foreign exchange rate, and gains and losses resulting from such remeasurement are included in foreign exchange gains (losses). Foreign currency denominated income and expenses are remeasured using the average exchange rate for the period.

Share-Based Compensation

Share-Based Compensation

The Company applies the provisions of ASC Topic 718, Compensation — Stock Compensation. The Company measures the cost of employee and non-employee services received in exchange for awards of equity instruments at the fair value of the award on the grant date and recognizes the cost over the requisite service period which the employee and non-employee are required to provide services in exchange for the award. Compensation costs are recognized on a straight-line basis over the requisite service period of the awards which are expected to be vested. For non-employee vesting periods that have implicit service periods based on the achievement of a performance condition, a change in the estimated achievement of performance conditions will be recognized prospectively over the revised non-employee vesting period. For awards with performance conditions, compensation cost is recognized when the condition is probable of being achieved, or in the case of a liquidity event, when the liquidity event occurs. The Company uses option pricing methods that require the input of subjective assumptions, including the expected term, expected volatility, dividend yield and risk-free interest rate. For awards with market conditions, the Company uses a hybrid method between a discounted cash flow method and Monte Carlo simulation models to value the awards. The Company has elected to recognize forfeitures as they occur.

Revenue Recognition

Revenue Recognition

The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) for all periods presented in the consolidated financial statements. To determine the appropriate amount of revenue to be recognized in accordance with ASC 606, the Company follows a five-step model as follows:

1 – Identification of the contract with a customer;

2 – Identification of the performance obligation in the contract;

3 – Determination of the transaction price;

4 – Allocation of the transaction price to the performance obligation in the contract; and

5 – Recognition of revenue when, or as, a performance obligation is satisfied.

The Company’s revenue is primarily derived from the Durables Vertical and the Commercial Healthcare Vertical. The Company’s services are marketed and sold directly to the customers. The Company assesses the contract term as the period in which the parties to the contract have enforceable rights and obligations. The contract term may differ from the stated term in contracts with certain termination or renewal rights, depending on whether there are substantive penalties associated with those rights. Customer contracts are generally standardized and noncancellable for the duration of the stated contract term. Consumption taxes collected and remitted to tax authorities are excluded from revenue. The Company may use third-party vendors to provide certain goods or services to its customers. The Company evaluates those relationships to determine whether revenue should be reported gross or net. The Company recognizes revenue on a gross basis where it acts as principal and controls the goods and services used to fulfill the performance obligations to the customer and on a net basis where it acts as an agent. The Company has not acted as an agent during the fiscal years ended March 31, 2023, 2022, and 2021.

Durables Vertical:

Performance Obligations

Revenue from the Durables Vertical is primarily comprised of sponsorship fees from Corporate Sponsors in exchange for Participant Users’ personal information or Participant Clinics’ information (collectively, “Participants’ Data”). During the sponsorship campaigns, the Company aggregates Participants’ Data, organizes that data, and then provides it to Corporate Sponsors. The Company has identified one performance obligation, the delivery of Participants’ Data. All other immaterial deliverables occur prior to this, but revenue is not recognized until the delivery of Participants’ Data which is the performance obligation. Accordingly, the Company recognizes revenue at a point in time when the personal information is provided to, or accepted by, Corporate Sponsors upon satisfying its single distinct performance obligation.

Contractual Consideration

The transaction price is generally fixed at contract inception. However, the Company’s contracts with Corporate Sponsors within Durables Vertical may include a specified quantity, which entitles the customer to refunds, when defined quantity levels are not met at the end of the provision period. These arrangements represent a form of variable consideration, which is estimated using the most likely amount method to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of March 31, 2023 and 2022.

Commercial Healthcare Vertical:

Performance Obligations

Revenue from the Commercial Healthcare Vertical is primarily comprised of sponsorship fees from Corporate Sponsors in exchange for healthcare-related promotional campaigns. During healthcare-related promotional campaigns targeted to Participant Users based on results of their free genetic test kits, the Company has the stand-ready obligation to provide promotional services for the duration of the campaign promotion period. Accordingly, revenue is recognized ratably based on the time-elapsed method over the contractual term with the Corporate Sponsor.

Contractual Consideration

The transaction price may be fixed at contract inception within the Commercial Healthcare Vertical in a form of non-refundable minimum guarantee but may also have a component of variable consideration such as sales incentives which are calculated by multiplying the amount of work accomplished by a fixed unit price of remuneration. Due to the variable consideration being entirely constrained, the sales incentive is excluded from the transaction price until the uncertainty is subsequently resolved. During the fiscal years ended March 31, 2023, 2022, and 2021, no revenue was recognized from estimates that had not been resolved as of March 31, 2023 and 2022.

Other Revenue:

System Development: System development revenue is generated by the development and the delivery of the system that meets the customer’s specifications. There is one performance obligation as all promises are interrelated to delivering a completed system. The title to the system is transferred to the customer upon acceptance. The Company typically recognizes revenue upon the customer’s acceptance as the control over the product is transferred to the customer and the Company’s performance obligations are satisfied. When third-party vendors participate in the provisioning of the system, the Company recognizes the related revenue on a gross basis as the Company is the principal in these arrangements.

Transaction Price

The transaction price is the amount of consideration to which the Company expects to be entitled to for transferring goods and services to the customer.

Payments from the customers are often made in advance before satisfaction of the performance obligations. Generally, payments are due within 30 days of delivery of the goods or service. In instances where the timing of revenue recognition differs from the timing of the right to invoice, the Company has determined that a significant financing component generally does not exist. Additionally, the Company has elected the practical expedient that permits an entity not to recognize a significant financing component if the time between the transfer of a good or service and payment is one year or less.

Disaggregation of Revenue

The table reflects revenue by major source for the following periods:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Sources of revenue:
Durables Vertical	¥	213,218	¥	224,727	¥	85,000
Commercial Healthcare Vertical		30,000		—		107,000
System Development		—		—		20,000
Total revenue	¥	243,218	¥	224,727	¥	212,000

Contract Balances

The timing of revenue recognition may not align with the right to invoice the customer. The Company records trade accounts receivable when it has the unconditional right to issue an invoice and receive payment regardless of whether revenue has been recognized. If revenue has not yet been recognized, then deferred revenue is also recorded. Deferred revenue classified as current on the Consolidated Balance Sheets are expected to be recognized as revenue within one year. If revenue is recognized in advance of the right to invoice, a contract asset is recorded.

Changes in deferred revenue were as follows:

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Balance, beginning of year	¥	33,000	¥	—	¥	106,919
Revenue earned		(33,000)		—		(106,919)
Deferral of revenue		9,831		33,000		—
Balance, end of year	¥	9,831	¥	33,000	¥	—

Changes in deferred revenue are primarily due to the timing of revenue recognition and cash collections.

Remaining Performance Obligations

Remaining performance obligations represent the aggregate amount of the transaction price allocated to the remaining obligations that the Company has not performed under its customer contracts. The Company has elected to use the optional exemption in ASC 606-10-50-14, which exempts an entity from such disclosures if a performance obligation is part of a contract with an original expected duration of one year or less.

As of March 31, 2023, deferred revenue represented the Company’s remaining performance obligations related to prepaid consideration for the campaign starting during the year ending March 31, 2024 with a new customer, all of which is expected to be recognized within one year.

Deferred Contract Costs

Sales commissions that are incremental to the acquisition of customer contracts, are capitalized as deferred contract costs on the Consolidated Balance Sheets when the period of benefit is determined to be greater than one year. Amortization of deferred contract acquisition costs is included within selling, general and administrative expenses in the Consolidated Statements of Income (Loss).

The Company also capitalizes certain costs to fulfill a contract related to its proprietary products or services if they are identifiable, generate or enhance resources used to satisfy future performance obligations and are expected to be recovered under ASC Topic 340-40, Other Assets and Deferred Costs-Contracts with Customers. Amortization of deferred contract fulfillment costs is included within cost of revenue in the Consolidated Statements of Income (Loss).

Deferred contract costs are amortized to be consistent with the timing of transfer to the customer of the goods or services to which the costs relate, either at a point in time or over time in proportion to the amount of the related goods and services transferred to the customer. The Company periodically reviews these capitalized contract costs to determine whether changes in events or circumstances have occurred that could impact the period of benefit of these assets. There were no impairment losses recorded for the periods presented.

As of March 31, 2023 and 2022, the Company had no deferred costs to obtain and fulfill a contract. During the fiscal years ended March 31, 2022 and 2021, the Company amortized ¥1,500 thousand and ¥17,692 thousand of costs to obtain and fulfill the contract, respectively, and capitalized ¥1,575 thousand of costs to fulfill the contract during the fiscal year ended March 31, 2021.

Cost of Revenue

Cost of Revenue

For the fiscal years ended March 31, 2023 and 2022, cost of revenue primarily comprised of the insurance costs, depreciation and amortization and personnel-related expenses. For the fiscal year ended March 31, 2021, the cost of revenue also included the direct cost to develop software products, Participant User recruiting costs for the Durables Vertical, and genetic testing costs for Commercial Healthcare Vertical.

Advertising Costs

Advertising Costs

Advertising costs are expensed as incurred and presented within selling, general and administrative expenses in the Consolidated Statements of Income (Loss). Advertising costs were ¥11,790 thousand, ¥325 thousand, and ¥888 thousand for the fiscal years ended March 31, 2023, 2022, and 2021, respectively.

Income Taxes

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the differences between the financial statement and tax basis of assets, liabilities and net operating loss by using enacted tax rate in effect for the year in which the differences are expected to reverse. The effect of a change in tax rate on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that these assets are believed to be more likely than not to be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts that are more likely than not expected to be realized. In making such a determination, all available positive and negative evidence is considered, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations.

Warrantee and its subsidiary file tax returns in the tax jurisdictions of Japan and Singapore. Tax benefits for uncertain tax positions are based upon management’s evaluation of the information available at the reporting date. To be recognized in the consolidated financial statements, a tax benefit must be at least more likely than not of being sustained based on technical merits. The benefit for positions meeting the recognition threshold is measured as the largest benefit more likely than not of being realized upon settlement with a taxing authority that has full knowledge of all relevant information.

Net Income (Loss) per Share

Net Income (Loss) per Share

Basic net income (loss) per common share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.

For purposes of the diluted net income (loss) per common share calculation, stock options are considered to be potentially dilutive securities. However, as disclosed in Note 8, Share-Based Compensation, the Company’s 2nd and 3rd Series stock options include a triggering liquidation performance condition prior to vesting. As such, these are treated as contingently issuable shares and will be excluded from potential dilutive impact until the triggering liquidation performance condition is satisfied.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

As an emerging growth company, the Jumpstart Our Business Startups Act allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to delay adoption of certain new or revised accounting standards. As a result, the Company’s consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective date for new or revised accounting standards that are applicable to public companies.

Financial Instruments — Credit Losses

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which is intended to provide more decision-useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. ASU 2016-13 revises the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in more timely recognition of losses on financial instruments, including, but not limited to accounts receivable. This standard is effective for annual reporting periods beginning after December 15, 2022 for non-public entities, including interim periods within that reporting period. Early adoption is permitted. The Company is currently in process of evaluating the impact of this standard on the Company’s consolidated financial statements. The Company does not expect the adoption of this standard to have a material effect on the Company’s consolidated financial statements. As an emerging growth company, the Company will adopt this standard effective April 1, 2023.

XML

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Mar. 31, 2023

Summary of Significant Accounting Policies

Schedule of concentration of customers

	Percentage of Revenue
	For the fiscal years ended March 31,
	2023		2022		2021
Customer A	88	%	100	%	—
Customer B	—		—		51	%
Customer C	12	%	—		33	%

Schedule of disaggregation of revenue

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Sources of revenue:
Durables Vertical	¥	213,218	¥	224,727	¥	85,000
Commercial Healthcare Vertical		30,000		—		107,000
System Development		—		—		20,000
Total revenue	¥	243,218	¥	224,727	¥	212,000

Schedule of changes in deferred revenue

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Balance, beginning of year	¥	33,000	¥	—	¥	106,919
Revenue earned		(33,000)		—		(106,919)
Deferral of revenue		9,831		33,000		—
Balance, end of year	¥	9,831	¥	33,000	¥	—

XML

Property and Equipment, Net (Tables)

12 Months Ended

Mar. 31, 2023

Property and Equipment, Net

Schedule of property and equipment, net

	Yen in thousands
	March 31,
	2023		2022
Capitalized software	¥	43,598	¥	34,928
Computers		999		999
Furniture and fixtures		632		632
Total property and equipment		45,229		36,559
Less: Accumulated depreciation and amortization		(9,299)		(2,399)
Total property and equipment, net	¥	35,930	¥	34,160

XML

Leases (Tables)

12 Months Ended

Mar. 31, 2023

Leases

Schedule of amounts recorded on the Consolidated Balance Sheets relating to the Company's operating leases

	Yen in thousands
	March 31,
	2023		2022
Right-of-Use Assets
Operating lease assets	¥	60,692	¥	—
Lease Liabilities
Operating lease liabilities	¥	60,692	¥	—

Schedule of supplemental balance sheet information related to leases

	For the fiscal years ended March 31,
	2023		2022
Remaining lease term and discount rate:
Weighted average remaining lease term (years)	1.8		—
Weighted average discount rate	4.24	%	—

Schedule of future minimum lease payments under non-cancelable leases

Fiscal Year ending March 31,
2024	¥	33,360
2025		27,370
Total lease payments		60,730
Less amounts representing interest		(38)
Present value of lease payments		60,692

XML

Debt (Tables)

12 Months Ended

Mar. 31, 2023

Debt

Schedule of short-term and long-term borrowings

			Yen in thousands
			March 31,
	Interest Rate	Maturity	2023		2022
Amended term loan with Japan Finance Corporation	0.36% to 1.26%	August 31, 2026	¥	13,975	¥	15,500
Term loan with Resona Bank, Limited	0.00% to 1.20%	November 30, 2030		24,220		25,000
Term loan with SBI Estate Finance Co., Ltd.	6.00%	September 5, 2037		43,187		45,011
Total long-term debt				81,382		85,511
Less: unamortized debt issuance costs				(998)		(1,067)
Subtotal				80,384		84,444
Current portion of long-term debt, net of debt issuance costs				(9,791)		(4,970)
Long-term debt, excluding current portion, net of debt issuance costs			¥	70,593	¥	79,474

Schedule of contractual maturities of long-term debt

	(Yen in thousands)
2024	¥	9,860
2025		9,076
2026		9,203
2027		7,062
2028		5,575
Thereafter		40,606
Total	¥	81,382

XML

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2023

Share-Based Compensation

Summary of assumptions used in the Monte Carlo calculation for Series 4 stock options

Expected life of options		10 years
Expected volatility		60.0	%
Risk-free interest rate		1.2% - 1.7	%
Expected dividend yield		—
Weighted-average grant-date fair value of stock option	¥	72

Summary of activity of 2nd, 3rd, and 4th Series stock options

				Years
		Yen		Weighted-
		Weighted-		average	Thousands of Yen
		average		remaining	Aggregate
	Number of	exercise		contractual	intrinsic
	shares	price		term	value
Outstanding as of April 1, 2020	54,000	¥	25	6.4	¥	—
Granted	2,019,000		56	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2021	2,073,000		55	9.7		—
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2022	2,073,000		55	8.7		183,497
Exercisable as of March 31, 2022	2,019,000	¥	56	8.8	¥	177,073
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited	—		—	—		—
Outstanding as of March 31, 2023	2,073,000		55	7.7		183,497
Exercisable as of March 31, 2023	2,019,000	¥	56	7.8	¥	177,073

XML

Net Income (Loss) per Share (Tables)

12 Months Ended

Mar. 31, 2023

Net Income (Loss) per Share

Schedule of computation of basic and diluted net loss per share

	Yen in thousands, except share and per share data
	For the fiscal years ended March 31,
	2023		2022		2021
Basic:
Numerator:
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share		20,004,000		20,004,000		20,004,000
Basic net income (loss) per share	¥	2.06	¥	(4.85)	¥	(1.29)
Assuming Dilution:
Numerator:
Net income (loss)	¥	41,303	¥	(97,080)	¥	(25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share		20,004,000		20,004,000		20,004,000
Dilutive securities issuable - Stock option plans		1,218,348		—		—
Total weighted-average diluted shares outstanding		21,222,348		20,004,000		20,004,000
Diluted net income (loss) per share	¥	1.95	¥	(4.85)	¥	(1.29)

Schedule of potentially dilutive shares have been excluded from calculation of diluted net loss per share

	March 31,
	2023	2022	2021
2nd and 3rd Series stock options outstanding	54,000	54,000	54,000
4th Series stock options outstanding	—	2,019,000	2,019,000
Total potentially dilutive shares	54,000	2,073,000	2,073,000

XML

Income Taxes (Tables)

12 Months Ended

Mar. 31, 2023

Income Taxes

Schedule of components of income (loss) before income taxes

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Japan	¥	78,203	¥	(80,543)	¥	(11,355)
Singapore		(36,900)		(16,537)		(14,443)
Income (Loss) before income taxes	¥	41,303	¥	(97,080)	¥	(25,798)

Schedule of reconciliation of income tax expenses to the amount of income tax benefit at the statutory rate

		Yen in thousands
		For the fiscal years ended March 31,
	2023		2022		2021
Income tax expenses (benefit) at the statutory rate	¥	14,286	¥	(33,580)	¥	(8,923)
Increase (reduction) in taxes resulting from:
Non-deductible share-based compensation expense		1,502		29,047		38,631
Deferred offering costs		(11,449)		(17,323)		(19,707)
Change in valuation allowance		(19,371)		15,982		(15,139)
Different tax rates in different jurisdictions		6,491		2,844		2,541
Disallowed losses		6,273		2,748		2,455
Other		2,268		282		142
Income tax expense	¥	—	¥	—	¥	—

Schedule of components of deferred tax assets and liabilities

	Yen in thousands
	For the fiscal years ended
	March 31,
	2023	2022
Deferred tax assets:
Net operating loss carryforwards	102,559	135,400
Operating lease liabilities	20,980	—
Accrued expenses and reserves	12,209	—
Other	615	2,223
Total deferred tax assets	136,363	137,623
Deferred tax liabilities:
Right-of-use assets	(20,980)	—
Debt issuance costs	(346)	(369)
Other receivables	—	(2,274)
Capitalized software	(64)	(1,011)
Other	(737)	(362)
Total deferred tax liabilities	(22,127)	(4,016)
Less: valuation allowance	(114,236)	(133,607)
Net deferred tax assets	—	—

Schedule of net changes in the total valuation allowance for net deferred tax assets

	Yen in thousands
	For the fiscal years ended March 31,
	2023		2022		2021
Valuation allowance at beginning of year	¥	133,607	¥	117,625	¥	117,527
Additions (deductions)		(19,371)		15,982		(15,139)
Change in statutory tax rate		—		—		15,237
Valuation allowance at end of year	¥	144,236	¥	133,607	¥	117,625

Schedule of expiration of net operating loss carryforwards available as an offset against future taxable income

Fiscal years ending March 31,	Yen in thousands
Between 2024 and 2027	¥	122,286
Between 2028 and 2031		125,915
2032 and thereafter		48,298
Total	¥	296,499

XML

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Mar. 31, 2023

Accrued Expenses and Other Current Liabilities

Schedule of accrued expenses and other current liabilities

	Yen in thousands
	March 31,
	2023		2022
Accrued compensation	¥	4,846	¥	2,737
Accrued offering costs		—		4,400
Accrued audit fees		44,392		50,188
Accrued professional fees		35,519		19,273
Withholding taxes payable		4,455		2,435
Accrued purchases of property and equipment		639		14,087
Other accrued expenses and current liabilities		10,534		7,915
Total	¥	100,385	¥	101,035

XML

Nature of Operations (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Nature of Operations
Amount received from subsidy program			¥ 2,000
Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]			Other Nonoperating Income (Expense)
Working capital	¥ (156,400)	¥ (112,700)
Loss from operations	52,593	(89,842)	¥ (27,754)
Accumulated deficit	¥ 470,605	¥ 511,908

XML

Summary of Significant Accounting Policies (Details) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023 JPY (¥) segment	Mar. 31, 2021 JPY (¥)	Mar. 31, 2022 JPY (¥)
Summary of Significant Accounting Policies
Foreign currency loss, net reclassified from other income		¥ 591
Number of operating segments | segment	1
Bad debt expense or allowance for doubtful accounts	¥ 0	¥ 0	¥ 0

XML

Summary of Significant Accounting Policies - Concentration of Customers (Details) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023 JPY (¥) customer	Mar. 31, 2022 JPY (¥) customer	Mar. 31, 2021 JPY (¥) customer
Concentration of Customers
Number of customers | customer	2	1	2
Revenues | ¥	¥ 243,218	¥ 224,727	¥ 177,000
Sales revenue | Customer concentration risk | Customer A
Concentration of Customers
Percentage of Revenue	88.00%	100.00%
Sales revenue | Customer concentration risk | Customer B
Concentration of Customers
Percentage of Revenue			51.00%
Sales revenue | Customer concentration risk | Customer C
Concentration of Customers
Percentage of Revenue	12.00%		33.00%

XML

Summary of Significant Accounting Policies - Property and Equipment, Net (Details)	Mar. 31, 2023
Computers
Property and Equipment, Net
Estimated useful life	4 years
Furniture and fixtures | Minimum
Property and Equipment, Net
Estimated useful life	3 years
Furniture and fixtures | Maximum
Property and Equipment, Net
Estimated useful life	6 years

XML

Summary of Significant Accounting Policies - Capitalized Software, Net (Details)	Mar. 31, 2023
Internal Use Software
Capitalized Software, Net
Estimated useful life	5 years

XML

Summary of Significant Accounting Policies - Disaggregation of revenue (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Revenue Recognition
Revenue	¥ 243,218	¥ 224,727	¥ 212,000	¥ 212,000
Durables Vertical
Revenue Recognition
Revenue from estimates that had not been resolved	0	0		0
Revenue	213,218	224,727	85,000
Commercial Healthcare Vertical
Revenue Recognition
Revenue from estimates that had not been resolved		¥ 0		¥ 0	¥ 0
Revenue	¥ 30,000		107,000
System Development
Revenue Recognition
Revenue			¥ 20,000

XML

Summary of Significant Accounting Policies - Changes in deferred revenue (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Changes in deferred revenue
Balance, beginning of year	¥ 33,000
Revenue earned	(33,000)		¥ (106,919)
Deferral of revenue	9,831	¥ 33,000
Balance, end of year	¥ 9,831	¥ 33,000

XML

Summary of Significant Accounting Policies - Deferred Contract Costs (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Deferred Contract Costs
Impairment losses on capitalized contract costs	¥ 0
Advertising costs	¥ 11,790	¥ 325	¥ 888
Capitalized costs to obtain and fulfill a contract
Deferred Contract Costs
Amortization of capitalized contract costs		¥ 1,500	17,692
Capitalized costs to fulfill a contract
Deferred Contract Costs
Contract costs capitalized			¥ 1,575

XML

Property and Equipment, Net (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Property and Equipment, Net
Total property and equipment	¥ 45,229	¥ 36,559
Less: Accumulated depreciation and amortization	(9,299)	(2,399)
Total property and equipment, net	35,930	34,160
Depreciation and amortization expenses	6,900	862	¥ 115
Capitalized software
Property and Equipment, Net
Total property and equipment	43,598	34,928
Computers
Property and Equipment, Net
Total property and equipment	999	999
Furniture and fixtures
Property and Equipment, Net
Total property and equipment	632	632
Asset under construction
Property and Equipment, Net
Total property and equipment	¥ 6,386	¥ 28,136

XML

Leases (Details) ¥ in Thousands	Mar. 31, 2023 JPY (¥)
Leases
Operating lease assets	¥ 60,692
Operating lease liabilities	¥ 60,692

XML

Leases - Supplemental balance sheet information (Details)	Mar. 31, 2023
Remaining lease term and discount rate:
Weighted average remaining lease term (years)	1 year 9 months 18 days
Weighted average discount rate	4.24%

XML

Leases - Future minimum lease payments under non-cancelable leases (Details) ¥ in Thousands	Mar. 31, 2023 JPY (¥)
Fiscal Year ending March 31,
2024	¥ 33,360
2025	27,370
Total lease payments	60,730
Less amounts representing interest	(38)
Present value of lease payments	¥ 60,692

XML

Fair Value of Financial Instruments (Details) - Fair Value, Recurring - JPY (¥) ¥ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Fair Value of Financial Instruments
Assets	¥ 0	¥ 0
Liabilities	¥ 0	¥ 0

XML

Commitments and Contingencies (Details)	Mar. 31, 2023 JPY (¥)
Commitments and Contingencies
Maximum potential loss	¥ 13,027,000
Loss per annum	¥ 14.6

XML

Debt - Summary of borrowings (Details) - JPY (¥) ¥ in Thousands			12 Months Ended
	Sep. 30, 2021	Aug. 31, 2017	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Dec. 18, 2020	Sep. 03, 2014
Debt
Total long-term debt			¥ 81,382
Current portion of long-term debt, net of debt issuance costs			(9,791)	¥ (4,970)
Long-term debt, excluding current portion, net of debt issuance costs			70,593	79,474
Proceeds from long-term debt				500	¥ 25,000
Interest expense, amortization of issuance costs			69	69	68
Borrowings, including short-term
Debt
Total long-term debt			81,382	85,511
Less: unamortized debt issuance costs			(998)	(1,067)
Subtotal			80,384	84,444
Current portion of long-term debt, net of debt issuance costs			(9,791)	(4,970)
Long-term debt, excluding current portion, net of debt issuance costs			¥ 70,593	79,474
Amended term loan with Japan Finance Corporation | Minimum
Debt
Interest Rate			0.36%
Amended term loan with Japan Finance Corporation | Maximum
Debt
Interest Rate			1.26%
Amended term loan with Japan Finance Corporation | Borrowings, including short-term
Debt
Total long-term debt			¥ 13,975	15,500
Term loan with Japan Finance Corporation
Debt
Term loan, principal amount							¥ 15,000
Proceeds from long-term debt	¥ 500
Term loan with Japan Finance Corporation | Minimum
Debt
Contract interest rate	0.36%						0.90%
Term loan with Japan Finance Corporation | Maximum
Debt
Contract interest rate	1.26%						8.55%
Term loan with Resona Bank, Limited
Debt
Term loan, principal amount						¥ 25,000
Term loan with Resona Bank, Limited | Minimum
Debt
Interest Rate			0.00%
Contract interest rate						0.00%
Term loan with Resona Bank, Limited | Maximum
Debt
Interest Rate			1.20%
Contract interest rate						1.20%
Term loan with Resona Bank, Limited | Borrowings, including short-term
Debt
Total long-term debt			¥ 24,220	¥ 25,000
Term loan with SBI Estate Finance Co., Ltd.
Debt
Interest Rate			6.00%
Term loan, principal amount		¥ 52,000
Proceeds from long-term debt		50,623
Contract interest rate			6.00%	6.00%
Effective interest rate			6.28%	6.28%
Equal monthly repayments, principal and interest		¥ 373
Debt issuance costs			¥ 1,377
Life of term loan (in years)			20 years
Interest expense, amortization of issuance costs			¥ 69	¥ 69	¥ 68
Unamortized debt issuance costs			998	1,067
Term loan with SBI Estate Finance Co., Ltd. | Borrowings, including short-term
Debt
Total long-term debt			¥ 43,187	¥ 45,011

XML

Debt - Maturities (Details) ¥ in Thousands	Mar. 31, 2023 JPY (¥)
Contractual maturities of long-term debt
2024	¥ 9,860
2025	9,076
2026	9,203
2027	7,062
2028	5,575
Thereafter	40,606
Total	¥ 81,382

XML

Share-Based Compensation - Summary of plans (Details) - JPY (¥) ¥ / shares in Units, ¥ in Thousands				12 Months Ended
	Jan. 29, 2021	Mar. 30, 2017	Jun. 26, 2016	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation
Proceeds from stock options issued						¥ 1,707
2nd and 3rd Series stock options outstanding
Share-Based Compensation
Number of options granted		81,000	540,000
Number of shares which may be issued for each option exercised		1	1
Contractual term of awards		10 years	10 years
Fair value as of grant date		¥ 35	¥ 11
Exercise price		¥ 56	¥ 19
Unrecognized compensation cost				¥ 825
4th Series stock options outstanding
Share-Based Compensation
Number of options granted	2,019,000
Number of shares which may be issued for each option exercised	1
Contractual term of awards	10 years
Fair value as of grant date	¥ 100
Exercise price	56
Unrecognized compensation cost				190
Market condition, minimum price for common shares	55.66
Proceeds from stock options issued						1,707
Issue price per share resulting from stock split	¥ 1
4th Series stock options outstanding | Selling, general, and administrative expenses
Share-Based Compensation
Compensation costs recognized				¥ 4,343	¥ 83,976	¥ 111,684
4th Series stock options outstanding | Employee Stock Option
Share-Based Compensation
Fair value as of grant date				¥ 72
Expected dividend yield				0.00%

XML

Share-Based Compensation - Assumptions (Details) - 4th Series stock options outstanding - ¥ / shares		12 Months Ended
	Jan. 29, 2021	Mar. 31, 2023
Assumptions used in Monte Carlo calculation of stock options
Weighted-average grand-date fair value of stock option	¥ 100
Employee Stock Option
Assumptions used in Monte Carlo calculation of stock options
Expected life of options		10 years
Expected volatility		60.00%
Risk-free interest rate, minimum		1.20%
Risk-free interest rate, maximum		1.70%
Expected dividend yield		0.00%
Weighted-average grand-date fair value of stock option		¥ 72

XML

Share-Based Compensation - Activity (Details) - 2nd and 3rd and 4th Series Stock Options - Employee Stock Option - JPY (¥) ¥ / shares in Units, ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Number of Shares
Outstanding	2,073,000	2,073,000	54,000
Granted			2,019,000
Outstanding	2,073,000	2,073,000	2,073,000	54,000
Exercisable	2,019,000	2,019,000
Weighted-average exercise price
Outstanding	¥ 55	¥ 55	¥ 25
Granted			56
Outstanding	55	55	¥ 55	¥ 25
Exercisable	¥ 56	¥ 56
Additional disclosures
Weighted-average remaining contractual term, outstanding	7 years 8 months 12 days	8 years 8 months 12 days	9 years 8 months 12 days	6 years 4 months 24 days
Weighted-average remaining contractual term, exercisable	7 years 9 months 18 days	8 years 9 months 18 days
Aggregate intrinsic value, outstanding	¥ 183,497	¥ 183,497		¥ 0
Aggregate intrinsic value, exercisable	¥ 177,073	¥ 177,073
Estimated fair value of common shares	¥ 144

XML

Net Income (Loss) per Share - Computation of basic and diluted net loss per share (Details) - JPY (¥) ¥ / shares in Units, ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net Income (Loss)	¥ 41,303	¥ (97,080)	¥ (25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share	20,004,000	20,004,000	20,004,000
Basic net income (loss) per share	¥ 2.06	¥ (4.85)	¥ (1.29)
Numerator:
Net Income (Loss)	¥ 41,303	¥ (97,080)	¥ (25,798)
Denominator:
Weighted-average common shares outstanding used to compute net income (loss) per share	20,004,000	20,004,000	20,004,000
Dilutive securities issuable - Stock option plans	1,218,348
Total weighted-average diluted shares outstanding	21,222,348	20,004,000	20,004,000
Diluted net income (loss) per share	¥ 1.95	¥ (4.85)	¥ (1.29)

XML

Net Income (Loss) per Share - Potentially dilutive shares have been excluded from calculation of diluted net loss per share (Details) - shares	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Potentially dilutive shares have been excluded from calculation of diluted net loss per share
Total potentially dilutive shares	54,000	2,073,000	2,073,000
2nd and 3rd Series stock options outstanding
Potentially dilutive shares have been excluded from calculation of diluted net loss per share
Total potentially dilutive shares	54,000	54,000	54,000
4th Series stock options outstanding
Potentially dilutive shares have been excluded from calculation of diluted net loss per share
Total potentially dilutive shares		2,019,000	2,019,000

XML

Income Taxes - Income before income taxes (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Components of income (loss) before income taxes
Japan	¥ 78,203	¥ (80,543)	¥ (11,355)
Singapore	(36,900)	(16,537)	(14,443)
Income (loss) before income taxes	¥ 41,303	¥ (97,080)	¥ (25,798)
Statutory rate (as a percent)	34.59%	34.59%	34.59%

XML

Income Taxes - Reconciliation of income tax to statutory rate (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
A reconciliation of income tax expenses to the amount of income tax benefit at the statutory rate
Income tax expenses (benefit) at the statutory rate	¥ 14,286	¥ (33,580)	¥ (8,923)
Increase (reduction) in taxes resulting from:
Non-deductible share-based compensation expense	1,502	29,047	38,631
Deferred offering costs	(11,449)	(17,323)	(19,707)
Change in valuation allowance	(19,371)	15,982	(15,139)
Different tax rates in different jurisdictions	6,491	2,844	2,541
Disallowed losses	6,273	2,748	2,455
Other	¥ 2,268	¥ 282	¥ 142

XML

Income Taxes - Deferred tax assets and liabilities (Details) - JPY (¥) ¥ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	¥ 102,559	¥ 135,400
Operating lease liabilities	20,980
Accrued expenses and reserves	12,209
Other	615	2,223
Total deferred tax assets	136,363	137,623
Deferred tax liabilities:
Right-of-use assets	(20,980)
Debt issuance costs	(346)	(369)
Other receivables		(2,274)
Capitalized software	(64)	(1,011)
Other	(737)	(362)
Total deferred tax liabilities	(22,127)	(4,016)
Less: Valuation allowance	¥ (114,236)	¥ (133,607)	¥ (117,625)	¥ (117,527)

XML

Income Taxes - Valuation allowance (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Net changes in valuation allowance for net deferred tax assets
Valuation allowance at beginning of year	¥ 133,607	¥ 117,625	¥ 117,527
Additions (deductions)	(19,371)	15,982	(15,139)
Change in statutory tax rate			15,237
Valuation allowance at end of year	¥ 114,236	¥ 133,607	¥ 117,625

XML

Income Taxes - Operating loss carryforwards (Details) ¥ in Thousands	Mar. 31, 2023 JPY (¥)
Income Taxes
Between 2024 and 2027	¥ 122,286
Between 2028 and 2031	125,915
2032 and thereafter	48,298
Total	¥ 296,499

XML

Income Taxes - Other information (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Income Taxes
Provision for the income taxes on undistributed earnings of a foreign subsidiary	¥ 0
Uncertain tax benefit recognized	0
Uncertain tax positions anticipated to significantly increase or decrease within 12 months	0	¥ 0	¥ 0
Interest or penalties associated with any uncertain tax benefits	0	¥ 0	¥ 0
Singapore
Income Taxes
Income tax benefit related to net operating loss	¥ 0

XML

Accrued Expenses and Other Current Liabilities (Details) - JPY (¥) ¥ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities
Accrued compensation	¥ 4,846	¥ 2,737
Accrued offering costs		4,400
Accrued audit fees	44,392	50,188
Accrued professional fees	35,519	19,273
Withholding taxes payable	4,455	2,435
Accrued purchases of property and equipment	639	14,087
Other accrued expenses and current liabilities	10,534	7,915
Total	¥ 100,385	¥ 101,035

XML

Shareholders' Equity (Details) ¥ in Thousands		12 Months Ended
	Oct. 12, 2021 shares	Mar. 31, 2023 Vote shares	Mar. 31, 2021 JPY (¥)	Nov. 14, 2022 shares	Nov. 13, 2022 shares	Mar. 31, 2022 shares	Oct. 11, 2021 shares
Class of Stock
Common shares authorized (in shares)		80,000,000				80,000,000
Common shares outstanding (in shares)		20,004,000				20,004,000
The Company's Act
Class of Stock
Percentage of dividends appropriated as legal reserve		10.00%
Legal reserve threshold, percentage of outstanding common shares		25.00%
Reduction in common share capital | ¥			¥ 125,636
Reduction in additional paid in capital | ¥			135,399
Transfers to reduce accumulated deficit | ¥			¥ 261,035
Common Stock
Class of Stock
Common shares authorized (in shares)		80,000,000
Voting rights per common share | Vote		1
Common shares outstanding (in shares)		20,004,000
Percentage of proceeds allocated to common share account		50.00%
Common Stock | 1500-for-one Stock Split
Class of Stock
Stock split conversion ratio	1,500
Common shares authorized (in shares)	40,000,000						10,000,000
Common Stock | 2-for-one Stock Split
Class of Stock
Common shares authorized (in shares)				80,000,000	40,000,000
Common shares authorized after stock splits				2

XML

Related-Party Transactions (Details) - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2023
Related Party | ZENY Inc.
Related-Party Transactions
Non-controlling interests' ownership		10.40%
Related Party | Yusuke Shono and ZENY Inc
Related-Party Transactions
Amount of funding transactions with related party for general operating needs		¥ 28,640
Repayment of short-term debt		30,053
Related Party | ZENY Inc.
Related-Party Transactions
Amount of receivables collected from related party		17
Payables	¥ 0	0
Receivables	¥ 0	¥ 0
CEO
Related-Party Transactions
Percentage of shares assumed after dissolution by non-controlling interest	10.40%
CEO | Non-interest bearing short-term funding
Related-Party Transactions
Proceeds from short-term funding	¥ 6,112
CEO | Guarantor of lease
Related-Party Transactions
Lease payment per month			¥ 148
CEO | ZENY Inc.
Related-Party Transactions
Percentage of ownership interest		78.10%

XML

Subsequent Events (Details) - Subsequent Events ¥ in Thousands	Jul. 27, 2023 JPY (¥) item shares	Aug. 01, 2023 JPY (¥)	Jul. 27, 2023 $ / shares
Subsequent Events
Net proceeds	¥ 7,191
Term loan agreement
Subsequent Events
Interest rate		6.00%
Term loan agreement | CEO
Subsequent Events
Principal amount of loan		¥ 2,700
American Depositary Shares
Subsequent Events
Number of common shares each ADS represents | item	1
IPO | American Depositary Shares
Subsequent Events
Number of shares sold | shares	2,400,000
Share price per share | $ / shares			$ 4.00

XML

Pay vs Performance Disclosure - JPY (¥) ¥ in Thousands	12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Pay vs Performance Disclosure
Net Income (Loss)	¥ 41,303	¥ (97,080)	¥ (25,798)

XML

Insider Trading Arrangements	12 Months Ended
	Mar. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML

Insider Trading Policies and Procedures	12 Months Ended
	Mar. 31, 2023
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	false